Original Article
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
N Engl J Med 1996; 334:1349-1355May 23, 1996
- Abstract
Background
Controlled clinical trials have shown that beta-blockers can produce hemodynamic and symptomatic improvement in chronic heart failure, but the effect of these drugs on survival has not been determined.
Methods
We enrolled 1094 patients with chronic heart failure in a double-blind, placebo-controlled, stratified program, in which patients were assigned to one of four treatment protocols on the basis of their exercise capacity. Within each of the four protocols patients with mild, moderate, or severe heart failure with left ventricular ejection fractions ≤0.35 were randomly assigned to receive either placebo (n = 398) or the beta-blocker carvedilol (n = 696); background therapy with digoxin, diuretics, and an angiotensin-converting–enzyme inhibitor remained constant. Patients were observed for the occurrence of death or hospitalization for cardiovascular reasons during the following 6 months (12 months for the group with mild heart failure).
Results
The overall mortality rate was 7.8 percent in the placebo group and 3.2 percent in the carvedilol group; the reduction in risk attributable to carvedilol was 65 percent (95 percent confidence interval, 39 to 80 percent; P<0.001). This finding led the Data and Safety Monitoring Board to recommend termination of the study before its scheduled completion. In addition, as compared with placebo, carvedilol therapy was accompanied by a 27 percent reduction in the risk of hospitalization for cardiovascular causes (19.6 percent vs. 14.1 percent, P = 0.036), as well as a 38 percent reduction in the combined risk of hospitalization or death (24.6 percent vs. 15.8 percent, P<0.001). Worsening heart failure as an adverse reaction during treatment was less frequent in the carvedilol group than in the placebo group.
Conclusions
Carvedilol reduces the risk of death as well as the risk of hospitalization for cardiovascular causes in patients with heart failure who are receiving treatment with digoxin, diuretics, and an angiotensin-converting–enzyme inhibitor.
Media in This Article
Figure 2
Kaplan–Meier Analysis of Survival without Hospitalization for Cardiovascular Reasons (Event-free Survival) in the Placebo and Carvedilol Groups.Figure 1
Kaplan–Meier Analysis of Survival among Patients with Chronic Heart Failure in the Placebo and Carvedilol Groups.Article Activity
- Article
Activation of the sympathetic nervous system is one of the cardinal pathophysiologic abnormalities in patients with chronic heart failure. Levels of circulating catecholamines increase in patients with heart failure in proportion to the severity of disease,1 and those with the highest plasma levels of norepinephrine have the most unfavorable prognosis.2 These observations have led to the hypothesis that sympathetic activation plays an important part in the progression of heart failure.3,4 Norepinephrine can exert adverse effects on the circulation, both directly and indirectly,5,6 and interference with its actions can retard the progression of heart failure in animal models of the disease.7,8
These findings have led investigators to propose that sympathetic antagonists (e.g., beta-blockers) might be useful in the management of heart failure. Such drugs were previously considered to be contraindicated in this disorder because of their short-term adverse effects,9 but studies in Sweden in the 1970s raised the possibility that long-term therapy with these drugs might produce hemodynamic and clinical benefits.10,11 Controlled trials of several different beta-blockers have shown that these drugs can reduce symptoms, improve left ventricular function, and increase functional capacity,12-18 but recent large-scale studies19,20 have not clarified the effects of beta-blockers on morbidity and mortality in patients with heart failure.
Hence, when a large clinical trial program with carvedilol in heart failure was being designed in 1992, we prospectively defined an overall objective of the program to be an evaluation of the effect of the drug on survival. Our principal goal was to assess the safety of carvedilol while recognizing its potential to prolong life, demonstrated by the results of experimental studies.7,8,21 Carvedilol is a nonselective β-receptor antagonist that also blocks α1-receptors and, unlike other beta-blockers, exerts antioxidant effects, which may contribute to its actions in heart failure.22-24 This report summarizes the effects of carvedilol on survival and on hospitalization for cardiovascular causes.
Methods
Study Patients
All patients in the study had had symptoms of heart failure for at least three months and had ejection fractions ≤0.35, despite at least two months of treatment with diuretics and an angiotensin-converting–enzyme inhibitor (if tolerated); treatment with digoxin, hydralazine, or nitrates was permitted but not required. Patients were excluded from the trial if they had had a major cardiovascular event or had undergone a major surgical procedure within three months of entry into the study, or if they had uncorrected, primary valvular disease; active myocarditis; sustained ventricular tachycardia or advanced heart block not controlled by antiarrhythmic intervention or a pacemaker; systolic blood pressure of more than 160 or less than 85 mm Hg or diastolic blood pressure of more than 100 mm Hg; a heart rate of less than 68 beats per minute; clinically important hepatic or renal disease; or any condition other than heart failure that could limit exercise or survival. Patients receiving calcium-channel blockers, α- or β-adrenergic agonists or antagonists, or class IC or III antiarrhythmic agents were also not enrolled. The protocol was approved by the institutional review boards of all 65 participating institutions; written informed consent was obtained from all patients.
Study Procedures
The patients' eligibility was assessed during a three-week screening period, during which exercise capacity was measured by a six-minute corridor-walk test. Enrollment was stratified into one of four treatment protocols on the basis of the patients' performance on the exercise test. According to the original design, patients able to walk between 426 and 550 m when tested were assigned to the mild-heart-failure protocol; those able to walk between 150 and 425 m were assigned either to the moderate-heart-failure protocol or to a dose-ranging protocol, depending on the location of the study center; and those able to walk only less than 150 m were assigned to the severe-heart-failure protocol.
After a base-line evaluation, all patients received 6.25 mg of carvedilol twice daily for two weeks (the open-label portion of the study); if this dose was not tolerated, it could be temporarily reduced to 3.125 mg twice daily and then later increased. Patients who could tolerate 6.25 mg twice daily were randomly assigned to receive carvedilol or placebo on a double-blind basis, in addition to their usual medication. The allocation ratio (of patients given carvedilol to patients given placebo) was one-to-one in the moderate-heart-failure protocol and two-to-one in the mild- and severe-heart-failure protocols; for these patients, the dose of medication was initially 12.5 mg twice daily and was increased, if tolerated, to 25 to 50 mg twice daily. Patients assigned to the dose-ranging protocol were randomly assigned to one of four parallel treatment groups (placebo or 6.25 mg, 12.5 mg, or 25 mg of carvedilol, twice daily). For all four protocols, the dose was gradually adjusted upward to the target level over a period of 2 to 10 weeks, after which double-blind therapy was maintained for an additional 6 months (except in the mild-heart-failure protocol, in which patients were treated for an additional 12 months). During this time, the patients' other drug therapies for heart failure were kept constant, unless side effects occurred that were thought to be related either to these other medications or to the study drug itself.
Study Objectives and Monitoring
Because of concern that new drugs for heart failure might increase the risk of death, the sponsors of the program agreed with the Food and Drug Administration in July 1992 to enroll a sufficient number of patients in placebo-controlled trials of carvedilol to rule out (with 95 percent confidence) the risk of a 33 percent increase in mortality with active therapy, assuming an annual mortality rate of 12 percent in the placebo group. As a result of these discussions, an evaluation of mortality was prospectively defined for the present stratified trial program, primarily for reasons of safety, with the intent to enroll 1101 patients. However, since it was anticipated (on the basis of earlier studies) that carvedilol could reduce mortality, all statistical analyses were two-sided. All deaths were classified by investigators who had no knowledge of the patients' treatment assignments. In addition, a major secondary objective of each of the component protocols was to evaluate the effect of carvedilol on cardiovascular morbidity, defined as hospitalization for heart failure or other cardiovascular causes.
A data and safety monitoring board was constituted before recruitment began, met periodically to review the unblinded results, and was empowered to recommend early termination of the program if its members observed a clinically important treatment effect. No formal rules for stopping the trial were adopted before the initiation of enrollment.
Statistical Analysis
The base-line characteristics of the two treatment groups were compared with use of the t-test and the chi-square statistic. Cumulative survival curves were constructed as time-to-first-event plots by Kaplan–Meier survivorship methods,25 and differences between the curves were tested for significance by the log-rank statistic with use of a Cox proportional-hazards regression model (which included the protocol as a covariate).26 The analyses included all randomized patients, and all events were assigned to the patients' original treatment group (on the intention-to-treat principle). In the analysis of mortality, data on patients were censored at the time of cardiac transplantation. Differences between treatment groups in post-randomization measures or events were evaluated by analysis of variance and with the chi-square statistic. All data are reported as means ±SD.
Results
Randomization began on April 29, 1993, and the study was stopped early on the recommendation of the Data and Safety Monitoring Board on February 3, 1995. This decision was based on the finding of a significant effect of carvedilol on survival — an effect that exceeded all conventional boundaries used to stop clinical trials.27,28
At the time of the study's early termination, 1197 patients had entered the open-label, run-in period. Of these, 5.6 percent failed to complete this period because of adverse events (e.g., worsening heart failure in 1.4 percent and death in 0.6 percent); another 3.0 percent failed to do so because of violations of the protocol or for other administrative reasons. Accordingly, 1094 patients were randomly assigned to double-blind treatment: 398 with placebo and 696 with carvedilol.
The placebo and carvedilol groups were similar in all pretreatment characteristics (Table 1Table 1
Pretreatment Characteristics of Patients in the Study.). After randomization and the adjustment of dosage, patients received a mean total daily dose of 45±27 mg of carvedilol or 60±24 mg of placebo; these doses were maintained at similar levels throughout the study period. Eighty percent of the patients received target doses of the study drugs. The duration of therapy ranged from 1 day to 15.1 months (median, 6.5 months). No patient was lost to follow-up with respect to mortality.Effect of Carvedilol on Survival
In the intention-to-treat analysis, there were 31 deaths (7.8 percent) in the placebo group and 22 deaths (3.2 percent) in the carvedilol group; this difference represents a 65 percent decrease in the risk of death (95 percent confidence interval, 39 to 80 percent; P<0.001) in patients assigned to carvedilol (Figure 1Figure 1
Kaplan–Meier Analysis of Survival among Patients with Chronic Heart Failure in the Placebo and Carvedilol Groups.). Treatment with the drug was associated with a large decrease in the risk of dying of progressive heart failure and in the risk of sudden death (Table 2Table 2
Cause of Death in the Patients in the Study.). The reduction in mortality due to carvedilol was similar regardless of age, sex, the cause of heart failure, ejection fraction, exercise tolerance, systolic blood pressure, heart rate, or protocol assignment (Table 3Table 3
Effect of Placebo and Carvedilol Treatment on Mortality in Patient Subgroups.).Effect of Carvedilol on Cardiovascular Morbidity
During double-blind therapy, 98 patients (14.1 percent) in the carvedilol group and 78 patients (19.6 percent) in the placebo group had at least one hospitalization for cardiovascular causes; this difference represents a 27 percent reduction in the risk of hospitalization (95 percent confidence interval, 3 to 45 percent; P = 0.036). To avoid the analytic problem of competing risks (since patients who have died cannot be hospitalized), the effect of carvedilol on the combined risk of death or hospitalization for cardiovascular causes was evaluated with the use of a time-to-first-event analysis. As tested for significance with use of the log-rank test, the combined risk of either dying or being hospitalized for cardiovascular reasons was reduced from 24.6 percent in the placebo group to 15.8 percent in the carvedilol group, a 38 percent reduction (95 percent confidence interval, 18 to 53 percent; P<0.001) (Figure 2Figure 2
Kaplan–Meier Analysis of Survival without Hospitalization for Cardiovascular Reasons (Event-free Survival) in the Placebo and Carvedilol Groups.).Safety
At the end of double-blind therapy, the mean heart rate decreased significantly more in the carvedilol group than in the placebo group (by 12.6±12.8 beats per minute vs. 1.4±12.2, P<0.001), although neither group had significant changes in systolic or diastolic blood pressure. Frequently reported adverse reactions are listed in Table 4Table 4
Most Frequent Adverse Reactions.; those necessitating discontinuation of the study drug are shown in Table 5Table 5
Most Frequent Adverse Reactions Leading to Discontinuation of Double-Blind Treatment.. The most common side effect of carvedilol was dizziness, which occurred during the initiation of therapy or during the dose-adjustment period but which subsided either spontaneously or after the adjustment of concomitant medications; it did not generally lead to the withdrawal of treatment with the study drug. The most common reason for the discontinuation of double-blind treatment was worsening heart failure, which occurred more frequently in the placebo group. Overall, 7.8 percent of the placebo group and 5.7 percent of the carvedilol group discontinued the study medication because of adverse reactions; 1.5 percent and 1.1 percent, respectively, were withdrawn from the study medication after cardiac transplantation. When the program was terminated, more patients were receiving or had completed double-blind treatment in the carvedilol group than in the placebo group (89 percent vs. 83 percent, P = 0.002).Discussion
The present report indicates that the addition of carvedilol to conventional therapy is associated with a decrease in mortality among patients with chronic heart failure. Patients treated with carvedilol had a 65 percent lower risk of death than those given placebo during follow-up that averaged 6.5 months and extended to 15 months. The beneficial effect of carvedilol on survival was consistent in all evaluated subgroups and was reflected in a decrease in the risk of death from progressive heart failure as well as in the risk of sudden death. In addition, carvedilol therapy was associated with a 26 percent reduction in hospitalization for cardiovascular causes, a 38 percent decrease in the risk of death or hospitalization, and a lower rate of withdrawal from the trial due to worsening heart failure.
Previous controlled studies have shown that beta- blockade can improve cardiac function, reduce the symptoms of heart failure, improve functional capacity, and enhance exercise tolerance.12-20 Most of these trials were too small to evaluate the effects of beta-blockers on morbidity or mortality, but one single-center study with carvedilol18 and two multicenter studies with the β1-selective agents metoprolol and bisoprolol19,20 suggested that long-term beta-blockade may have favorable effects on the course of heart failure. In the single-center study,18 treatment with carvedilol for four months reduced the risk of cardiovascular events. In the two multicenter studies,19,20 treatment with metoprolol for 12 to 18 months or with bisoprolol for 4 to 44 months was associated with fewer hospitalizations for worsening heart failure and a reduced risk of clinical deterioration requiring cardiac transplantation. The decrease in hospitalizations for cardiovascular causes seen with carvedilol in our study reaffirms these earlier observations.
Yet previous trials in heart failure have not demonstrated a reduction in mortality during beta-blockade. In the two multicenter studies,19,20 treatment with metoprolol or bisoprolol did not significantly decrease the risk of death. One of the trials retrospectively noted a reduction in mortality only among patients with nonischemic dilated cardiomyopathy.20 In contrast, in our study, carvedilol therapy was associated with a decrease in mortality, and the benefits of the drug were apparent in all the subgroups we examined, including patients with underlying ischemic heart disease. The fact that two earlier multicenter studies did not find an effect on survival may have been related to the sample sizes, to the study designs, or to chance. Alternatively, the effects of carvedilol on survival may differ from those of other beta-blockers. Unlike metoprolol and bisoprolol, carvedilol blocks both α1- and β2-adrenergic receptors, reduces cardiac norepinephrine levels, and does not elicit up-regulation of cardiac β-receptors.29-31 Furthermore, unlike other beta-blockers, carvedilol has potent antioxidant effects,24 which may protect against the continuing loss of cardiac myocytes that characterizes the progression of heart failure.21,32
The initiation of therapy with carvedilol in our study produced side effects consistent with its antiadrenergic actions, but most of these reactions disappeared — either spontaneously or after the adjustment of concomitant medications — and did not require the discontinuation of double-blind treatment. Thus, most patients were able to tolerate target doses of carvedilol. The most feared side effect of beta-blockade — worsening heart failure during the initiation of therapy — was not an important limitation of treatment; 5.9 percent of the patients had this side effect during the open-label period, and an additional 5.1 percent in the carvedilol group and 4.1 percent in the placebo group had this reaction after increases in dose during the early phases of double-blind therapy. It must be emphasized, however, that carvedilol therapy was initiated in the study with extreme care by physicians experienced in the management of heart failure, who followed specific guidelines that encouraged changes in concomitant medications to ensure the safety of the patient. Furthermore, our program recruited few patients with New York Heart Association class IV heart failure,33 and patients who required hospitalization for intravenous drug support were not enrolled. Hence, our study does not allow any conclusions to be drawn about the safety of carvedilol when it is administered without rigorous supervision or in bedridden patients with advanced heart failure.
To enhance the safety of patients, therapy with carvedilol was initiated in small doses that were gradually increased over a period of several weeks. This cautious approach has been followed in studies of other beta-blockers12-20,34 and is designed to minimize the adverse effects that may occur after the abrupt withdrawal of the homeostatic support provided by the sympathetic nervous system. Despite such care, however, the frequency of early side effects was expected to be high enough potentially to unblind both the patient and the investigator as to the treatment-group assignment. To avoid this difficulty, we required patients to complete a two-week, open-label period before randomly assigning them to double-blind therapy; this design feature has been part of many trials studying survival in heart failure19,35,36 and of all previous controlled trials with carvedilol. The use of an open-label period not only allows drug-related side effects to subside before randomization (thus maintaining the blindedness of the study) but also enhances the study's power, since a trial is less likely to detect a true effect on survival if patients are randomly assigned to treatment that cannot be maintained for the planned length of the study. Although deaths may occur during the open-label period, they cannot be validly assigned to either the treatment or the placebo group, since they may be related either to the natural history of heart failure or to carvedilol. Fortunately, the mortality rate during the two-week, open-label period was low (0.6 percent) and was similar to — if not less than — the rate in the preceding three weeks (1.7 percent), during which patients were being screened for the program but were receiving only their usual medications for heart failure.
Our findings should be interpreted with the knowledge that the trial program had several unusual characteristics for a study of the effect of a drug on survival. Most such trials are designed as long-term studies in which nonfatal events are considered to be secondary end points. In our program, however, the individual protocols were designed first to evaluate nonfatal end points as components of a single stratified trial program, and then mortality was specified a priori to assess safety and potential benefit. As a result, the duration of follow-up was short and fixed. Although several trials examining mortality in heart failure have also used a fixed follow-up period,19,37 such a design necessarily reduces the number of events that can be observed. This explains why, although the annual mortality in our placebo group (14 to 15 percent) was similar to that in many studies,35,38 we recorded only 53 deaths (since the average follow-up was only 6.5 months). This limited experience restricts our ability to reach conclusions about the true magnitude or persistence of any effect on survival. Yet it should be noted that the number of events during follow-up in our trial was not small if morbidity and mortality are combined; 25 percent of the placebo group died or were hospitalized for cardiovascular reasons, and this combined rate was substantially lower in the carvedilol group. Furthermore, a long follow-up period may not be possible if the finding of a large treatment effect leads the Data and Safety Monitoring Board to recommend early termination of a study, as occurred in this case; the mean duration of follow-up in the present program was similar to that in other trials that have been terminated early.36,39,40 Fortunately, long-term data on carvedilol have recently become available from a trial of 415 patients with mild-to-moderate heart failure due to ischemic heart disease who were treated for 18 to 24 months. In that study, carvedilol reduced the combined risk of death or hospitalization by 26 percent (Sharpe N: personal communication) — a finding similar to the 38 percent reduction in mortality and hospitalization we observed.
Our finding that carvedilol reduces morbidity and mortality supports the hypothesis that a beta-blocker can favorably influence the course of disease in patients with heart failure. However, because carvedilol exerts pharmacologic effects atypical of and in addition to its action on adrenergic receptors,22-24 experience with this drug does not allow us to conclude that all beta-blockers will favorably alter the natural history of this disorder. The question of whether other beta-blockers (such as metoprolol, bisoprolol, and bucindolol) prolong survival in heart failure is being addressed in ongoing trials.
Supported by grants from SmithKline Beecham Pharmaceuticals and Boehringer–Mannheim Therapeutics.
Source Information
From the College of Physicians and Surgeons, Columbia University, New York (M.P.); University of Colorado Health Sciences Center, Denver (M.R.B.); University of Minnesota Medical School, Minneapolis (J.N.C.); Boston University School of Medicine, Boston (W.S.C.); Stanford University School of Medicine, Palo Alto, Calif. (M.B.F.); University of Utah School of Medicine, Salt Lake City (E.M.G.); and SmithKline Beecham Pharmaceuticals, King of Prussia, Pa. (N.H.S.).
Address reprint requests to Dr. Packer at the Division of Circulatory Physiology, Columbia University College of Physicians and Surgeons, 630 W. 168th St., New York, NY 10032.
The U.S. Carvedilol Heart Failure Study Group investigators are listed in the Appendix.
Appendix
The following centers and principal investigators composed the U.S. Carvedilol Heart Failure Study Group: Albuquerque, N.M. — Lovelace Scientific Resources, L. Kuo; Baltimore — Johns Hopkins University Hospital, E. Kasper and A.M. Feldman; Union Memorial Hospital, H. Meilman and D. Goldscher; and University of Maryland, S.S. Gottlieb; Beverly Hills, Calif. — Cardiovascular Research Institute of Southern California, R. Karlsburg; Boston — Boston City Hospital, R.H. Falk; Brigham and Women's Hospital, W.S. Colucci and W. Carlson; Massachusetts General Hospital, G.W. Dec; and New England Medical Center, J.E. Udelson; Bronx, N.Y. — Albert Einstein College of Medicine, T.H. Le Jemtel; Chapel Hill, N.C. — University of North Carolina, K. Adams; Cleveland — Cleveland Clinic, R. Hobbs; Columbus — Ohio State University Hospital, R.J. Cody; Dallas — University of Texas Southwestern Medical Center, C.W. Yancy; and Veterans Affairs Medical Center (VAMC), E. Eichhorn; Denver — University of Colorado, M.R. Bristow; East Meadow, N.Y. — Nassau County Medical Center, E. Brown and I. Freeman; Elmhurst, N.Y. — Elmhurst Hospital Center, N. Kantrowitz; Falls Church, Va. — INOVA Health System, J. Kiernan, J. O'Brien, and P. Carson; Grosse Pointe, Mich. — Henry Ford Health System and Pierson Clinic, V. Kinhal; Houston — Baylor College of Medicine, J. Young; University of Texas Medical School, G. Schroth and S.E. El Hafi; Jackson — University of Mississippi Medical Center, J. O'Connell; Jacksonville — University of Florida, A. Miller; Las Vegas — Heart Institute of Nevada, J.A. Bowers; Lincoln — Nebraska Heart Institute, S. Krueger; Los Angeles — University of Southern California School of Medicine, V. DeQuattro; Madison — University of Wisconsin School of Medicine, P.S. Rahko; Memphis — University of Tennessee School of Medicine, K.B. Ramanathan; Miami — University of Miami, E. deMarchena; Mineola, N.Y. — Cardiovascular Medical Associates, M. Goodman; and Winthrop University Hospital, R. Steingart; Minneapolis — University of Minnesota Medical School, S. Kubo and J.N. Cohn; Nashville — Vanderbilt University Medical Center, J.R. Wilson and T.-K. Yeoh; New Haven, Conn. — Yale University School of Medicine, F. Lee; New York — Columbia–Presbyterian Medical Center, J. Sackner-Bernstein, G. W. Neuberg, and M. Packer; Mount Sinai Medical Center, M. Kukin; and St. Luke's–Roosevelt Medical Center, M. Klapholz; Northport, N.Y. — VAMC, G. Mallis; Oklahoma City — University of Oklahoma and VAMC, U. Thadani; Park Ridge, Ill. — Lutheran General Hospital, R.P. Sorkin; Philadelphia — Temple University Hospital, I. Pina; Phoenix, Ariz. — Carl T. Hayden VAMC, J.V. Felicetta; Pittsburgh — Presbyterian University Hospital, B. Uretsky and S. Murali; and Western Pennsylvania Hospital, A. Gradman; Portland — Oregon Health Sciences Center, R. Hershberger; Richmond — Medical College of Virginia, G.W. Vetrovec; Rochester, Minn. — Mayo Medical School, L.J. Olson; Rochester, N.Y. — University of Rochester Medical Center, C.-S. Liang; Salt Lake City — University of Utah, E.M. Gilbert; San Diego, Calif. — Cardiology Associates Medical Group of East San Diego, L. Yellen; and Sharp Rees–Stealy Medical Center, H. Ingersoll; San Francisco — California Pacific Medical Center, S. Woodley; and VAMC, B.M. Massie; Sellersville, Pa. — Buxmont Cardiology Associates, M. Greenspan; St. Louis — St. Louis University Medical Center, L.W. Miller, S.H. Jennison, A.J. Lonigro, and H. Stratman; Stanford, Calif. — Stanford University School of Medicine, M.B. Fowler; Summit, N.J. — Overlook Hospital, J.J. Gregory; Torrance, Calif. — Harbor–UCLA Medical Center, K.A. Narahara; Tucson — University of Arizona Medical Center, S. Butman; Washington, D.C. — Georgetown University Hospital, D. Pearle; Winston-Salem, N.C. — Bowman Gray School of Medicine, F. Kahl; and Worcester — University of Massachusetts Medical Center, L. Heller.
Committee members were as follows: Executive Committee — M. Packer, M.R. Bristow, J.N. Cohn, W.S. Colucci, M.B. Fowler, and E.M. Gilbert; Data and Safety Monitoring Board — A.M. Katz (chair), T. Bashore, C.E. Davis, and P. Kowey; Biostatistics — J. Hosking and S.T. Young; and Study Operations and Monitoring — N.H. Shusterman, M.A. Lukas, A. Flagg, T. Holcslaw, and L.G. Parchman.
- References
References
1
Thomas JA ,Marks BH . Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978;41:233-243
CrossRef | Web of Science | Medline2
Cohn JN ,Levine TB ,Olivari MT , et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823
Full Text | Web of Science | Medline3
Packer M . The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-254
CrossRef | Web of Science | Medline4
Bristow MR . Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol 1993;71:12C-22C
CrossRef | Web of Science | Medline5
Yates JC ,Beamish RE ,Dhalla NS . Ventricular dysfunction and necrosis produced by adrenochrome metabolite of epinephrine: relation to pathogenesis of catecholamine cardiomyopathy. Am Heart J 1981;102:210-221
CrossRef | Web of Science | Medline6
Mann DL ,Kent RL ,Parsons B ,Cooper G IV . Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804
Web of Science | Medline7
ver Donck L ,Wouters L ,Olbrich HG ,Mutschler E ,Borgers M . Nebivolol increases survival in cardiomyopathic hamsters with congestive heart failure. J Cardiovasc Pharmacol 1991;18:1-3
CrossRef | Web of Science | Medline8
Sabbah HN ,Shimoyama H ,Kono T , et al. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994;89:2852-2859
Web of Science | Medline9
Epstein SE ,Braunwald E . The effect of beta adrenergic blockade on patterns of urinary sodium excretion: studies in normal subjects and in patients with heart disease. Ann Intern Med 1966;65:20-27
Web of Science | Medline10
Waagstein F ,Hjalmarson A ,Varnauskas E ,Wallentin I . Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-1036
CrossRef | Web of Science | Medline11
Swedberg K ,Hjalmarson A ,Waagstein F ,Wallentin I . Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979;1:1374-1376
CrossRef | Web of Science | Medline12
Eichhorn EJ ,Heesch CM ,Barnett JH , et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994;24:1310-1320
CrossRef | Web of Science | Medline13
Fisher ML ,Gottlieb SS ,Plotnick GD , et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994;23:943-950
CrossRef | Web of Science | Medline14
Woodley SL ,Gilbert EM ,Anderson JL , et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-2441
Web of Science | Medline15
Bristow MR ,O'Connell JB ,Gilbert EM , et al. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994;89:1632-1642
Web of Science | Medline16
Olsen SL ,Gilbert EM ,Renlund DG ,Taylor DO ,Yanowitz FD ,Bristow MR . Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-1231
CrossRef | Web of Science | Medline17
Metra M ,Nardi M ,Giubbini R ,Cas LD . Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-1687
CrossRef | Web of Science | Medline18
Krum H ,Sackner-Bernstein JD ,Goldsmith RL , et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-1506
Web of Science | Medline19
Waagstein F ,Bristow MR ,Swedberg K , et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-1446
CrossRef | Web of Science | Medline20
CIBIS Investigators and Committees
Web of Science | Medline21
Bril A ,Slivjak M ,DiMartino MJ , et al. Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetized minipigs: comparison with propranolol. Cardiovasc Res 1992;26:518-525
CrossRef | Web of Science | Medline22
Ruffolo RR Jr ,Gellai M ,Heible JP ,Willette RN ,Nicholas AJ . The pharmacology of carvedilol. Eur J Clin Pharmacol 1990;38:Suppl 2:S82-S88
CrossRef | Web of Science | Medline23
Yoshikawa T, Port JD, Asano K, et al. Cardiac adrenergic effects of carvedilol. Eur Heart J (in press).
24
Yue T-L ,Cheng H-Y ,Lysko PG , et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263:92-98
Web of Science | Medline25
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science26
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-20227
O'Brien PC ,Fleming TR . A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556
CrossRef | Web of Science | Medline28
Peto R ,Pike MC ,Armitage P , et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34:585-612
CrossRef | Web of Science | Medline29
Gilbert EM ,Olsen SL ,Renlund DG ,Bristow MR . Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol 1993;71:23C-29C
CrossRef | Web of Science | Medline30
Newton GE ,Parker JD . β1 vs nonselective β-blockade in human congestive heart failure: acute effects on cardiac sympathetic activity. Circulation 1995;92:Suppl I:I-395 abstract.31
Bristow MR ,Olsen S ,Gilbert EM , et al. β-blockade with carvedilol selectively lowers cardiac adrenergic drive in the failing human heart. J Am Coll Cardiol 1992;19:146A-146A abstract.32
Dhalla AK ,Singh N ,Singal PK . Antioxidant therapy associated with the reversal of oxidative stress delays the pathogenesis of heart failure. Circulation 1994;90:I-491 abstract.33
Sackner-Bernstein J ,Krum H ,Goldsmith RL , et al. Should worsening heart failure early after initiation of beta-blocker therapy for chronic heart failure preclude long-term treatment? Circulation 1995;92:Suppl I:I-395 abstract.34
Waagstein F ,Caidahl K ,Wallentin I ,Bergh CH ,Hjalmarson A . Long-term β-blockade in dilated cardiomyopathy: effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989;80:551-563
CrossRef | Web of Science | Medline35
The SOLVD Investigators
Full Text | Web of Science | Medline36
Packer M ,Rouleau J ,Swedberg K , et al. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE Study. Circulation 1993;88:Suppl I:I-301 abstract.37
Feldman AM ,Bristow MR ,Parmley WW , et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-155
Full Text | Web of Science | Medline38
Cohn JN ,Archibald DG ,Ziesche S , et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-1552
Full Text | Web of Science | Medline39
The Consensus Trial Study Group
Full Text | Web of Science | Medline40
Packer M ,Carver JR ,Rodeheffer RJ , et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475
Full Text | Web of Science | Medline
- Citing Articles (1133)
Citing Articles
1
Alessandra Stangherlin, Manuela Zaccolo. (2012) cGMP–cAMP interplay in cardiac myocytes: a local affair with far-reaching consequences for heart function. Biochemical Society Transactions 40:1, 11-14
CrossRef2
Anastasios Lymperopoulos, Ashley Bathgate. (2012) Pharmacogenomics of the heptahelical receptor regulators G-protein-coupled receptor kinases and arrestins: the known and the unknown. Pharmacogenomics 13:3, 323-341
CrossRef3
Roberto Spoladore, Gabriele Fragasso, Gianluca Perseghin, Francesco De Cobelli, Antonio Esposito, Francesco Maranta, Giliola Calori, Massimo Locatelli, Guido Lattuada, Paola Scifo, Alessandro Del Maschio, Alberto Margonato. (2012) Beneficial effects of beta-blockers on left ventricular function and cellular energy reserve in patients with heart failure. Fundamental & Clinical Pharmacologyno-no
CrossRef4
James J DiNicolantonio, Daniel G Hackam. (2012) Carvedilol: a third-generation β-blocker should be a first-choice β-blocker. Expert Review of Cardiovascular Therapy 10:1, 13-25
CrossRef5
Mohammad F. Huque, Mohamed Alosh. (2012) A Consistency-Adjusted Strategy for Accommodating an Underpowered Primary Endpoint. Journal of Biopharmaceutical Statistics 22:1, 160-179
CrossRef6
Charalampos D. Kriatselis, Sotirios Nedios, Sebastian Kelle, Sebastian Helbig, Martin Gottwik, Christian von Bary. (2012) Oxygen Kinetics and Heart Rate Response during Early Recovery from Exercise in Patients with Heart Failure. Cardiology Research and Practice 2012, 1-7
CrossRef7
Rory F. McQuillan, Christopher T. Chan. (2012) The Intuitive Case for β-blockers in Patients with ESRD. Seminars in Dialysis 25:1, 15-21
CrossRef8
Dennis Ladage, Robert H.G. Schwinger, Klara Brixius. (2012) Cardio-Selective Beta-Blocker: Pharmacological Evidence and Their Influence on Exercise Capacity. Cardiovascular Therapeuticsno-no
CrossRef9
Gail B. Rattinger, Sarah K. Dutcher, Pankdeep T. Chhabra, Christine S. Franey, Linda Simoni-Wastila,, Stephen S. Gottlieb, Bruce Stuart, Ilene H. Zuckerman. (2012) The Effect of Dementia on Medication Use and Adherence Among Medicare Beneficiaries With Chronic Heart Failure. The American Journal of Geriatric Pharmacotherapy
CrossRef10
Kathy Hebert, Ilia Gogichaishvili, Stephanie Gopie, Lee Arcement. (2011) Pathways in Heart Failure Disease Management Across Socioeconomic Spectra. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 10:4, 169-172
CrossRef11
Ben W.J. Boxall, Andrew L. Clark. (2011) Beta-Blockers and Weight Change in Patients With Chronic Heart Failure. Journal of Cardiac Failure
CrossRef12
Biykem Bozkurt, Mariana Bolos, Anita Deswal, Sameer Ather, Wenyaw Chan, Douglas L. Mann, Blase Carabello. (2011) New Insights into Mechanisms of Action of Carvedilol Treatment in Chronic Heart Failure Patients—A Matter of Time for Contractility. Journal of Cardiac Failure
CrossRef13
Diane L. Frankenfield, Eric D. Weinhandl, Christopher A. Powers, Benjamin L. Howell, Charles A. Herzog, Wendy L. St. Peter. (2011) Utilization and Costs of Cardiovascular Disease Medications in Dialysis Patients in Medicare Part D. American Journal of Kidney Diseases
CrossRef14
Vijayakumar Sukumaran, Punniyakoti T. Veeraveedu, Narasimman Gurusamy, Arun Prasath Lakshmanan, Ken'ichi Yamaguchi, Meilei Ma, Kenji Suzuki, Makoto Kodama, Kenichi Watanabe. (2011) Telmisartan acts through the modulation of ACE-2/ANG 1–7/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis. Life Sciences
CrossRef15
E. de Teresa Galván, J.M. García Pinilla, R. de Teresa Herrera. (2011) Tratamiento de la insuficiencia cardiaca. Medicine - Programa de Formación Médica Continuada Acreditado 10:92, 6240-6248
CrossRef16
Daniel Jacoby, Oltjan Albajrami, Lavanya Bellumkonda. (2011) Natural History of End-stage LV Dysfunction: Has It Improved from the Classic Franciosa and Cohn Graph?. Cardiology Clinics 29:4, 485-495
CrossRef17
Bilal Yilmaz, Duygu Ekinci. (2011) Voltammetric behavior of carvedilol in non-aqueous media and its analytical determination in pharmaceutical preparations. Reviews in Analytical Chemistry 30:3-4, 187-193
CrossRef18
Sidney C. Smith, Emelia J. Benjamin, Robert O. Bonow, Lynne T. Braun, Mark A. Creager, Barry A. Franklin, Raymond J. Gibbons, Scott M. Grundy, Loren F. Hiratzka, Daniel W. Jones, Donald M. Lloyd-Jones, Margo Minissian, Lori Mosca, Eric D. Peterson, Ralph L. Sacco, John Spertus, James H. Stein, Kathryn A. Taubert. (2011) AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Journal of the American College of Cardiology
CrossRef19
Sherief Mansour, Amr Youssef, Mona Rayan, M. Ayman Saleh. (2011) Efficacy of ivabradine in idiopathic dilated cardiomyopathy patients with chronic heart failure. The Egyptian Heart Journal
CrossRef20
Wilbert S. Aronow, Michael W. Rich, Sarah J. Goodlin, Thomas Birkner, Yan Zhang, Margaret A. Feller, Inmaculada B. Aban, Linda G. Jones, Donna M. Bearden, Richard M. Allman, Ali Ahmed. (2011) In-Hospital Cardiology Consultation and Evidence-Based Care for Nursing Home Residents with Heart Failure. Journal of the American Medical Directors Association
CrossRef21
Tania Ferrer, Daniela Ponce-Balbuena, Angélica López-Izquierdo, Ivan A. Aréchiga-Figueroa, Teun P. de Boer, Marcel A.G. van der Heyden, José A. Sánchez-Chapula. (2011) Carvedilol inhibits Kir2.3 channels by interference with PIP2-channel interaction. European Journal of Pharmacology 668:1-2, 72-77
CrossRef22
Jasper Truijen, Olav R. de Peuter, Yu-Sok Kim, Bas van den Bogaard, Wouter E. Kok, Pieter W. Kamphuisen, Johannes J. van Lieshout. (2011) Beta2-adrenergic receptor genotype influences the effect of nonselective vs. selective beta-blockade on baroreflex function in chronic heart failure. International Journal of Cardiology
CrossRef23
Elske Sieswerda, Elvira C van Dalen, Aleida Postma, Daniel KL Cheuk, Huib N Caron, Leontien CM Kremer, Elske Sieswerda. 2011. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. .
CrossRef24
Giuseppe Marazzi, Maurizio Volterrani, Giuseppe Caminiti, Luigi Iaia, Rosalba Massaro, Cristiana Vitale, Barbara Sposato, Giuseppe Mercuro, Giuseppe Rosano. (2011) Comparative Long Term Effects of Nebivolol and Carvedilol in Hypertensive Heart Failure Patients. Journal of Cardiac Failure 17:9, 703-709
CrossRef25
Dennis M. McNamara, Randall C. Starling, Leslie T. Cooper, John P. Boehmer, Paul J. Mather, Karen M. Janosko, John Gorcsan, Kevin E. Kip, G. William Dec. (2011) Clinical and Demographic Predictors of Outcomes in Recent Onset Dilated Cardiomyopathy. Journal of the American College of Cardiology 58:11, 1112-1118
CrossRef26
J. J. V. McMurray. (2011) CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. European Journal of Heart Failure 13:9, 929-936
CrossRef27
Charles F. Jackson, Nanette K. Wenger. (2011) Enfermedad cardiovascular en el anciano. Revista Española de Cardiología 64:8, 697-712
CrossRef28
Juan A. Sanchez, Lise L. Sanchez, Stanley J. Dudrick. (2011) Nutritional Considerations in Adult Cardiothoracic Surgical Patients. Surgical Clinics of North America 91:4, 857-875
CrossRef29
Christopher M. O'Connor, Mona Fiuzat, Karl Swedberg, Michael Caron, Bruce Koch, Peter E. Carson, Wendy Gattis-Stough, Gordon W. Davis, Michael R. Bristow. (2011) Influence of Global Region on Outcomes in Heart Failure Beta-Blocker Trials. Journal of the American College of Cardiology 58:9, 915-922
CrossRef30
K. Wittkopper, D. Dobrev, T. Eschenhagen, A. El-Armouche. (2011) Phosphatase-1 inhibitor-1 in physiological and pathological -adrenoceptor signalling. Cardiovascular Research 91:3, 392-401
CrossRef31
Bruce J. Kimura, Norihiro Yogo, Charles W. O'Connell, James N. Phan, Brian K. Showalter, Tanya Wolfson. (2011) Cardiopulmonary Limited Ultrasound Examination for “Quick-Look” Bedside Application. The American Journal of Cardiology 108:4, 586-590
CrossRef32
Charles F. Jackson, Nanette K. Wenger. (2011) Cardiovascular Disease in the Elderly. Revista Española de Cardiología (English Edition) 64:8, 697-712
CrossRef33
Henry Krum, John R Teerlink. (2011) Medical therapy for chronic heart failure. The Lancet 378:9792, 713-721
CrossRef34
Murray Esler. (2011) The sympathetic nervous system through the ages: from Thomas Willis to resistant hypertension. Experimental Physiology 96:7, 611-622
CrossRef35
Johanna Schneider, Achim Lother, Lutz Hein, Ralf Gilsbach. (2011) Chronic cardiac pressure overload induces adrenal medulla hypertrophy and increased catecholamine synthesis. Basic Research in Cardiology 106:4, 591-602
CrossRef36
Thomas Yeoh, Christopher Hayward, Victoria Benson, Angela Sheu, Zara Richmond, Michael P. Feneley, Anne M. Keogh, Peter Macdonald, Diane Fatkin. (2011) A Randomised, Placebo-controlled Trial of Carvedilol in Early Familial Dilated Cardiomyopathy. Heart, Lung and Circulation
CrossRef37
Paul A. Sobotka, Felix Mahfoud, Markus P. Schlaich, Uta C. Hoppe, Michael Böhm, Henry Krum. (2011) Sympatho-renal axis in chronic disease. Clinical Research in Cardiology
CrossRef38
Ryan P. Morrissey, Lawrence Czer, Prediman K. Shah. (2011) Chronic Heart Failure. American Journal Cardiovascular Drugs 11:3, 153-171
CrossRef39
Somya A. Chandrasekaran, Hector O. Ventura, Carl J. Lavie, Ileana Pina. (2011) Disparities in Women with Heart Failure. Current Cardiovascular Risk Reports 5:3, 261-265
CrossRef40
Ravi V. Desai, Jason L. Guichard, Marjan Mujib, Mustafa I. Ahmed, Margaret A. Feller, Gregg C. Fonarow, Philippe Meyer, Ami E. Iskandrian, Herman J. Bogaard, Michel White, Inmaculada B. Aban, Wilbert S. Aronow, Prakash Deedwania, Finn Waagstein, Ali Ahmed. (2011) Reduced right ventricular ejection fraction and increased mortality in chronic systolic heart failure patients receiving beta-blockers: Insights from the BEST trial. International Journal of Cardiology
CrossRef41
David N. Rosenthal, Gregory B. Hammer. (2011) Cardiomyopathy and heart failure in children: anesthetic implications. Pediatric Anesthesia 21:5, 577-584
CrossRef42
Angela Yee-Moon Wang, John E. Sanderson. (2011) Treatment of Heart Failure in Long-term Dialysis Patients: A Reappraisal. American Journal of Kidney Diseases 57:5, 760-772
CrossRef43
2011. Heart Disease. , 59-84.
CrossRef44
Christer Kubon, Nisha B. Mistry, Irene Grundvold, Sigrun Halvorsen, Sverre E. Kjeldsen, Arne S. Westheim. (2011) The role of beta-blockers in the treatment of chronic heart failure. Trends in Pharmacological Sciences 32:4, 206-212
CrossRef45
I. M. Hamour, A. Khaghani, P. K. Kanagala, A. G. Mitchell, N. R. Banner. (2011) Current outcome of heart transplantation: a 10-year single centre perspective and review. QJM 104:4, 335-343
CrossRef46
Dalane W. Kitzman. (2011) Understanding Results of Trials in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology 57:16, 1687-1689
CrossRef47
Melanie D. Everitt, Amy E. Donaldson, Josef Stehlik, Aditya K. Kaza, Deborah Budge, Rami Alharethi, Emily A. Bullock, Abdallah G. Kfoury, Anji T. Yetman. (2011) Would access to device therapies improve transplant outcomes for adults with congenital heart disease? Analysis of the United Network for Organ Sharing (UNOS). The Journal of Heart and Lung Transplantation 30:4, 395-401
CrossRef48
, Julia Lemmer, Grit Heise, Axel Rentzsch, Petra Boettler, Titus Kuehne, Karl Otto Dubowy, Brigitte Peters, Bjoern Lemmer, Alfred Hager, Brigitte Stiller. (2011) Right ventricular function in grown-up patients after correction of congenital right heart disease. Clinical Research in Cardiology 100:4, 289-296
CrossRef49
Ying-xue Dong, John C. Burnett, Horng H. Chen, Sharon Sandberg, Yan-zhong Yang, Yanhua Zhang, Peng-Sheng Chen, Yong-Mei Cha. (2011) Effect of cardiac resynchronization therapy on broad neurohormone biomarkers in heart failure. Journal of Interventional Cardiac Electrophysiology 30:3, 241-249
CrossRef50
Darius Lucian Lazarus, Cynthia Anne Jackevicius, Hassan Behlouli, Helen Johansen, Louise Pilote. (2011) Population-Based Analysis of Class Effect of β Blockers in Heart Failure. The American Journal of Cardiology 107:8, 1196-1202
CrossRef51
Paul J. Hauptman, Douglas L. Mann. (2011) The vagus nerve and autonomic imbalance in heart failure: past, present, and future. Heart Failure Reviews 16:2, 97-99
CrossRef52
Hari Prasad, Jaspinder Sra, Wayne C. Levy, Dwight D. Stapleton. (2011) Influence of Predictive Modeling in Implementing Optimal Heart Failure Therapy. The American Journal of the Medical Sciences 341:3, 185-190
CrossRef53
Christopher Adlbrecht, Martin Huelsmann, Rudolf Berger, Deddo Moertl, Guido Strunk, August Oesterle, Roozbeh Ahmadi, Thomas Szucs, Richard Pacher. (2011) Cost analysis and cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home-based nurse care. European Journal of Clinical Investigation 41:3, 315-322
CrossRef54
Youhua Zhang, Todor N. Mazgalev. (2011) Arrhythmias and vagus nerve stimulation. Heart Failure Reviews 16:2, 147-161
CrossRef55
J. Daniel Hothersall, James Black, Stephen Caddick, Jeremy G Vinter, Andrew Tinker, James R. Baker. (2011) The design, synthesis and pharmacological characterization of novel β2-adrenoceptor antagonists. British Journal of Pharmacologyno-no
CrossRef56
Nagara Tamaki, Keiichiro Yoshinaga. (2011) Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology. Journal of Nuclear Cardiology 18:1, 135-143
CrossRef57
Finn Akerström, Luis Rodríguez-Padial. (2011) Hypertension, the J-Curve and the INVEST Trial. The American Journal of Cardiology 107:3, 490-491
CrossRef58
Emmae N Ramsay, Elizabeth E Roughead, Ben Ewald, Nicole L Pratt, Philip Ryan. (2011) A self-controlled case series to assess the effectiveness of beta blockers for heart failure in reducing hospitalisations in the elderly. BMC Medical Research Methodology 11:1, 106
CrossRef59
Zhongwei Cheng, Kongbo Zhu, Taibo Chen, Peng Gao, Kang’an Cheng, Ligang Fang, Hua Deng, Wenling Zhu, Quan Fang. (2011) Poor Prognosis in Chronic Heart Failure Patients With Reduced Ejection Fraction in China : poor prognosis in chronic HF patients in China. Congestive Heart Failureno
CrossRef60
Victoria Nesbitt, Roger G Whittaker, Douglass M Turnbull, Robert McFarland, Robert W Taylor. (2011) mtDNA disease for the neurologist. Future Neurology 6:1, 63-80
CrossRef61
D. Chang, T. Okano. 2011. Medical Applications of Cell Sheet Engineering. , 405-419.
CrossRef62
Lutz Frankenstein, Andrew L. Clark, Jorge P. Ribeiro. (2011) Influence of Sex on Treatment and Outcome in Chronic Heart Failure. Cardiovascular Therapeuticsno-no
CrossRef63
William Simonson, Lisa F. Han, H. Edward Davidson. (2011) Hypertension Treatment and Outcomes in US Nursing Homes: Results From the US National Nursing Home Survey. Journal of the American Medical Directors Association 12:1, 44-49
CrossRef64
Richard E. Katholi, Daniel M. Couri. (2011) Left Ventricular Hypertrophy: Major Risk Factor in Patients with Hypertension: Update and Practical Clinical Applications. International Journal of Hypertension 2011, 1-10
CrossRef65
M. Demede, A. Pandey, L. Innasimuthu, G. Jean-Louis, S. I. McFarlane, G. Ogedegbe. (2011) Management of Hypertension in High-Risk Ethnic Minority with Heart Failure. International Journal of Hypertension 2011, 1-8
CrossRef66
Arnold M. Katz. 2011. A Modern View of Heart Failure: Practical Applications of Cardiovascular Physiology. .
CrossRef67
Sangeeta C. Ahluwalia, Cary P. Gross, Sarwat I. Chaudhry, Linda Leo-Summers, Peter H. Ness, Terri R. Fried. (2011) Change in Comorbidity Prevalence with Advancing Age Among Persons with Heart Failure. Journal of General Internal Medicine
CrossRef68
Frans H Rutten. (2011) β-blockers and their mortality benefits: underprescribed in heart failure and chronic obstructive pulmonary disease. Future Cardiology 7:1, 43-53
CrossRef69
Wawaimuli Arozal, Flori R. Sari, Kenichi Watanabe, Somasundaram Arumugam, Punniyakoti T. Veeraveedu, Meilei Ma, Rajarajan A. Thandavarayan, Vijayakumar Sukumaran, Arun Prasath Lakshmanan, Yoshiyasu Kobayashi, Sayaka Mito, Vivian Soetikno, Kenji Suzuki. (2011) Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo: Effects on Cardiac Fibrosis and Hypertrophy. ISRN Pharmacology 2011, 1-8
CrossRef70
Cherissa Hanson, Keith C. Kocis, Ana Lía Graciano. 2011. Myocardial Dysfunction, Ventricular Assist Devices, and Extracorporeal Life Support. , 319-337.
CrossRef71
Vesna Radovic. (2011) Use of beta blockers in various clinical states. Medicinski pregled 64:1-2, 55-60
CrossRef72
Rachid Bouallal, François Godart, Charles Francart, Adélaïde Richard, Claude Foucher-Hossein, Christophe Lions. (2010) Interest of β-blockers in patients with right ventricular systemic dysfunction. Cardiology in the Young 20:06, 615-619
CrossRef73
Keith A Thompson, Parag Bharadwaj, Kiran J Philip, Ernst R Schwarz. (2010) Heart failure therapy: beyond the guidelines. Journal of Cardiovascular Medicine 11:12, 919-927
CrossRef74
Jian Shan, Alexander Kushnir, Matthew J. Betzenhauser, Steven Reiken, Jingdong Li, Stephan E. Lehnart, Nicolas Lindegger, Marco Mongillo, Peter J. Mohler, Andrew R. Marks. (2010) Phosphorylation of the ryanodine receptor mediates the cardiac fight or flight response in mice. Journal of Clinical Investigation 120:12, 4388-4398
CrossRef75
Jian Shan, Matthew J. Betzenhauser, Alexander Kushnir, Steven Reiken, Albano C. Meli, Anetta Wronska, Miroslav Dura, Bi-Xing Chen, Andrew R. Marks. (2010) Role of chronic ryanodine receptor phosphorylation in heart failure and β-adrenergic receptor blockade in mice. Journal of Clinical Investigation 120:12, 4375-4387
CrossRef76
Akihide Kurita, Takumi Taniguchi, Ken Yamamoto. (2010) The Effects of Carvedilol Administration on Cardiopulmonary Resuscitation in a Rat Model of Cardiac Arrest Induced by Airway Obstruction. Anesthesia & Analgesia 111:5, 1207-1210
CrossRef77
R. Bauer, A. Blain, E. Greally, K. Bushby, H. Lochmuller, S. Laval, V. Straub, G. A. MacGowan. (2010) Intolerance to -blockade in a mouse model of -sarcoglycan-deficient muscular dystrophy cardiomyopathy. European Journal of Heart Failure 12:11, 1163-1170
CrossRef78
Gennaro Cice, Attilio Di Benedetto, Salvatore D'Isa, Antonello D'Andrea, Daniele Marcelli, Emanuele Gatti, Raffaele Calabrò. (2010) Effects of Telmisartan Added to Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Hemodialysis Patients With Chronic Heart Failure. Journal of the American College of Cardiology 56:21, 1701-1708
CrossRef79
Paul Wojciechowski. (2010) Perioperative Optimization of the Heart Failure Patient. International Anesthesiology Clinics 47:4, 121-135
CrossRef80
Neiko Ozasa, Takeshi Kimura, Takeshi Morimoto, Heigen Hou, Toshihiro Tamura, Satoshi Shizuta, Yoshihisa Nakagawa, Yutaka Furukawa, Yasuhiko Hayashi, Koichi Nakao, Masunori Matsuzaki, Masakiyo Nobuyoshi, Kazuaki Mitsudo. (2010) Lack of Effect of Oral Beta-Blocker Therapy at Discharge on Long-Term Clinical Outcomes of ST-Segment Elevation Acute Myocardial Infarction After Primary Percutaneous Coronary Intervention. The American Journal of Cardiology 106:9, 1225-1233
CrossRef81
Arthur E. Fass. (2010) Chronic Coronary Disease in the Post-COURAGE Era. Cardiology in Review 18:6, 292-297
CrossRef82
Ronald Freudenberger. 2010. Management of Advanced Heart Failure. , 357-383.
CrossRef83
Ruchika Dutta, Barry H. Greenberg. 2010. Neurohormonal Blocking Agents in the Treatment of Patients with Left Ventricular Dysfunction and Heart Failure. , 83-116.
CrossRef84
Matthew J. O'Connor, David N. Rosenthal, Robert E. Shaddy. (2010) Outpatient Management of Pediatric Heart Failure. Heart Failure Clinics 6:4, 515-529
CrossRef85
Gaia Cattadori, Elisabetta Salvioni, Erica Gondoni, Piergiuseppe Agostoni. (2010) Evaluation of noninvasive exercise cardiac output determination in chronic heart failure patients: a proposal of a new diagnostic and prognostic method. Journal of Cardiovascular Medicine1
CrossRef86
Jondavid Menteer, Paul M. Macey, Mary A. Woo, Ashok Panigrahy, Ronald M. Harper. (2010) Central Nervous System Changes in Pediatric Heart Failure: A Volumetric Study. Pediatric Cardiology 31:7, 969-976
CrossRef87
David Ho, Lin Yan, Kousaku Iwatsubo, Dorothy E. Vatner, Stephen F. Vatner. (2010) Modulation of β-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5. Heart Failure Reviews 15:5, 495-512
CrossRef88
Cara N. Pellegrini, Melvin M. Scheinman. (2010) Clinical Management of Ventricular Tachycardia. Current Problems in Cardiology 35:9, 453-504
CrossRef89
John R Teerlink. (2010) Ivabradine in heart failure—no paradigm SHIFT…yet. The Lancet 376:9744, 847-849
CrossRef90
Kensuke Kimura, Hideaki Kanazawa, Masaki Ieda, Haruko Kawaguchi-Manabe, Yoshiko Miyake, Takashi Yagi, Takahide Arai, Motoaki Sano, Keiichi Fukuda. (2010) Norepinephrine-induced nerve growth factor depletion causes cardiac sympathetic denervation in severe heart failure. Autonomic Neuroscience 156:1-2, 27-35
CrossRef91
Robert McFarland, Robert W Taylor, Douglass M Turnbull. (2010) A neurological perspective on mitochondrial disease. The Lancet Neurology 9:8, 829-840
CrossRef92
Li Yue-Chun, Ge Li-Sha, Yang Peng-Lin, Tang Ji-Fei, Lin Jia-Feng, Chen Peng, Guan Xue-qiang. (2010) Carvedilol treatment ameliorates acute coxsackievirus B3-induced myocarditis associated with oxidative stress reduction. European Journal of Pharmacology 640:1-3, 112-116
CrossRef93
Willem J. Remme. (2010) Which Beta-Blocker is Most Effective in Heart Failure?. Cardiovascular Drugs and Therapy 24:4, 351-358
CrossRef94
Colin Petko, L. LuAnn Minich, Melanie D. Everitt, Richard Holubkov, Robert E. Shaddy, Lloyd Y. Tani. (2010) Echocardiographic Evaluation of Children With Systemic Ventricular Dysfunction Treated With Carvedilol. Pediatric Cardiology 31:6, 780-784
CrossRef95
Jun Wang, Kenjiro Ono, Dara L. Dickstein, Isabel Arrieta-Cruz, Wei Zhao, Xianjuan Qian, Ashley Lamparello, Rakesh Subnani, Mario Ferruzzi, Constantine Pavlides, Lap Ho, Patrick R. Hof, David B. Teplow, Giulio M. Pasinetti. (2010) Carvedilol as a potential novel agent for the treatment of Alzheimer's disease. Neurobiology of Aging
CrossRef96
Daniel G. Kramer, Thomas A. Trikalinos, David M. Kent, George V. Antonopoulos, Marvin A. Konstam, James E. Udelson. (2010) Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction. Journal of the American College of Cardiology 56:5, 392-406
CrossRef97
Andrew Voigt, Alaa Shalaby, Evan Adelstein, Samir Saba. (2010) Beta-blocker Utilization and Outcomes in Patients Receiving Cardiac Resynchronization Therapy. Clinical Cardiology 33:7, E1-E5
CrossRef98
Barry Greenberg. (2010) Managing hyponatremia in patients with heart failure. Journal of Hospital Medicine 5:S3, S33-S39
CrossRef99
(2010) Section 13: Evaluation and Therapy for Heart Failure in the Setting of Ischemic Heart Disease. Journal of Cardiac Failure 16:6, e157-e165
CrossRef100
Heart Failure Society of America. (2010) Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure 16:6, 475-539
CrossRef101
(2010) Section 7: Heart Failure in Patients With Reduced Ejection Fraction. Journal of Cardiac Failure 16:6, e73-e97
CrossRef102
D. Logeart, A. Cohen Solal. (2010) Intérêt des bêtabloquants vasodilatateurs dans l’insuffisance cardiaque. Annales de Cardiologie et d'Angéiologie 59:3, 160-167
CrossRef103
Manuel Anguita Sánchez, Manuel Jiménez-Navarro, Marisa Crespo, Luis Alonso-Pulpón, Eduardo de Teresa, Alfonso Castro-Beiras, Eulàlia Roig, Remei Artigas, Antonio Zapata, Ignacio López de Ulibarri, Javier Muñiz. (2010) Efecto de un programa de formación en atención primaria sobre la optimización del tratamiento con bloqueadores beta en pacientes ancianos con insuficiencia cardiaca. Revista Española de Cardiología 63:6, 677-685
CrossRef104
Bodh I Jugdutt. (2010) Heart failure in the elderly: advances and challenges. Expert Review of Cardiovascular Therapy 8:5, 695-715
CrossRef105
Dawood Darbar. (2010) Genomics, heart failure and sudden cardiac death. Heart Failure Reviews 15:3, 229-238
CrossRef106
Mohammad F. Huque, Mohamed Alosh, Satya D. Dubey, Rafia Bhore. 2010. P -Values, Evidence, and Multiplicity Considerations for Controlled Clinical Trials. , 949-961.
CrossRef107
Andrew Jabbour, Peter S. Macdonald, Anne M. Keogh, Eugene Kotlyar, Soren Mellemkjaer, Cathie F. Coleman, Maros Elsik, Henry Krum, Christopher S. Hayward. (2010) Differences Between Beta-Blockers in Patients With Chronic Heart Failure and Chronic Obstructive Pulmonary Disease. Journal of the American College of Cardiology 55:17, 1780-1787
CrossRef108
Massimo Giammaria, Claudio Bruna, Roberto Gnavi. (2010) Trend in implantable cardioverter defibrillators and relation to need. Journal of Cardiovascular Medicine 11:4, 265-270
CrossRef109
Hannah Asghar, Peter S. Rahko. (2010) Quality of Heart Failure Management: A Comparison of Care Between a Comprehensive Heart Failure Program and a General Cardiology Practice. Congestive Heart Failure 16:2, 65-70
CrossRef110
Jennifer NA Silva, Charles E Canter. (2010) Current management of pediatric dilated cardiomyopathy. Current Opinion in Cardiology 25:2, 80-87
CrossRef111
Joana Mascarenhas, Ana Azevedo, Paulo Bettencourt. (2010) Coexisting chronic obstructive pulmonary disease and heart failure: implications for treatment, course and mortality. Current Opinion in Pulmonary Medicine 16:2, 106-111
CrossRef112
Bernhard Maisch, Sabine Pankuweit. (2010) Therapie der fortgeschrittenen Herz - insuffizienz: medikamentös, Resynchronisation (CRT), Operation. Herz 35:2, 94-101
CrossRef113
Charles R Salters, Alison L Bailey, Thomas F Whayne. (2010) Current treatment of heart failure in the USA. Expert Review of Cardiovascular Therapy 8:2, 279-290
CrossRef114
Peter C. Hastings, Ali Vazir, Guy E. Meadows, Mark Dayer, Philip A. Poole-Wilson, Hugh F. McIntyre, Mary J. Morrell, Martin R. Cowie, Anita K. Simonds. (2010) Adaptive servo-ventilation in heart failure patients with sleep apnea: A real world study. International Journal of Cardiology 139:1, 17-24
CrossRef115
Mahdi Chowdhury, Suzanne Adams, David J. Whellan. (2010) Sleep-Disordered Breathing and Heart Failure: Focus on Obstructive Sleep Apnea and Treatment With Continuous Positive Airway Pressure. Journal of Cardiac Failure 16:2, 164-174
CrossRef116
Kyung-Duk Min, Masanori Asakura, Yulin Liao, Kenji Nakamaru, Hidetoshi Okazaki, Tomoko Takahashi, Kazunori Fujimoto, Shin Ito, Ayako Takahashi, Hiroshi Asanuma, Satoru Yamazaki, Tetsuo Minamino, Shoji Sanada, Osamu Seguchi, Atsushi Nakano, Yosuke Ando, Toshiaki Otsuka, Hidehiko Furukawa, Tadashi Isomura, Seiji Takashima, Naoki Mochizuki, Masafumi Kitakaze. (2010) Identification of genes related to heart failure using global gene expression profiling of human failing myocardium. Biochemical and Biophysical Research Communications 393:1, 55-60
CrossRef117
Miguel Yebra-Yebra, Jesús Recio, José Carlos Arévalo-Lorido, Luis Cornide-Santos, José Manuel Cerqueiro-González, Luis Manzano. (2010) Seguridad y tolerancia del tratamiento con bloqueadores beta en el paciente anciano con insuficiencia cardíaca. Estudio BETANIC. Medicina Clínica 134:4, 141-145
CrossRef118
M. T. Vidan, H. Bueno, Y. Wang, G. Schreiner, J. S. Ross, J. Chen, H. M. Krumholz. (2010) The relationship between systolic blood pressure on admission and mortality in older patients with heart failure. European Journal of Heart Failure 12:2, 148-155
CrossRef119
Akash R Patel, Robert E Shaddy. (2010) Role of β-blocker therapy in pediatric heart failure. Pediatric Health 4:1, 45-58
CrossRef120
O M Dekkers, E v. Elm, A Algra, J A Romijn, J P Vandenbroucke. (2010) How to assess the external validity of therapeutic trials: a conceptual approach. International Journal of Epidemiology 39:1, 89-94
CrossRef121
Melita Moioli, Mario Valenzano Menada, Giorgio Bentivoglio, Simone Ferrero. (2010) Peripartum cardiomyopathy. Archives of Gynecology and Obstetrics 281:2, 183-188
CrossRef122
John Lynn Jefferies, Jeffrey A Towbin. (2010) Dilated cardiomyopathy. The Lancet 375:9716, 752-762
CrossRef123
Isao Horiuchi, Yuya Kato, Arisa Nakamura, Kazuya Ishida, Masato Taguchi, Yukiya Hashimoto. (2010) Inhibitory and Stimulative Effects of Amiodarone on Metabolism of Carvedilol in Human Liver Microsomes. Biological & Pharmaceutical Bulletin 33:4, 717-720
CrossRef124
Christian Gratzke, Javier Angulo, Kanchan Chitaley, Yu-tian Dai, Noel N. Kim, Jaw-Seung Paick, Ulf Simonsen, Stefan Ãckert, Eric Wespes, Karl E. Andersson, Tom F. Lue, Christian G. Stief. (2010) Anatomy, Physiology, and Pathophysiology of Erectile Dysfunction. Journal of Sexual Medicine 7:1pt2, 445-475
CrossRef125
Mohamed Alosh, Mohammad F. Huque. (2010) A consistency-adjusted alpha-adaptive strategy for sequential testing. Statistics in Medicinen/a-n/a
CrossRef126
Tsuyoshi Matsumura, Takuhisa Tamura, Satoshi Kuru, Yasuki Kikuchi, Mitsuru Kawai. (2010) Carvedilol can Prevent Cardiac Events in Duchenne Muscular Dystrophy. Internal Medicine 49:14, 1357-1363
CrossRef127
Nezam Haider, Ragavendra R. Baliga, Y. Chandrashekhar, Jagat Narula. (2010) Adrenergic Excess, hNET1 Down-Regulation, and Compromised mIBG Uptake in Heart Failure. JACC: Cardiovascular Imaging 3:1, 71-75
CrossRef128
H. Liu, W. Li, W. Gu, Y. Kong, N. Yang, L. Chen. (2010) Immunoregulatory Effects of Carvedilol on Rat Experimental Autoimmune Myocarditis. Scandinavian Journal of Immunology 71:1, 38-44
CrossRef129
Juan Pablo Kaski, Perry Elliott. 2010. Cardiomyopathies. , 1003-1034.
CrossRef130
Yoshihisa Okazaki, Can Zheng, Meihua Li, Masaru Sugimachi. (2010) Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failure. The Journal of Physiological Sciences 60:1, 67-74
CrossRef131
Robert E. Shaddy, Daniel J. Penny. 2010. Chronic Cardiac Failure. , 257-268.
CrossRef132
Jens Seiler, William G. Stevenson. (2010) Atrial Fibrillation in Congestive Heart Failure. Cardiology in Review 18:1, 38-50
CrossRef133
Marcus L. Koller, Burghard Schumacher. (2010) Medikamentöse Therapie von Herzrhythmusstörungen. Medizinische Klinik 105:1, 26-40
CrossRef134
Anders Hovland, Anne Fagerheim, Randolf Hardersen, Erik Nielsen. (2010) Eldre mann med kjent hjertesvikt innlagt med kardiogent sjokk. Tidsskrift for Den norske legeforening 130:13, 1352-1354
CrossRef135
Gerald W. Dorn. (2009) Pharmacogenetic profiling in the treatment of heart disease. Translational Research 154:6, 295-302
CrossRef136
Usman Javed, Prakash C. Deedwania. (2009) Beta-Adrenergic Blockers for Chronic Heart Failure. Cardiology in Review 17:6, 287-292
CrossRef137
A. L. Clark, M. J. Lammiman, K. Goode, J. G.F. Cleland. (2009) Is taking part in clinical trials good for your health? A cohort study. European Journal of Heart Failure 11:11, 1078-1083
CrossRef138
Filippos Triposkiadis, George Karayannis, Grigorios Giamouzis, John Skoularigis, George Louridas, Javed Butler. (2009) The Sympathetic Nervous System in Heart Failure. Journal of the American College of Cardiology 54:19, 1747-1762
CrossRef139
Brian J. Lipworth, Peter A. Williamson. (2009) Think the impossible: β-blockers for treating asthma. Clinical Science 118:2, 115-120
CrossRef140
Elske Sieswerda, Elvira C van Dalen, Aleida Postma, Huib N Caron, Leontien CM Kremer, Elske Sieswerda. 2009. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. .
CrossRef141
(2009) Journal Club. Medizinische Klinik 104:10, 817-827
CrossRef142
D.-Y. Zhan, S. Morimoto, C.-K. Du, Y.-Y. Wang, Q.-W. Lu, A. Tanaka, T. Ide, Y. Miwa, F. Takahashi-Yanaga, T. Sasaguri. (2009) Therapeutic effect of -adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation. Cardiovascular Research 84:1, 64-71
CrossRef143
Ying Han, Lu Fu, Weiju Sun, Junxian Cao, Rongsheng Xie, Ping Zhou, Ningning Kang, Junfeng Sun. (2009) Neuroprotective effects of testosterone upon cardiac sympathetic function in rats with induced heart failure. European Journal of Pharmacology 619:1-3, 68-74
CrossRef144
Piergiuseppe Agostoni, Pietro Palermo, Mauro Contini. (2009) Respiratory Effects of β-blocker Therapy in Heart Failure. Cardiovascular Drugs and Therapy 23:5, 377-384
CrossRef145
José M. Verdú Rotellar, Alberto Barroso, María J. Bernáldez, Marcel Domínguez, Magda Pie, Francisca Sancho, Montserrat Simó, Mar Domingo. (2009) Betabloqueantes en el tratamiento de la insuficiencia cardiaca estable en atención primaria. Revista Española de Cardiología 62:10, 1141-1148
CrossRef146
Darshan Doshi, Steven O Marx. (2009) Ion Channels, Transporters, and Pumps as Targets for Heart Failure Therapy. Journal of Cardiovascular Pharmacology 54:4, 273-278
CrossRef147
G. Jondeau, Y. Neuder, J.-C. Eicher, P. Jourdain, E. Fauveau, M. Galinier, A. Jegou, F. Bauer, J. N. Trochu, A. Bouzamondo, M.-L. Tanguy, P. Lechat, . (2009) B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. European Heart Journal 30:18, 2186-2192
CrossRef148
E. Visús, E. Gargallo, P. Conthe. (2009) Novedades terapéuticas: estudio I-PRESERVE. Revista Clínica Española 209, 36-40
CrossRef149
Kuldeep Maradia, Maya Guglin. (2009) Pharmacologic Prevention of Anthracycline-Induced Cardiomyopathy. Cardiology in Review 17:5, 243-252
CrossRef150
Takumi Taniguchi, Akihide Kurita, Ken Yamamoto, Hideo Inaba. (2009) EFFECTS OF CARVEDILOL ON MORTALITY AND INFLAMMATORY RESPONSES TO SEVERE HEMORRHAGIC SHOCK IN RATS. Shock 32:3, 272-275
CrossRef151
P.A. Mehta, S. McDonagh, J. Phillips, R. Grocott-Mason, S.W. Dubrey. (2009) Angiotensin Receptor Blocker Therapy for Heart Failure Patients: Is Combination Treatment a Feasible Prospect?. Clinical Cardiology 32:9, 513-518
CrossRef152
Annick Préfontaine, Angelino Calderone, Jocelyn Dupuis. (2009) Downregulation of the Endothelin System of Lung Myofibroblasts in Congestive Heart Failure. Journal of Cardiovascular Pharmacology 54:2, 147-153
CrossRef153
Eileen M. Hsich, Ileana L. Piña. (2009) Heart Failure in Women. Journal of the American College of Cardiology 54:6, 491-498
CrossRef154
James S Zebrack, Mark Munger, John MacGregor, William L Lombardi, Gregory P Stoddard, Edward M Gilbert. (2009) β-Receptor Selectivity of Carvedilol and Metoprolol Succinate in Patients with Heart Failure (SELECT Trial): A Randomized Dose-Ranging Trial. Pharmacotherapy 29:8, 883-890
CrossRef155
M. Klapholz. (2009) -Blocker Use for the Stages of Heart Failure. Mayo Clinic Proceedings 84:8, 718-729
CrossRef156
Michala E Pedersen, John R Cockcroft. (2009) What is the role, if any, for beta-blockers as initial therapy for uncomplicated hypertension?. Current Opinion in Cardiology 24:4, 325-332
CrossRef157
Steven M. Shaw, Jonathan Hasleton, Simon G. Williams. (2009) β-Blocker Use in Heart Failure Patients with Airways Disease. Clinical Cardiology 32:7, 393-396
CrossRef158
K. De Silva, R. Katbamna. (2009) Principles of heart failure. InnovAiT 2:7, 423-429
CrossRef159
Andrew D. Sumner, John P. Boehmer, Leslie A. Saxon, Peter Carson, Arthur M. Feldman, Elizabeth Galle, Michael R. Bristow. (2009) Statin Use Is Associated With Improved Survival in Patients With Advanced Heart Failure Receiving Resynchronization Therapy. Congestive Heart Failure 15:4, 159-164
CrossRef160
Paolo Palatini. (2009) Elevated Heart Rate in Cardiovascular Diseases: A Target for Treatment?. Progress in Cardiovascular Diseases 52:1, 46-60
CrossRef161
Veselin Mitrovic, Karl-Friedrich Appel, Nicolaos Proskynitopoulos, Seyfettin Dereli, Christian Wilhelm Hamm. (2009) Effects of candesartan cilexetil “add-on” treatment in congestive heart failure outpatients in daily practice. Clinical Research in Cardiology 98:6, 379-389
CrossRef162
Jason H Karnes, Rhonda M Cooper-DeHoff. (2009) Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. Expert Review of Cardiovascular Therapy 7:6, 689-702
CrossRef163
Simonetta Genovesi, Daniela M. Prata Pizzala, Massimo Pozzi, Laura Ratti, Maria Milanese, Federico Pieruzzi, Antonio Vincenti, Andrea Stella, Giuseppe Mancia, Marco Stramba
Badiale. (2009) QT interval prolongation and decreased heart rate variability in cirrhotic patients: relevance of hepatic venous pressure gradient and serum calcium. Clinical Science 116:12, 851-859
CrossRef164
Gerald W. Dorn. (2009) GRK mythology: G-protein receptor kinases in cardiovascular disease. Journal of Molecular Medicine 87:5, 455-463
CrossRef165
Ramzan M. Zakir, Alain Folefack, Muhamed Saric, Robert L. Berkowitz. (2009) The Use of Midodrine in Patients With Advanced Heart Failure. Congestive Heart Failure 15:3, 108-111
CrossRef166
Rodrigo Troncoso, Francisco Moraga, Mario Chiong, Juan Roldán, Roberto Bravo, Rodrigo Valenzuela, Guillermo Díaz-Araya, Andrea del Campo, Carlos Sanhueza, Andrea Rodriguez, José Luis Vukasovic, Rosemarie Mellado, Douglas Greig, Pablo F. Castro, Sergio Lavandero. (2009) Gln 27 →Gluβ 2 -Adrenergic Receptor Polymorphism in Heart Failure Patients: Differential Clinical and Oxidative Response to Carvedilol. Basic & Clinical Pharmacology & Toxicology 104:5, 374-378
CrossRef167
Gregg C Fonarow. (2009) Role of carvedilol controlled-release in cardiovascular disease. Expert Review of Cardiovascular Therapy 7:5, 483-498
CrossRef168
G. Tasevska-Dinevska, L. M. A. Kennedy, P. M. Nilsson, R. Willenheimer. (2009) Gender aspects on heart failure incidence and mortality in a middle-aged, urban, community-based population sample: the Malmö preventive project. European Journal of Epidemiology 24:5, 249-257
CrossRef169
Krishna K. Gaddam, Anil Verma, Mark Thompson, Rohit Amin, Hector Ventura. (2009) Hypertension and Cardiac Failure in its Various Forms. Medical Clinics of North America 93:3, 665-680
CrossRef170
Mitsunori Nishiyama, In-Sam Park, Tadahiro Yoshikawa, Yoshiho Hatai, Makoto Ando, Yukihiro Takahashi, Katsuhiko Mori, Yasuo Murakami. (2009) Efficacy and safety of carvedilol for heart failure in children and patients with congenital heart disease. Heart and Vessels 24:3, 187-192
CrossRef171
Jinyao Liu, Seiko Shirafuji, Tatsuya Fujimiya. (2009) Rats in acute withdrawal from ethanol exhibit left ventricular systolic dysfunction and cardiac sympathovagal balance shift. Alcohol 43:3, 207-216
CrossRef172
Yuji Nagatomo, Tsutomu Yoshikawa, Takashi Kohno, Akihiro Yoshizawa, Akiyasu Baba, Toshihisa Anzai, Tomomi Meguro, Toru Satoh, Satoshi Ogawa. (2009) A Pilot Study on the Role of Autoantibody Targeting the β1-Adrenergic Receptor in the Response to β-blocker Therapy for Congestive Heart Failure. Journal of Cardiac Failure 15:3, 224-232
CrossRef173
Saraswathy Manickavasagam, Ramanna Merla, Michael M Koerner, Ken Fujise, Sanjay Kunapuli, Salvatore Rosanio, Alejandro Barbagelata. (2009) Management of hypertension in chronic heart failure. Expert Review of Cardiovascular Therapy 7:4, 423-433
CrossRef174
Giorgio Costantino, Anna Maria Rusconi, Pier Giorgio Duca, Stefano Guzzetti, Ilaria Bossi, Marta Medico, Giuseppina Pisano, Mara Bulgheroni, Monica Solbiati, Raffaello Furlan, Nicola Montano. (2009) Eligibility criteria in heart failure randomized controlled trials: a gap between evidence and clinical practice. Internal and Emergency Medicine 4:2, 117-122
CrossRef175
GRZEGORZ PIETRASIK, ILAN GOLDENBERG, SCOTT McNITT, BRONISLAVA POLONSKY, ARTHUR J. MOSS, WOJCIECH ZAREBA. (2009) Efficacy of Medical Therapy for the Reduction of Heart Failure Events in Patients with Implanted Cardioverter Defibrillators. Journal of Cardiovascular Electrophysiology 20:4, 395-400
CrossRef176
Sharon Ann Hunt, William T. Abraham, Marshall H. Chin, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Mariell Jessup, Marvin A. Konstam, Donna M. Mancini, Keith Michl, John A. Oates, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy. (2009) 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology 53:15, e1-e90
CrossRef177
Mariell Jessup, William T. Abraham, Donald E. Casey, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Marvin A. Konstam, Donna M. Mancini, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy. (2009) 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology 53:15, 1343-1382
CrossRef178
Nicholas J. Stamato. (2009) On Being Critical of Implantable Cardioverter-Defibrillator Therapy. Journal of the American College of Cardiology 53:13, 1162-1162
CrossRef179
M. J Calvert, A. Shankar, R. J McManus, R. Ryan, N. Freemantle. (2009) Evaluation of the management of heart failure in primary care. Family Practice 26:2, 145-153
CrossRef180
R. Willenheimer. (2009) The current role of beta-blockers in chronic heart failure: with special emphasis on the CIBIS III trial. European Heart Journal Supplements 11:Suppl A, A15-A20
CrossRef181
Donah Zachariah, Philip A. Kalra, Paul R. Kalra. (2009) OPTIMAL MANAGEMENT OF CHRONIC HEART FAILURE IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Journal of Renal Care 35:1, 2-10
CrossRef182
Seine Chiang, Kimberly A Gerten, Evelyn Granieri, Holly E Richter. (2009) Pharmacologic management of the older woman undergoing surgery. Women's Health 5:2, 205-219
CrossRef183
E. Erdmann. (2009) Safety and tolerability of beta-blockers: prejudices and reality. European Heart Journal Supplements 11:Suppl A, A21-A25
CrossRef184
Salvador Manoel Serra, Ricardo Vivacqua Costa, Renata Rodrigues Teixeira De Castro, Sergio Salles Xavier, Antonio Claudio Lucas Da Nóbrega. (2009) Cholinergic Stimulation Improves Autonomic and Hemodynamic Profile During Dynamic Exercise in Patients With Heart Failure. Journal of Cardiac Failure 15:2, 124-129
CrossRef185
Priyesh A. Patel, Douglas G. Tilley, Howard A. Rockman. (2009) Physiologic and cardiac roles of β-arrestins. Journal of Molecular and Cellular Cardiology 46:3, 300-308
CrossRef186
P.A. Mehta, S.W. Dubrey. (2009) High output heart failure. QJM 102:4, 235-241
CrossRef187
John F. MacGregor, S. Blake Wachter, Mark Munger, Greg Stoddard, Michael R. Bristow, Edward M. Gilbert. (2009) Carvedilol Produces Sustained Long-Term Benefits: Follow-Up at 12 Years. Congestive Heart Failure 15:1, 5-8
CrossRef188
Matthew R.G. Taylor, Dobromir Slavov, Kurt Humphrey, Lan Zhao, Jennifer Cockroft, Xiao Zhu, Philip Lavori, Michael R. Bristow, Luisa Mestroni, Laura C. Lazzeroni. (2009) Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure. Pharmacogenetics and Genomics 19:1, 35-43
CrossRef189
Denis Roy, Mario Talajic, Marc Dubuc, Bernard Thibault, Peter Guerra, Laurent Macle, Paul Khairy. (2009) Atrial fibrillation and congestive heart failure. Current Opinion in Cardiology 24:1, 29-34
CrossRef190
Kazuya Ishida, Masato Taguchi, Teruaki Akao, Yukiya Hashimoto. (2009) Involvement of the CYP1A Subfamily in Stereoselective Metabolism of Carvedilol in β-Naphthoflavone-Treated Caco-2 Cells. Biological & Pharmaceutical Bulletin 32:3, 513-516
CrossRef191
Gus Q. Zhang, Weiguo Zhang. (2009) Heart rate, lifespan, and mortality risk. Ageing Research Reviews 8:1, 52-60
CrossRef192
Beate Aurich-Barrera, Lynda V. Wilton, Saad A.W. Shakir. (2009) Use and Risk Management of Carvedilol for the Treatment of Heart Failure in the Community in England. Drug Safety 32:1, 43-54
CrossRef193
Brian J Lipworth, Peter A Williamson. (2009) β blockers for asthma: a double-edged sword. The Lancet 373:9658, 104-105
CrossRef194
Adrian F. Hernandez, Bradley G. Hammill, Christopher M. O'Connor, Kevin A. Schulman, Lesley H. Curtis, Gregg C. Fonarow. (2009) Clinical Effectiveness of Beta-Blockers in Heart Failure. Journal of the American College of Cardiology 53:2, 184-192
CrossRef195
Laurent Fauchier, Caroline Grimard, Bertrand Pierre, Emilie Nonin, Laurent Gorin, Bruno Rauzy, Pierre Cosnay, Dominique Babuty, Bernard Charbonnier. (2009) Comparison of Beta Blocker and Digoxin Alone and in Combination for Management of Patients With Atrial Fibrillation and Heart Failure. The American Journal of Cardiology 103:2, 248-254
CrossRef196
George V. Moukarbel, Scott D. Solomon. (2008) Treatment of asymptomatic left ventricular dysfunction. Current Treatment Options in Cardiovascular Medicine 10:6, 476-485
CrossRef197
K ITO, Y KIMURA, Y HIROOKA, Y SAGARA, K SUNAGAWA. (2008) Activation of Rho-kinase in the brainstem enhances sympathetic drive in mice with heart failure. Autonomic Neuroscience 142:1-2, 77-81
CrossRef198
Murray D. Esler, Nina Eikelis, Elisabeth Lambert, Nora Straznicky. (2008) Neural mechanisms and management of obesity-related hypertension. Current Cardiology Reports 10:6, 456-463
CrossRef199
Todd Neideen, Michelle Lam, Karen J. Brasel. (2008) Preinjury Beta Blockers are Associated With Increased Mortality in Geriatric Trauma Patients. The Journal of Trauma: Injury, Infection, and Critical Care 65:5, 1016-1020
CrossRef200
Ji Chen, Ernest V. Garcia, Stamatios Lerakis, Maureen M. Henneman, Jeroen J. Bax, Mark A. Trimble, Salvador Borges-Neto, Eric J. Velazquez, Ami E. Iskandrian. (2008) Left Ventricular Mechanical Dyssynchrony as Assessed by Phase Analysis of ECG-Gated SPECT Myocardial Perfusion Imaging. Echocardiography 25:10, 1186-1194
CrossRef201
Willem J. Remme. (2008) Beta-blockade as First-line Therapy in the Elderly Heart Failure Patient—the Proper Approach or Asking for Trouble?. Cardiovascular Drugs and Therapy 22:5, 347-350
CrossRef202
Hamza Duygu, Ugur Turk, Oner Ozdogan, Serdar Akyuz, Bahadir Kirilmaz, Emin Alioglu, Ramazan Gunduz, Yasemin Turan Bozkaya, Cuneyt Turkoglu, Serdar Payzin. (2008) Levosimendan versus Dobutamine in Heart Failure Patients Treated Chronically with Carvedilol. Cardiovascular Therapeutics 26:3, 182-188
CrossRef203
David C. Ishizawar, Karen M. Janosko, Jeffrey J. Teuteberg, Linda M. Cadaret, Michael A. Mathier, Dennis M. McNamara. (2008) The ß1-Adrenergic Receptor Mediates the Pharmacogenetic Interaction of the ACE D Allele and ß-Blockers. Clinical and Translational Science 1:2, 151-154
CrossRef204
Daniel E. Forman. (2008) Heart failure in older adults. Current Cardiovascular Risk Reports 2:5, 390-397
CrossRef205
George Mak, Niamh F. Murphy, Akbar Ali, Alison Walsh, Christina O'loughlin, Carmel Conlon, Dermot McCaffrey, Mark Ledwidge, Kenneth McDonald. (2008) Multiple Neurohumoral Modulating Agents in Systolic Dysfunction Heart Failure: Are We Lowering Blood Pressure Too Much?. Journal of Cardiac Failure 14:7, 555-560
CrossRef206
Theresa A McDonagh. (2008) Challenges in advanced chronic heart failure: drug therapy. Future Cardiology 4:5, 517-525
CrossRef207
William T. Abraham. (2008) Switching to Evidence-Based Once-Daily β-Blockers for Improved Adherence to Medication Across the Continuum of Post-Myocardial Infarction Left Ventricular Dysfunction and Heart Failure. Congestive Heart Failure 14:5, 272-280
CrossRef208
Julian O.M. Ormerod, Houman Ashrafian, Michael P. Frenneaux. (2008) Impaired energetics in heart failure — A new therapeutic target. Pharmacology & Therapeutics 119:3, 264-274
CrossRef209
A. Mano, T. Nakatani, N. Oda, T. Kato, K. Niwaya, O. Tagusari, H. Nakajima, T. Funatsu, S. Hashimoto, K. Komamura, A. Hanatani, I.H. Ueda, M. Kitakaze, J. Kobayashi, T. Yagihara, S. Kitamura. (2008) Which Factors Predict the Recovery of Natural Heart Function After Insertion of a Left Ventricular Assist System?. The Journal of Heart and Lung Transplantation 27:8, 869-874
CrossRef210
Marc A. Simon, John Watson, J. Timothy Baldwin, William R. Wagner, Harvey S. Borovetz. (2008) Current and Future Considerations in the Use of Mechanical Circulatory Support Devices*. Annual Review of Biomedical Engineering 10:1, 59-84
CrossRef211
Dimitris Tousoulis, Charalambos Antoniades, Apostolos Drolias, Elli Stefanadi, Kyriakoyla Marinou, Carmen Vasiliadou, Costas Tsioufis, Kostas Toutouzas, George Latsios, Christodoulos Stefanadis. (2008) Selective Serotonin Reuptake Inhibitors Modify the Effect of β-Blockers on Long-Term Survival of Patients With End-Stage Heart Failure and Major Depression. Journal of Cardiac Failure 14:6, 456-464
CrossRef212
Murray Esler, Rosemary Schwarz, Marlies Alvarenga. (2008) Mental stress is a cause of cardiovascular diseases: from scepticism to certainty. Stress and Health 24:3, 175-180
CrossRef213
Michael Kindermann, M. Bohm. (2008) Aktuelle konservative Therapie der chronischen Herzinsuffizienz. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 22:4, 184-196
CrossRef214
Kazuhiko Hanada, Kazuhiko Asari, Masako Saito, Jun-ichi Kawana, Mitsuo Mita, Hiroyasu Ogata. (2008) Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: Effects of carvedilol enantiomers. European Journal of Pharmacology 589:1-3, 194-200
CrossRef215
D. P. Macfarlane, K. R. Paterson, M. Fisher. (2008) Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes. Diabetes, Obesity and Metabolism 10:7, 533-544
CrossRef216
W. J. Remme, J. J.V. McMurray, F.D. R. Hobbs, A. Cohen-Solal, J. Lopez-Sendon, A. Boccanelli, F. Zannad, B. Rauch, K. Keukelaar, C. Macarie, W. Ruzyllo, C. Cline, . (2008) Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. European Heart Journal 29:14, 1739-1752
CrossRef217
George D. Giannoglou, Yiannis S. Chatzizisis, Chrysanthos Zamboulis, George E. Parcharidis, Dimitri P. Mikhailidis, George E. Louridas. (2008) Elevated heart rate and atherosclerosis: An overview of the pathogenetic mechanisms
. International Journal of Cardiology 126:3, 302-312
CrossRef218
J. H. O’Keefe, H. Abuissa, B. Pitt. (2008) Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes, Obesity and Metabolism 10:6, 492-497
CrossRef219
Emmanuel M. Kanoupakis, Emmanuel G. Manios, Hercules E. Mavrakis, Eleftherios M. Kallergis, George M. Lyrarakis, Emmanuel P. Koutalas, Panos E. Vardas. (2008) Electrophysiological Effects of Carvedilol Administration in Patients with Dilated Cardiomyopathy. Cardiovascular Drugs and Therapy 22:3, 169-176
CrossRef220
Mototsugu Nishii, Takayuki Inomata, Hitoshi Takehana, Takashi Naruke, Tomoyoshi Yanagisawa, Masahiko Moriguchi, Sadao Takeda, Tohru Izumi. (2008) Prognostic Utility of B-Type Natriuretic Peptide Assessment in Stable Low-Risk Outpatients With Nonischemic Cardiomyopathy After Decompensated Heart Failure. Journal of the American College of Cardiology 51:24, 2329-2335
CrossRef221
Alberto J. Kaumann, Peter Molenaar. (2008) The low-affinity site of the β1-adrenoceptor and its relevance to cardiovascular pharmacology. Pharmacology & Therapeutics 118:3, 303-336
CrossRef222
Howard J. Eisen. (2008) Exercise Training and Myocardial Energetics in Patients With Heart Failure. Journal of the American College of Cardiology 51:19, 1892-1895
CrossRef223
Meinrad Beer, Doris Wagner, Jonathan Myers, Jörn Sandstede, Herbert Köstler, Dietbert Hahn, Stefan Neubauer, Paul Dubach. (2008) Effects of Exercise Training on Myocardial Energy Metabolism and Ventricular Function Assessed by Quantitative Phosphorus-31 Magnetic Resonance Spectroscopy and Magnetic Resonance Imaging in Dilated Cardiomyopathy. Journal of the American College of Cardiology 51:19, 1883-1891
CrossRef224
Andreas Brieke, Joseph Cleveland, JoAnn Lindenfeld. (2008) Mechanical support in acute and chronic heart failure. Current Cardiology Reports 10:3, 168-175
CrossRef225
Aysha Arshad, Anisha Mandava, Ganesh Kamath, Dan Musat. (2008) Sudden Cardiac Death and the Role of Medical Therapy. Progress in Cardiovascular Diseases 50:6, 420-438
CrossRef226
Carter Coberley, Greg Morrow, Matthew McGinnis, Aaron Wells, Sadie Coberley, Patty Orr, Dexter Shurney. (2008) Increased Adherence to Cardiac Standards of Care during Participation in Cardiac Disease Management Programs. Disease Management 11:2, 111-118
CrossRef227
Tamara B. Horwich, Holly R. Middlekauff. (2008) Potential Autonomic Nervous System Effects of Statins in Heart Failure. Heart Failure Clinics 4:2, 163-170
CrossRef228
Thomas Dieterle, Matthias Pfisterer, Hanspeter Brunner-La Rocca. (2008) Heart failure in the elderly. Aging Health 4:2, 137-155
CrossRef229
Stefanie Albers, Bernd Meibohm, Thomas S. Mir, Stephanie Läer. (2008) Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. British Journal of Clinical Pharmacology 65:4, 511-522
CrossRef230
David S Feldman, Terry S Elton, Benjamin Sun, Mickey M Martin, Mark T Ziolo. (2008) Mechanisms of Disease: detrimental adrenergic signaling in acute decompensated heart failure. Nature Clinical Practice Cardiovascular Medicine 5:4, 208-218
CrossRef231
N S Kirkby, P W F Hadoke, A J Bagnall, D J Webb. (2008) The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?. British Journal of Pharmacology 153:6, 1105-1119
CrossRef232
Shigefumi Fukui, Yoshihiro Fukumoto, Jun Suzuki, Kenya Saji, Jun Nawata, Shunsuke Tawara, Tsuyoshi Shinozaki, Yutaka Kagaya, Hiroaki Shimokawa. (2008) Long-term Inhibition of Rho-kinase Ameliorates Diastolic Heart Failure in Hypertensive Rats. Journal of Cardiovascular Pharmacology 51:3, 317-326
CrossRef233
Joana Mascarenhas, Patrícia Lourenço, Ricardo Lopes, Ana Azevedo, Paulo Bettencourt. (2008) Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. American Heart Journal 155:3, 521-525
CrossRef234
Maurizio Gasparini, François Regoli, Carlo Ceriotti, Paola Galimberti, Renato Bragato, Stefano De Vita, Daniela Pini, Bruno Andreuzzi, Maurizio Mangiavacchi, Catherine Klersy. (2008) Remission of left ventricular systolic dysfunction and of heart failure symptoms after cardiac resynchronization therapy: Temporal pattern and clinical predictors. American Heart Journal 155:3, 507-514
CrossRef235
Genevieve Flannery, Rosie Gehrig-Mills, Baki Billah, Henry Krum. (2008) Analysis of Randomized Controlled Trials on the Effect of Magnitude of Heart Rate Reduction on Clinical Outcomes in Patients With Systolic Chronic Heart Failure Receiving Beta-Blockers. The American Journal of Cardiology 101:6, 865-869
CrossRef236
Y. O. Xu-Cai, D. J. Brotman, C. O. Phillips, F. A. Michota, W. H. W. Tang, C. M. Whinney, A. Panneerselvam, E. D. Hixson, M. Garcia, G. S. Francis, A. K. Jaffer. (2008) Outcomes of Patients With Stable Heart Failure Undergoing Elective Noncardiac Surgery. Mayo Clinic Proceedings 83:3, 280-288
CrossRef237
Nicola A. Hanania, Supria Singh, Rami El-Wali, Michael Flashner, Amie E. Franklin, William J. Garner, Burton F. Dickey, Sergio Parra, Stephen Ruoss, Felix Shardonofsky, Brian J. O’Connor, Clive Page, Richard A. Bond. (2008) The safety and effects of the beta-blocker, nadolol, in mild asthma: An open-label pilot study. Pulmonary Pharmacology & Therapeutics 21:1, 134-141
CrossRef238
S Nonen, H Okamoto, Y Fujio, Y Takemoto, M Yoshiyama, T Hamaguchi, Y Matsui, J Yoshikawa, A Kitabatake, J Azuma. (2008) Polymorphisms of norepinephrine transporter and adrenergic receptor α1D are associated with the response to β-blockers in dilated cardiomyopathy. The Pharmacogenomics Journal 8:1, 78-84
CrossRef239
William H Frishman, Wilbert S Aronow, Angela Cheng-Lai. 2008. Cardiovascular Drug Therapy in the Elderly. , 99-136.
CrossRef240
David M. Kaye, Masahiko Hoshijima, Kenneth R. Chien. (2008) Reversing Advanced Heart Failure by Targeting Ca 2+ Cycling. Annual Review of Medicine 59:1, 13-28
CrossRef241
John A. McClung, Michele Nanna, Wilbert S. Aronow. 2008. Cardiomyopathies in the Elderly. , 493-516.
CrossRef242
Jens Rosenberg, Finn Gustafsson. (2008) Bisoprolol for congestive heart failure. Expert Opinion on Pharmacotherapy 9:2, 293-300
CrossRef243
Rui Lin, Hui Peng, Long P. Nguyen, Noor B. Dudekula, Felix Shardonofsky, Brian J. Knoll, Sergio Parra, Richard A. Bond. (2008) Changes in β2-adrenoceptor and other signaling proteins produced by chronic administration of ‘β-blockers’ in a murine asthma model. Pulmonary Pharmacology & Therapeutics 21:1, 115-124
CrossRef244
Paul J. Hauptman. (2008) Medication adherence in heart failure. Heart Failure Reviews 13:1, 99-106
CrossRef245
M. Imazio, A. Cotroneo, G. Gaschino, A. Chinaglia, P. Gareri, R. Lacava, T. D. Voci, R. Trinchero. (2008) Management of heart failure in elderly people. International Journal of Clinical Practice 62:2, 270-280
CrossRef246
Salpy V. Pamboukian, Imran Nisar, Sheetal Patel, Liping Gu, Mary McLeod, Maria Rosa Costanzo, Alain Heroux. (2008) Factors Associated with Non-adherence to Therapy with Warfarin in a Population of Chronic Heart Failure Patients. Clinical Cardiology 31:1, 30-34
CrossRef247
John M. MacGregor, John E. Rush, Elizabeth A. Rozanski, Dawn M. Boothe, Albert A. Belmonte, Lisa M. Freeman. (2008) Comparison of pharmacodynamic variables following oral versus transdermal administration of atenolol to healthy cats. American Journal of Veterinary Research 69:1, 39-44
CrossRef248
Darcy A. Lamb, David F. Blackburn, Anne M. PausJenssen, William M. Semchuk, Patrick Robertson. (2008) Heart failure: Back to basics for pharmacists. Canadian Pharmacists Journal 141:1, 48-57
CrossRef249
J.-P. Emeriau, F. Lamouliatte. (2008) Gestione dell’insufficienza cardiaca delle persone anziane. EMC - AKOS - Trattato di Medicina 10:2, 1-10
CrossRef250
Philip F. Binkley, Amanda Lesinski, Jeanette Pohorence Ferguson, Patricia S. Hatton, Laura Yamokoski, Sheetal Hardikar, Glen E. Cooke, Carl V. Leier. (2008) Recovery of normal ventricular function in patients with dilated cardiomyopathy: Predictors of an increasingly prevalent clinical event. American Heart Journal 155:1, 69-74
CrossRef251
Kazuya Ishida, Shigehiro Taira, Hiroki Morishita, Yuichiro Kayano, Masato Taguchi, Yukiya Hashimoto. (2008) Stereoselective Oxidation and Glucuronidation of Carvedilol in Human Liver and Intestinal Microsomes. Biological & Pharmaceutical Bulletin 31:6, 1297-1300
CrossRef252
Søren Rasmussen, Steen Z. Abildstrom, Jeppe N. Rasmussen, Gunnar H. Gislason, Tina K. Schramm, Fredrik Folke, Lars Køber, Christian Torp-Pedersen, Mette Madsen. (2008) Hospital Variation in Use of Secondary Preventive Medicine After Discharge for First Acute Myocardial Infarction During 1995–2004. Medical Care 46:1, 70-77
CrossRef253
Seth B. Furgeson, Michel Chonchol. (2008) Review: β-Blockade in Chronic Dialysis Patients. Seminars in Dialysis 21:1, 43-48
CrossRef254
Dragan Kovačić, Matej Marinšek, Lidija Gobec, Mitja Lainščak, Matej Podbregar. (2008) Effect of selective and non-selective β-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clinical Research in Cardiology 97:1, 24-31
CrossRef255
Isao Horiuchi, Takashi Nozawa, Nozomu Fujii, Hiroshi Inoue, Mutsuko Honda, Takako Shimizu, Masato Taguchi, Yukiya Hashimoto. (2008) Pharmacokinetics of R- and S-Carvedilol in Routinely Treated Japanese Patients with Heart Failure. Biological & Pharmaceutical Bulletin 31:5, 976-980
CrossRef256
S. L. Nuttall, N. J. Langford, M. J. Kendall. (2008) Beta-blockers in heart failure. 2. Mode of action. Journal of Clinical Pharmacy and Therapeutics 26:1, 1
CrossRef257
RICHARD W. TROUGHTON, JAY RITZEMA-CARTER, M. GARY NICHOLLS. 2008. Role of Neurohormones. , 345-366.
CrossRef258
Masakazu Komoriya, Shinobu Imai, Hiroshi Aoyama, Hideki Yagi, Masaaki Nagashima, Mitsunobu Enomoto, Kazutaka Suzuki, Satoshi Yamaji, Hidehito Takase, Kagari Matsudaira, Naoyuki Takahashi, Fumio Saito, Hiroshi Yagi, Toshio Kushiro, Ken Nagao, Atsushi Hirayama. (2008) Long-term Prognosis for Non-ischemic Heart Disease Patients with Premature Ventricular Contraction and Non-sustained Ventricular Tachycardia. Journal of Arrhythmia 24:1, 18-25
CrossRef259
Li Yue-Chun, Ge Li-Sha, Ren Jiang-Hua, Yang Peng-Lin, Lin Jia-Feng, Tang Ji-Fei, Chen Peng, Yang Zhan-Qiu. (2008) Protective Effects of Carvedilol in Murine Model With the Coxsackievirus B3-Induced Viral Myocarditis. Journal of Cardiovascular Pharmacology 51:1, 92-98
CrossRef260
Arthur L. Riba. (2008) Evidence-Based Performance and Quality Improvement in the Acute Cardiac Care Setting. Critical Care Clinics 24:1, 201-229
CrossRef261
Benoît Allenet, Étienne Brudieu, Jean-Philippe Baguet, François Gimenez†, Claude Cassat. 2008. Traitement de l'insuffisance cardiaque. , 101-125.
CrossRef262
Vance W. Berger, Valerie L. Durkalski. 2007. Run-In Period. .
CrossRef263
Alipio Mangas Rojas, Francisco Gómez Rodríguez. (2007) Tratamiento multifactorial de la arteriosclerosis. Medicina Clínica 129:20, 785-796
CrossRef264
Chiung-Zuan Chiu, Jun-Jack Cheng. (2007) Congestive Heart Failure in the Elderly. International Journal of Gerontology 1:4, 143-152
CrossRef265
Julio A. Barcena, James C. Fang. (2007) Diagnosis and treatment of sleep apnea in heart disease. Current Treatment Options in Cardiovascular Medicine 9:6, 501-509
CrossRef266
Steven Sutcliffe, Charles Phillips, Des Watson, Chris Davidson. (2007) Trends in heart failure mortality in England and Wales since 1950. European Journal of Internal Medicine 18:8, 576-580
CrossRef267
Anastasios Lymperopoulos, Giuseppe Rengo, Walter J. Koch. (2007) Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. Trends in Molecular Medicine 13:12, 503-511
CrossRef268
Mark A. Oyama, D. David Sisson, Robert Prošek, Barret J. Bulmer, Mike W. Luethy, Virginia Luis Fuentes. (2007) Carvedilol in Dogs with Dilated Cardiomyopathy. Journal of Veterinary Internal Medicine 21:6, 1272-1279
CrossRef269
Mitja Lainscak, Christine Moullet, Norbert Schön, Michal Tendera. (2007) Treatment of chronic heart failure with carvedilol in daily practice: The SATELLITE survey experience. International Journal of Cardiology 122:2, 149-155
CrossRef270
Brian D. Lowes, Ronald Zolty, Simon F. Shakar, Andreas Brieke, Norman Gray, Michael Reed, Mihail Calalb, Wayne Minobe, JoAnn Lindenfeld, Eugene E. Wolfel, Mark Geraci, Michael R. Bristow, Joseph Cleveland. (2007) Assist Devices Fail to Reverse Patterns of Fetal Gene Expression Despite β-Blockers. The Journal of Heart and Lung Transplantation 26:11, 1170-1176
CrossRef271
Jin-Shiung Cheng, Chorng-Chih Huang, Chiang-Ting Chou, Chung-Ren Jan. (2007) Mechanisms of carvedilol-induced [Ca2+]i rises and death in human hepatoma cells. Naunyn-Schmiedeberg's Archives of Pharmacology 376:3, 185-194
CrossRef272
Wilbert S. Aronow. (2007) Heart Failure–Complicating Acute Myocardial Infarction. Heart Failure Clinics 3:4, 465-475
CrossRef273
P Molenaar, L Chen, ABT Semmler, WA Parsonage, AJ Kaumann. (2007) HUMAN HEART ?-ADRENOCEPTORS: ? 1 -ADRENOCEPTOR DIVERSIFICATION THROUGH ?AFFINITY STATES? AND POLYMORPHISM. Clinical and Experimental Pharmacology and Physiology 34:10, 1020-1028
CrossRef274
Ali Ahmed. (2007) DEFEAT Heart Failure: Clinical Manifestations, Diagnostic Assessment, and Etiology of Geriatric Heart Failure. Heart Failure Clinics 3:4, 389-402
CrossRef275
Gabriella Malfatto, Giovanna Branzi, Francesca Ciambellotti, Paola Valli, Caterina Bizzi, Mario Facchini. (2007) Different ventricular remodelling and autonomic modulation after long-term beta-blocker treatment in hypertensive, ischaemic and idiopathic dilated cardiomyopathy. Journal of Cardiovascular Medicine 8:10, 840-845
CrossRef276
David A Barton, Tye Dawood, Elisabeth A Lambert, Murray D Esler, Deepak Haikerwal, Celia Brenchley, Florentia Socratous, David M Kaye, Markus P Schlaich, Ian Hickie, Gavin W Lambert. (2007) Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk?. Journal of Hypertension 25:10, 2117-2124
CrossRef277
Aaron S. Blom, Michael A. Acker. (2007) The Surgical Treatment of End-Stage Heart Failure. Current Problems in Cardiology 32:10, 553-599
CrossRef278
Abdolkarim Sheikhi ., Yahya Jaberi ., Abdolreza Esmaeilzadeh ., Mohammad Khani ., Mehdi Moosaeefard ., Mostafa Shafaqatian .. (2007) The Effect of Cardiovascular Drugs on Pro-Inflammatory Cytokine Secretion and Natural Killer Activity of Peripheral Blood Mononuclear Cells of Patients with Chronic Heart Failure In vitro. Pakistan Journal of Biological Sciences 10:10, 1580-1587
CrossRef279
Wilbert S. Aronow. (2007) Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly. Heart Failure Clinics 3:4, 423-436
CrossRef280
James F. Neuenschwander, Ragavendra R. Baliga. (2007) Acute Decompensated Heart Failure. Critical Care Clinics 23:4, 737-758
CrossRef281
Aritomo Inoue, Shinichiro Fujimoto, Shohei Yamashina, Junichi Yamazaki. (2007) Prediction of cardiac events in patients with dilated cardiomyopathy using 123I-BMIPP and 201Tl myocardial scintigraphy. Annals of Nuclear Medicine 21:7, 399-404
CrossRef282
Sakir Arslan, Mustafa Kemal Erol, Engin Bozkurt, Mahmut Acikel, Fuat Gundogdu, Sebahattin Atesal, Huseyin Senocak. (2007) Effect of beta-blocker therapy on left atrial function in patients with heart failure: comparison of metoprolol succinate with carvedilol. The International Journal of Cardiovascular Imaging 23:5, 549-555
CrossRef283
J. W. Wisler, S. M. DeWire, E. J. Whalen, J. D. Violin, M. T. Drake, S. Ahn, S. K. Shenoy, R. J. Lefkowitz. (2007) A unique mechanism of beta-blocker action: Carvedilol stimulates beta-arrestin signaling. Proceedings of the National Academy of Sciences 104:42, 16657-16662
CrossRef284
Mario Marcondes-Santos, Flavio Tarasoutchi, Antonio P. Mansur, Célia M.C. Strunz. (2007) Effects of Carvedilol Treatment in Dogs with Chronic Mitral Valvular Disease. Journal of Veterinary Internal Medicine 21:5, 996-1001
CrossRef285
Lin-ya You, Chun-na Yu, Sheng-gu Xie, Shu-qing Chen, Su Zeng. (2007) Stereoselective glucuronidation of carvedilol by Chinese liver microsomes. Journal of Zhejiang University SCIENCE B 8:10, 756-764
CrossRef286
Na Li, Yishi Li, Fang Wang, Wen Jiang, Jie Huang, Zhimin Xu, Lu Hua, Congxiao Hua, Yan Huang, Ying Wu, Feiou Li. (2007) Does NT-proBNP Remain a Sensitive Biomarker for Chronic Heart Failure after Administration of a Beta-blocker?. Clinical Cardiology 30:9, 469-474
CrossRef287
Richard A. Bond, Domenico Spina, Sergio Parra, Clive P. Page. (2007) Getting to the heart of asthma: Can “β blockers” be useful to treat asthma?. Pharmacology & Therapeutics 115:3, 360-374
CrossRef288
Christian R. Dolder, Angie Veverka, Donald S. Nuzum, Jonathan McKinsey. (2007) <b>Cardiovascular Medication Prescribing in Older Adults with Psychiatric Disorders Research and Reports</b>. The Consultant Pharmacist 22:8, 660-668
CrossRef289
Robert E. Shaddy. (2007) Paediatric heart failure trials…and tribulations. Cardiology in the Young 17:04, 354
CrossRef290
Igor Bogdan Mrdovic, Lidija Zlatimir Savic, Jovan Petar Perunicic, Milika Risto Asanin, Ratko Milorad Lasica, Marinkovic Milutin Jelena, Mihailo Dragomir Matic, Zorana Mihailo Vasiljevic, Miodrag Caslav Ostojic. (2007) Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction. American Heart Journal 154:1, 116-122
CrossRef291
Martin Cadeiras, Manuel Prinz von Bayern, Mario C. Deng. (2007) Cardiac Transplantation: Any Role Left?. Heart Failure Clinics 3:3, 321-347
CrossRef292
Srinivasa R Kalidindi, WH Wilson Tang, Gary S Francis. (2007) Drug Insight: aldosterone-receptor antagonists in heart failure—the journey continues. Nature Clinical Practice Cardiovascular Medicine 4:7, 368-378
CrossRef293
Chang-seng LIANG. (2007) Cardiac sympathetic nerve terminal function in congestive heart failure. Acta Pharmacologica Sinica 28:7, 921-927
CrossRef294
Wilbert S. Aronow, William H. Frishman, Angela Cheng-Lai. (2007) Cardiovascular Drug Therapy in the Elderly. Cardiology in Review 15:4, 195-215
CrossRef295
Kartikya Ahuja, Gregory A. Crooke, Eugene A. Grossi, Aubrey C. Galloway, Ulrich P. Jorde. (2007) Reversing Left Ventricular Remodeling in Chronic Heart Failure. Cardiology in Review 15:4, 184-190
CrossRef296
Srinivas Iyengar, William T. Abraham. (2007) Diuretics for the treatment of acute decompensated heart failure. Heart Failure Reviews 12:2, 125-130
CrossRef297
Paul J. Mather, Marvin A. Konstam. (2007) Newer mechanical devices in the management of acute heart failure. Heart Failure Reviews 12:2, 167-172
CrossRef298
Steve Tsai, Marc Klapholz. (2007) Tips and tricks on outpatient initiation and uptitration of beta-blockade in heart failure. Current Heart Failure Reports 4:2, 110-116
CrossRef299
M FOWLER, S LOTTES, J NELSON, M LUKAS, E GILBERT, B GREENBERG, B MASSIE, W ABRAHAM, J FRANCIOSA. (2007) β-Blocker dosing in community-based treatment of heart failure. American Heart Journal 153:6, 1029-1036
CrossRef300
S. D. Naik, Ronald S. Freudenberger. (2007) Beta-blocker contraindications: Are there patients or situations where use is inappropriate?. Current Heart Failure Reports 4:2, 93-98
CrossRef301
K SUGIOKA, T HOZUMI, Y TAKEMOTO, S EHARA, K OGAWA, S IWATA, H OE, Y MATSUMURA, R OTSUKA, M YOSHIYAMA. (2007) Relation of early improvement in coronary flow reserve to late recovery of left ventricular function after β-blocker therapy in patients with idiopathic dilated cardiomyopathy. American Heart Journal 153:6, 1080.e1-1080.e6
CrossRef302
Ahmed A. Othman, David M. Tenero, Duane A. Boyle, Natalie D. Eddington, Michael J. Fossler. (2007) Population pharmacokinetics of S(−)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. The AAPS Journal 9:2, E208-E218
CrossRef303
Larisa H Cavallari, Kathryn M Momary, Vicki L Groo, Marlos A. G Viana, Joseph R Camp, Thomas D Stamos. (2007) Association of β-Blocker Dose with Serum Procollagen Concentrations and Cardiac Response to Spironolactone in Patients with Heart Failure. Pharmacotherapy 27:6, 801-812
CrossRef304
Lynn M. Fedoruk, Curtis G. Tribble, John A. Kern, Benjamin B. Peeler, Irving L. Kron. (2007) Predicting Operative Mortality After Surgery for Ischemic Cardiomyopathy. The Annals of Thoracic Surgery 83:6, 2029-2035
CrossRef305
Sudhiranjan Gupta, Biswajit Das, Subha Sen. (2007) Cardiac Hypertrophy: Mechanisms and Therapeutic Opportunities. Antioxidants & Redox Signaling 9:6, 623-652
CrossRef306
J. B. McGill, G. L. Bakris, V. Fonseca, P. Raskin, F. H. Messerli, R. A. Phillips, R. E. Katholi, J. T. Wright, M. Iyengar, K. M. Anderson, M. A. Lukas, M. R. Dalal, D. S. H. Bell. (2007) ?-Blocker use and diabetes symptom score: results from the GEMINI study. Diabetes, Obesity and Metabolism 9:3, 408-417
CrossRef307
V. A. Penniyainen, E. V. Lopatina, V. A. Tsyrlin. (2007) Effect of β-adrenoceptor blockers on growth of neurites in spinal ganglia in organotypic tissue culture. Bulletin of Experimental Biology and Medicine 143:5, 556-558
CrossRef308
Kamran Akram, Brian L. Pearlman. (2007) Congestive heart failure-related anemia and a role for erythropoietin. International Journal of Cardiology 117:3, 296-305
CrossRef309
Barry M. Massie, Jeanenne J. Nelson, Mary Ann Lukas, Barry Greenberg, Michael B. Fowler, Edward M. Gilbert, William T. Abraham, Sandra R. Lottes, Joseph A. Franciosa. (2007) Comparison of Outcomes and Usefulness of Carvedilol Across a Spectrum of Left Ventricular Ejection Fractions in Patients With Heart Failure in Clinical Practice. The American Journal of Cardiology 99:9, 1263-1268
CrossRef310
Heath E. Saltzman, Kumar Sharma, Paul J. Mather, Sharon Rubin, Suzanne Adams, David Joshua Whellan. (2007) Renal dysfunction in heart failure patients: what is the evidence?. Heart Failure Reviews 12:1, 37-47
CrossRef311
Michael E. Field, Michael O. Sweeney. (2007) Socio-economic analysis of cardiac resynchronization therapy. Journal of Interventional Cardiac Electrophysiology 17:3, 225-236
CrossRef312
Mark E Dunlap. (2007) New Studies Influencing Treatment of Heart Failure: 2006 Update. Pharmacotherapy 27:4 Part 2, 3S-11S
CrossRef313
Clyde W. Yancy. (2007) Heart Failure and Its Management With ?-Blockade: Potential Applications of Once-Daily Therapy. The Journal of Clinical Hypertension 9:s4, 28-35
CrossRef314
Parag Patel, Donna L. White, Anita Deswal. (2007) Translation of clinical trial results into practice: Temporal patterns of β-blocker utilization for heart failure at hospital discharge and during ambulatory follow-up. American Heart Journal 153:4, 515-522
CrossRef315
L MENICANTI, M DIDONATO. (2007) Left Ventricular Restoration: How Important is the Surgical Treatment of Ischemic Heart Failure Trial?. Heart Failure Clinics 3:2, 237-243
CrossRef316
Masayoshi Kojima, Koichi Sato, Genjiro Kimura, Ryuzo Ueda, Yasuaki Dohi. (2007) Carvedilol Reduces Elevated B-type Natriuretic Peptide in Dialyzed Patients Without Heart Failure: Cardioprotective Effect of the ??-blocker. Journal of Cardiovascular Pharmacology 49:4, 191-196
CrossRef317
Paresh Dandona, Husam Ghanim, David P Brooks. (2007) Antioxidant activity of carvedilol in cardiovascular disease. Journal of Hypertension 25:4, 731-741
CrossRef318
Massimo F. Piepoli. (2007) Immune activation and inflammatory system in chronic heart failure: novel pathophysiological hypotheses generate new therapeutic options. International Journal of Clinical Practice 61:4, 536-538
CrossRef319
Camille G. Frazier, Karen P. Alexander, L. Kristin Newby, Susan Anderson, Erik Iverson, Milton Packer, Jay Cohn, Sidney Goldstein, Pamela S. Douglas. (2007) Associations of Gender and Etiology With Outcomes in Heart Failure With Systolic Dysfunction. Journal of the American College of Cardiology 49:13, 1450-1458
CrossRef320
Fernando A. Botoni, Philip A. Poole-Wilson, Antonio L.P. Ribeiro, Darlington O. Okonko, Bráulio M.R. Oliveira, Airandes S. Pinto, Mauro M. Teixeira, Antonio L. Teixeira, Adelina M. Reis, Jackellyne B.P. Dantas, Cid S. Ferreira, Wilson C. Tavares, Manoel Otávio C. Rocha. (2007) A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. American Heart Journal 153:4, 544.e1-544.e8
CrossRef321
Maximilian T. Lobmeyer, Yan Gong, Steven G. Terra, Amber L. Beitelshees, Taimour Y. Langaee, Daniel F. Pauly, Richard S. Schofield, Karen K. Hamilton, J. Herbert Patterson, Kirkwood F. Adams, James A. Hill, Juan M. Aranda, Julie A. Johnson. (2007) Synergistic polymorphisms of ??1 and ??2C-adrenergic receptors and the influence on left ventricular ejection fraction response to ??-blocker therapy in heart failure. Pharmacogenetics and Genomics 17:4, 277-282
CrossRef322
Sorin V. Pusca, John D. Puskas. (2007) Revascularization in Heart Failure: Coronary Bypass or Percutaneous Coronary Intervention?. Heart Failure Clinics 3:2, 211-228
CrossRef323
K CHIU, H CHAN, S CHU, T LIN. (2007) Carvedilol can restore the multifractal properties of heart beat dynamics in patients with advanced congestive heart failure. Autonomic Neuroscience 132:1-2, 76-80
CrossRef324
Neubauer, Stefan, . (2007) The Failing Heart — An Engine Out of Fuel. New England Journal of Medicine 356:11, 1140-1151
Full Text325
Ioannis Paraskevaidis, Dimitrios Farmakis, John T. Parissis, Thomas Dodouras, Gerasimos Filippatos, Dimitrios Tsiapras, Dimitrios Th. Kremastinos. (2007) Carvedilol Improves Left Atrial and Left Ventricular Function and Reserve in Dilated Cardiomyopathy After 1 Year of Treatment. Journal of Cardiac Failure 13:2, 108-113
CrossRef326
Willem J. Remme, Christian Torp-Pedersen, John G.F. Cleland, Philip A. Poole-Wilson, Marco Metra, Michel Komajda, Karl Swedberg, Andrea Di Lenarda, Phillip Spark, Armin Scherhag, Christine Moullet, Mary Ann Lukas. (2007) Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure. Journal of the American College of Cardiology 49:9, 963-971
CrossRef327
Paul J. Mather, Marvin A. Konstam. (2007) Percutaneous mechanical devices in the management of decompensated heart failure. Current Heart Failure Reports 4:1, 43-47
CrossRef328
Anita Israel, Lida Esther Zavala, Maria Cierco, Antonio Gutierrez, Maria del Rosario Garrido. (2007) Effect of AT1 Angiotensin II Receptor Antagonists on the Sympathetic Response to a Cold Pressor Test in Healthy Volunteers. American Journal of Therapeutics 14:2, 183-188
CrossRef329
Archana Rao, John Walsh. (2007) Impact of specialist care in patients with newly diagnosed heart failure: A randomised controlled study. International Journal of Cardiology 115:2, 196-202
CrossRef330
Ali Ahmed. (2007) Clinical Manifestations, Diagnostic Assessment, and Etiology of Heart Failure in Older Adults. Clinics in Geriatric Medicine 23:1, 11-30
CrossRef331
David M. Kaye, Henry Krum. (2007) Drug discovery for heart failure: a new era or the end of the pipeline?. Nature Reviews Drug Discovery 6:2, 127-139
CrossRef332
Yasuhiko Takemoto, Takeshi Hozumi, Kenichi Sugioka, Yasuhiro Takagi, Yoshiki Matsumura, Minoru Yoshiyama, Theodore P. Abraham, Junichi Yoshikawa. (2007) Beta-Blocker Therapy Induces Ventricular Resynchronization in Dilated Cardiomyopathy With Narrow QRS Complex. Journal of the American College of Cardiology 49:7, 778-783
CrossRef333
Wilbert S. Aronow. (2007) Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly. Clinics in Geriatric Medicine 23:1, 61-81
CrossRef334
Marco Metra, Savina Nodari, Tania Bordonali, Patrizia Milani, Francesco Fracassi, Livio Dei Cas. (2007) β-blocker therapy of heart failure: an update. Expert Opinion on Pharmacotherapy 8:3, 289-298
CrossRef335
Wilbert S. Aronow. (2007) Heart-Failure–Complicating Acute Myocardial Infarction. Clinics in Geriatric Medicine 23:1, 123-139
CrossRef336
Ayumi Yokoyama, Nobuyuki Sato, Yuichiro Kawamura, Naoyuki Hasebe, Kenjiro Kikuchi. (2007) Electrophysiological Effects of Carvedilol on Rabbit Heart Pacemaker Cells. International Heart Journal 48:3, 347-358
CrossRef337
Robert Neil Doughty, Harvey D White. (2007) Carvedilol: use in chronic heart failure. Expert Review of Cardiovascular Therapy 5:1, 21-31
CrossRef338
Junichi Tsuboi, Kohei Kawazoe, Hiroshi Izumoto, Hitoshi Okabayashi. (2007) Postoperative Treatment With Carvedilol, a β-Adrenergic Blocker, Prevents Paroxysmal Atrial Fibrillation After Coronary Artery Bypass Grafting. Circulation Journal 72:4, 588-591
CrossRef339
Deborah Morley, Kenneth Litwak, Paul Ferber, Paul Spence, Robert Dowling, Bart Meyns, Bartley Griffith, Daniel Burkhoff. (2007) Hemodynamic effects of partial ventricular support in chronic heart failure: Results of simulation validated with in vivo data. The Journal of Thoracic and Cardiovascular Surgery 133:1, 21-28.e4
CrossRef340
Masayuki Matsumoto. (2007) Clinical aspects of cardiac failure in the elderly people. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 44:5, 582-584
CrossRef341
Frank C. Barone, Robert N. Willette, Allen H. Nelson, Eliot H. Ohlstein, David P. Brooks, Robert W. Coatney. (2007) Carvedilol Prevents and Reverses Hypertrophy-Induced Cardiac Dysfunction. Pharmacology 80:2-3, 166-176
CrossRef342
Keiichiro Yoshinaga, Ian G. Burwash, Judith A. Leech, Haissam Haddad, Chris B. Johnson, Robert A. deKemp, Linda Garrard, Li Chen, Kathryn Williams, Jean N. DaSilva, Rob S.B. Beanlands. (2007) The Effects of Continuous Positive Airway Pressure on Myocardial Energetics in Patients With Heart Failure and Obstructive Sleep Apnea. Journal of the American College of Cardiology 49:4, 450-458
CrossRef343
Yoshihiko Seino, Hidehiko Imai, Takaaki Nakamoto, Yoshihiko Araki, Shigetake Sasayama. (2007) Clinical Efficacy and Cost-Benefit Analysis of Nocturnal Home Oxygen Therapy in Patients With Central Sleep Apnea Caused by Chronic Heart Failure. Circulation Journal 71:11, 1738-1743
CrossRef344
Tsuyoshi Shiga, Hiroshi Kasanuki. (2007) Drug Therapy for Ventricular Tachyarrhythmia in Heart Failure. Circulation Journal 71:SupplementA, A90-A96
CrossRef345
(2007) Traitement médicamenteux du diabète de type 2recommandation de bonne pratique. Diabetes & Metabolism 33:1, S26-S105
CrossRef346
Peter Kleist. (2007) Composite Endpoints for Clinical Trials. International Journal of Pharmaceutical Medicine 21:3, 187-198
CrossRef347
Kazuya Ishida, Mutsuko Honda, Takako Shimizu, Masato Taguchi, Yukiya Hashimoto. (2007) Stereoselective Metabolism of Carvedilol by the β-Naphthoflavone-Inducible Enzyme in Human Intestinal Epithelial Caco-2 Cells. Biological & Pharmaceutical Bulletin 30:10, 1930-1933
CrossRef348
Maya Guglin, Khaled Esmaeel Awad, Latha Polavaram, Hema Vankayala. (2007) Aldosterone Antagonists. American Journal of Cardiovascular Drugs 7:1, 75-79
CrossRef349
Alan D. Waggoner, Deborah A. Agler, David B. Adams. (2007) Cardiac Resynchronization Therapy and the Emerging Role of Echocardiography (Part 1): Indications and Results from Current Studies. Journal of the American Society of Echocardiography 20:1, 70-75
CrossRef350
Yoh Takekuma, Toru Takenaka, Masami Kiyokawa, Koujiro Yamazaki, Hiroshi Okamoto, Akira Kitabatake, Hiroyuki Tsutsui, Mitsuru Sugawara. (2007) Evaluation of Effects of Polymorphism for Metabolic Enzymes on Pharmacokinetics of Carvedilol by Population Pharmacokinetic Analysis. Biological & Pharmaceutical Bulletin 30:3, 537-542
CrossRef351
Gregor Leibundgut, Matthias Pfisterer, Hans-Peter Brunner-La Rocca. (2007) Drug Treatment of Chronic Heart Failure in the Elderly. Drugs & Aging 24:12, 991-1006
CrossRef352
Kotaro Oe, Toshio Yamagata, Kiyoo Mori. (2007) Decline of Plasma Brain Natriuretic Peptide Level After Carvedilol Therapy to Treat Dilated Cardiomyopathy Presenting With Mechanical Alternans. International Heart Journal 48:1, 117-121
CrossRef353
Pradipta Bhakta, Binay K Biswas, Basudeb Banerjee. (2007) Peripartum Cardiomyopathy: Review of the Literature. Yonsei Medical Journal 48:5, 731
CrossRef354
Jaekyu Shin, Maximilian T. Lobmeyer, Yan Gong, Issam Zineh, Taimour Y. Langaee, Hossein Yarandi, Richard S. Schofield, Juan M. Aranda, James A. Hill, Daniel F. Pauly, Julie A. Johnson. (2007) Relation of β2-Adrenoceptor Haplotype to Risk of Death and Heart Transplantation in Patients With Heart Failure. The American Journal of Cardiology 99:2, 250-255
CrossRef355
Yoh Takekuma, Toru Takenaka, Koujiro Yamazaki, Kazuyuki Ueno, Mitsuru Sugawara. (2007) Stereoselective Metabolism of Racemic Carvedilol by UGT1A1 and UGT2B7, and Effects of Mutation of these Enzymes on Glucuronidation Activity. Biological & Pharmaceutical Bulletin 30:11, 2146-2153
CrossRef356
Daniela Dobre, Flora M Haaijer-Ruskamp, Adriaan A Voors, Dirk J van Veldhuisen. (2007) β-Adrenoceptor Antagonists in Elderly Patients with Heart Failure. Drugs & Aging 24:12, 1031-1044
CrossRef357
J ABBOTT. 2007. Canine Myocardial Disease. , 107-117.
CrossRef358
J ABBOTT. 2007. Management of Heart Failure. , 81-92.
CrossRef359
Sanjai Sinha, Matthew Goldstein, Joan Penrod, Tsivia Hochman, Mohammad Kamran, Craig Tenner, Gabriela Cohen, Mark D. Schwartz. (2006) BRIEF REPORT: ?-Blocker Use Among Veterans with Systolic Heart Failure. Journal of General Internal Medicine 21:12, 1306-1309
CrossRef360
Toni L Ripley, Jennifer S Chonlahan, Robin E Germany. (2006) Candesartan in heart failure. Clinical Interventions in Aging 1:4, 357-366
CrossRef361
Philip B. Adamson, Edward M. Gilbert. (2006) Reducing the Risk of Sudden Death in Heart Failure With β-Blockers. Journal of Cardiac Failure 12:9, 734-746
CrossRef362
Melvin R Echols, Clyde W Yancy. (2006) Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure. Vascular Health and Risk Management 2:4, 423-431
CrossRef363
Gregg C Fonarow. (2006) Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol. Expert Opinion on Pharmacotherapy 7:18, 2533-2546
CrossRef364
, D.G. Benditt. (2006) The ACCF/AHA Scientific Statement on Syncope. Clinical Autonomic Research 16:6, 363-368
CrossRef365
John D. Harding, Mariell Jessup. (2006) New Directions in the Medical Management of Heart Failure. Seminars in Thoracic and Cardiovascular Surgery 17:4, 334-342
CrossRef366
Adnan Siddiqui, Peter R Kowey. (2006) Sudden death secondary to cardiac arrhythmias: mechanisms and treatment strategies. Current Opinion in Internal Medicine 5:6, 544-552
CrossRef367
Bruno Laviolle, Danielle Pape, Bruno Turlin, Eric Bellissant. (2006) Direct Effects of 3 Combinations of Enalapril, Metoprolol, and Spironolactone on Cardiac Remodeling in Dilated Cardiomyopathic Hamsters. Journal of Cardiac Failure 12:9, 752-758
CrossRef368
Jacob A Udell, Joel G Ray. (2006) Primary and secondary prevention of heart failure with statins. Expert Review of Cardiovascular Therapy 4:6, 917-926
CrossRef369
N Khalifeh, A Vychytil, W H Hörl. (2006) The role of peritoneal dialysis in the management of treatment-resistant congestive heart failure: A European perspective. Kidney International 70, S72-S75
CrossRef370
Joseph A. Franciosa, Jeanenne J. Nelson, Mary Ann Lukas, Sandra R. Lottes, Barry M. Massie, Michael B. Fowler, Barry Greenberg, Edward M. Gilbert, William T. Abraham. (2006) Heart Failure in Community Practice: Relationship to Age and Sex in a ?-Blocker Registry. Congestive Heart Failure 12:6, 317-323
CrossRef371
2006. Migraine Prophylaxis. .
CrossRef372
Nicolas W Shammas. 2006. Congestive Heart Failure: Epidemiology, Pathophysiology, and Current Therapies. , 525-544.
CrossRef373
G. B. Miao, J. C. Liu, M. B. Liu, J. L. Wu, G. Zhang, J. Chang, L. Zhang. (2006) Autoantibody against β1-adrenergic receptor and left ventricular remodeling changes in response to metoprolol treatment. European Journal of Clinical Investigation 36:9, 614-620
CrossRef374
Gregg C. Fonarow, Preethi Srikanthan. (2006) Diabetic Cardiomyopathy. Endocrinology & Metabolism Clinics of North America 35:3, 575-599
CrossRef375
(2006) Guía sobre el manejo de la angina estable. Versión resumida. Revista Española de Cardiología 59:9, 919-970
CrossRef376
Michael W. Rich. (2006) Heart Failure in Older Adults. Medical Clinics of North America 90:5, 863-885
CrossRef377
Rana Billeh, David Hirsh, Colin Barker, Birgit Jorgensen, Raban Jeger, Krishnan Ramanathan, Chi-Hong Tseng, Alhakam Hudaihed, Francois Haas, Ulrich P. Jorde. (2006) Randomized, Double-Blind Comparison of Acute ? 1 -Blockade With 50 mg Metoprolol Tartrate vs 25 mg Carvedilol in Normal Subjects. Congestive Heart Failure 12:5, 254-257
CrossRef378
Leanne Groban, John Butterworth. (2006) Perioperative Management of Chronic Heart Failure. Anesthesia & Analgesia 103:3, 557-575
CrossRef379
Sachin S. Sule, William Frishman. (2006) Nebivolol. Cardiology in Review 14:5, 259-264
CrossRef380
Sanjai Sinha, Matthew Goldstein, Joan Penrod, Tsivia Hochman, Mohammad Kamran, Craig Tenner, Gabriela Cohen, Mark D. Schwartz. (2006) BRIEF REPORT: β-Blocker Use Among Veterans with Systolic Heart Failure. Journal of General Internal Medicine 0:0, 060822080320008-???
CrossRef381
J. Alexander Cole, Heather Norman, Lisa B Weatherby, Alexander M Walker. (2006) Drug Copayment and Adherence in Chronic Heart Failure: Effect on Cost and Outcomes. Pharmacotherapy 26:8, 1157-1164
CrossRef382
Jay N. Cohn. (2006) Efficacy and Safety in Clinical Trials in Cardiovascular Disease. Journal of the American College of Cardiology 48:3, 430-433
CrossRef383
David S. Frankel, John D. Piette, Mariell Jessup, Kimberly Craig, Faith Pickering, Lee R. Goldberg. (2006) Validation of Prognostic Models Among Patients With Advanced Heart Failure. Journal of Cardiac Failure 12:6, 430-438
CrossRef384
Daniel Burkhoff, William O'Neill, Corinna Brunckhorst, Dustin Letts, David Lasorda, Howard A. Cohen. (2006) Feasibility study of the use of the TandemHeart® percutaneous ventricular assist device for treatment of cardiogenic shock. Catheterization and Cardiovascular Interventions 68:2, 211-217
CrossRef385
Brian R Dulin, Henry Krum. (2006) Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence. Current Opinion in Cardiology 21:4, 393-399
CrossRef386
Albert Yuh-Jer Shen, Somjot S Brar, Steven S Khan, Dean A Kujubu. (2006) Association of race, heart failure and chronic kidney disease. Future Cardiology 2:4, 441-454
CrossRef387
Mário Marcondes Santos, Célia M. C. Strunz, Maria H. M. A. Larsson. (2006) Correlation between activation of the sympathetic nervous system estimated by plasma concentrations of norepinephrine and Doppler echocardiographic variables in dogs with acquired heart disease. American Journal of Veterinary Research 67:7, 1163-1168
CrossRef388
Michala E. Pedersen, John R. Cockcroft. (2006) The latest generation of beta-blockers: New pharmacologic properties. Current Hypertension Reports 8:4, 279-286
CrossRef389
Michael A. Crouch. (2006) Pharmacotherapy Implications of Revised Chronic Heart Failure Guidelines. The Consultant Pharmacist 21:7, 576-582
CrossRef390
Josef Stehlik, Matthew A Movsesian. (2006) Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure. Expert Opinion on Investigational Drugs 15:7, 733-742
CrossRef391
María G. Crespo Leiro, María J. Paniagua Martín. (2006) Insuficiencia cardiaca. ¿Son diferentes las mujeres?. Revista Española de Cardiología 59:7, 725-735
CrossRef392
Kathy Hebert, Lee Arcement, Ron Horswell. (2006) Hurricanes and heart failure: A review of the who, what, when, and where of beta-blocker therapy. Current Heart Failure Reports 3:2, 89-95
CrossRef393
Nadia Aspromonte, Mauro Feola, Angela Beatrice Scardovi, Claudio Coletta, Alessandra DʼEri, Prospero Giovinazzo, Alessandro Carunchio, Antonella Chiera, Renato Fanelli, Tiziana Di Giacomo, Roberto Ricci, Vincenzo Ceci, Loredano Milani, Roberto Valle. (2006) Early diagnosis of congestive heart failure: clinical utility of B-type natriuretic peptide testing associated with Doppler echocardiography. Journal of Cardiovascular Medicine 7:6, 406-413
CrossRef394
Sripal Bangalore, Khashayar Hematpour, Farooq A. Chaudhry. (2006) Dobutamine stress echocardiography: Does it predict response to beta-blockers in patients with heart failure?. Current Heart Failure Reports 3:2, 96-102
CrossRef395
Rachele Adorisio, Leonardo De Luca, Joseph Rossi, Mihai Gheorghiade. (2006) Pharmacological treatment of chronic heart failure. Heart Failure Reviews 11:2, 109-123
CrossRef396
Rami Alharethi, Ray E. Hershberger. (2006) Beta-blocker use in decompensated heart failure. Current Heart Failure Reports 3:2, 75-80
CrossRef397
E.D. Blume, C.E. Canter, R. Spicer, K. Gauvreau, S. Colan, K.J. Jenkins. (2006) Prospective Single-Arm Protocol of Carvedilol in Children with Ventricular Dysfunction. Pediatric Cardiology 27:3, 336-342
CrossRef398
Lee A. Biblo, Johan Aasbo. (2006) To catch a moving target. Heart Rhythm 3:6, 638-639
CrossRef399
Javed Butler, James B. Young, William T. Abraham, Robert C. Bourge, Kirkwood F. Adams, Robert Clare, Christopher O’Connor. (2006) Beta-Blocker Use and Outcomes Among Hospitalized Heart Failure Patients. Journal of the American College of Cardiology 47:12, 2462-2469
CrossRef400
Anita Israel, Lida E. Zavala, Maria Cierco, Antonio Gutierrez, Maria del Rosario Garrido. (2006) Effect of eprosartan on the sympathetic response to cold pressor test in healthy volunteers. Autonomic Neuroscience 126-127, 179-184
CrossRef401
Wilbert S. Aronow. (2006) Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure. Cardiology in Review 14:3, 108-124
CrossRef402
E. M. L. Wong, E. B. Wu, W. W. M. Chan, C. M. Yu. (2006) A review of the management of patients after percutaneous coronary intervention. International Journal of Clinical Practice 60:5, 582-589
CrossRef403
Vera Regitz-Zagrosek. (2006) Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nature Reviews Drug Discovery 5:5, 425-239
CrossRef404
A. A. Mangoni, S. H. D. Jackson. (2006) The implications of a growing evidence base for drug use in elderly patients. Part 3. beta-adrenoceptor blockers in heart failure and thrombolytics in acute myocardial infarction. British Journal of Clinical Pharmacology 61:5, 513-520
CrossRef405
Monica Colvin Adams, Syed Sohail Ali. (2006) Who should pay for home monitoring of heart failure?. Current Cardiology Reports 8:3, 191-197
CrossRef406
Robert E Shaddy. (2006) Drug trials in pediatric heart failure: hype or improved clinical science?. Future Cardiology 2:3, 281-286
CrossRef407
Marc A. Silver, W. Franklin Peacock, Deborah B. Diercks. (2006) Optimizing Treatment and Outcomes in Acute Heart Failure: Beyond Initial Triage. Congestive Heart Failure 12:3, 137-145
CrossRef408
Ioannis A. Paraskevaidis, Dimitrios Tsiapras, George Karavolias, Stamatis Adamopoulos, Thomas Dodouras, Philippos Cokkinos, Dimitrios Th Kremastinos. (2006) The Effect of Carvedilol Therapy on Myocardial Functional Reserve in Patients with Advanced Heart Failure Caused by Nonischemic Dilated Cardiomyopathy. Journal of the American Society of Echocardiography 19:5, 529-535
CrossRef409
Kevin A. Courville, Hector O. Ventura. (2006) Hypertension and heart failure: Diagnosis and management. Current Hypertension Reports 8:3, 185-190
CrossRef410
Lazaros A. Nikolaidis, Indu Poornima, Pratik Parikh, Megan Magovern, You-Tang Shen, Richard P. Shannon. (2006) The Effects of Combined Versus Selective Adrenergic Blockade on Left Ventricular and Systemic Hemodynamics, Myocardial Substrate Preference, and Regional Perfusion in Conscious Dogs With Dilated Cardiomyopathy. Journal of the American College of Cardiology 47:9, 1871-1881
CrossRef411
M. Böhm, N. Werner, M. Kindermann. (2006) Stand der medikamentösen Therapie bei chronischer Herzinsuffizienz. Clinical Research in Cardiology 95:S4, 36-56
CrossRef412
Srinivas Iyengar, William T. Abraham. (2006) Diuretic resistance in heart failure. Current Heart Failure Reports 3:1, 41-45
CrossRef413
C. W. Middeljans-Tijssen, R. W. M. M. Jansen. (2006) De oudere patiënt met hartfalen en de rol van bètablokkers bij de behandeling. Tijdschrift voor Gerontologie en Geriatrie 37:2, 70-81
CrossRef414
J. Herlitz, M. Castren, H. Friberg, J. Nolan, M. Skrifvars, K. Sunde, P.-A. Steen. (2006) Post resuscitation care. Resuscitation 69:1, 15-22
CrossRef415
Paolo Palatini, Athanase Benetos, Guido Grassi, Stevo Julius, Sverre E Kjeldsen, Giuseppe Mancia, Krzystof Narkiewicz, Gianfranco Parati, Achille C Pessina, Luis M Ruilope, Alberto Zanchetti. (2006) Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. Journal of Hypertension 24:4, 603-610
CrossRef416
Gastone Sabbadini, Marco Metra, Andrea Di Lenarda, Savina Nodari, Gianfranco Sinagra, Livio Dei Cas. (2006) Managing heart failure in the very old. Aging Health 2:2, 253-275
CrossRef417
Stuart D. Russell. 2006. Acute Heart Failure. , 203-226.
CrossRef418
Ulrich P. Jorde. (2006) Suppression of the Renin???Angiotensin???Aldosterone System in Chronic Heart Failure. Cardiology in Review 14:2, 81-87
CrossRef419
Shi Yin Foo, Anthony Rosenzweig. 2006. Gene Therapy for Heart Failure. , 573-588.
CrossRef420
Emily J. Tsai, Thomas P. Cappola. 2006. Beta-Blockers in Heart Failure. , 113-136.
CrossRef421
Weeranuj Yamreudeewong, E. Kurt Dolence, Deborah Pahl. (2006) Stability of Two Extemporaneously Prepared Oral Metoprolol and Carvedilol Liquids. Hospital Pharmacy 41:3, 254-259
CrossRef422
Anthony SL Tang, Kenneth A Ellenbogen. (2006) A futuristic perspective on clinical studies of cardiac resynchronization therapy for heart failure patients. Current Opinion in Cardiology 21:2, 78-82
CrossRef423
Heart Failure Society of America. (2006) Section 7: Heart Failure in Patients With Left Ventricular Systolic Dysfunction. Journal of Cardiac Failure 12:1, e38-e57
CrossRef424
Heart Failure Society of America. (2006) Section 13: Evaluation and Therapy for Heart Failure in the Setting of Ischemic Heart Disease. Journal of Cardiac Failure 12:1, e104-e111
CrossRef425
Jennifer J. G Steffensmeier, Michael E Ernst, Michael Kelly, Arthur J Hartz. (2006) Do Randomized Controlled Trials Always Trump Case Reports? A Second Look at Propranolol and Depression. Pharmacotherapy 26:2, 162-167
CrossRef426
Jeffrey J. Teuteberg, Eldrin F. Lewis, Anju Nohria, Sui W. Tsang, James C. Fang, Michael M. Givertz, John A. Jarcho, Gilbert H. Mudge, Kenneth L. Baughman, Lynne W. Stevenson. (2006) Characteristics of Patients Who Die With Heart Failure and a Low Ejection Fraction in the New Millennium. Journal of Cardiac Failure 12:1, 47-53
CrossRef427
Robert D Winslow, Sean Pinney, Valentin Fuster. (2006) Impact of implantable-cardioverter-defibrillator trials on clinical management of patients with heart failure. Nature Clinical Practice Cardiovascular Medicine 3:2, 86-93
CrossRef428
A URRUTIA, J LUPON, S ALTIMIR, B GONZALEZ, J HERREROS, C DIEZ, R COLL, V VALLE, C REYJOLY. (2006) Uso de bloqueadores beta en pacientes ancianos con insuficiencia cardíaca. Medicina Clínica 126:6, 206-210
CrossRef429
Takeshi Tsujino, Daizo Kawasaki, Tohru Masuyama. (2006) Left Ventricular Diastolic Dysfunction in Diabetic Patients. American Journal of Cardiovascular Drugs 6:4, 219-230
CrossRef430
S. Adam Strickberger, D. Woodrow Benson, Italo Biaggioni, David J. Callans, Mitchell I. Cohen, Kenneth A. Ellenbogen, Andrew E. Epstein, Paul Friedman, Jeffrey Goldberger, Paul A. Heidenreich, George J. Klein, Bradley P. Knight, Carlos A. Morillo, Robert J. Myerburg, Cathy A. Sila. (2006) AHA/ACCF Scientific Statement on the Evaluation of Syncope. Journal of the American College of Cardiology 47:2, 473-484
CrossRef431
Angela Ro, William H. Frishman. (2006) Peripartum Cardiomyopathy. Cardiology in Review 14:1, 35-42
CrossRef432
Kurt Stoschitzky, Gergana Stoschitzky, Helmut Brussee, Claudia Bonell, Harald Dobnig. (2006) Comparing Beta-Blocking Effects of Bisoprolol, Carvedilol and Nebivolol. Cardiology 106:4, 199-206
CrossRef433
Wilbert S. Aronow. (2006) Treatment of Systolic and Diastolic Heart Failure in the Elderly. Journal of the American Medical Directors Association 7:1, 29-36
CrossRef434
Barnett S. Kramer, Joan Wilentz, Duane Alexander, John Burklow, Lawrence M. Friedman, Richard Hodes, Ruth Kirschstein, Amy Patterson, Griffin Rodgers, Stephen E. Straus. (2006) Getting It Right: Being Smarter about Clinical Trials. PLoS Medicine 3:6, e144
CrossRef435
Michael J Lipinski, George W Vetrovec. (2006) Medical Treatment of Patients with Heart Failure or Left Ventricular Dysfunction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiovascular Drugs 6:5, 313-325
CrossRef436
Randall E. Williams. (2006) The effect of neurohormonal antagonists in reducing heart failure hospitalizations. Current Medical Research and Opinion 22:1, 139-150
CrossRef437
Roy S Gardner, Theresa A McDonagh. (2006) The prognostic value of anemia, right-heart catheterization and neurohormones in chronic heart failure. Expert Review of Cardiovascular Therapy 4:1, 51-57
CrossRef438
Peter S Macdonald, Julie Hill, Henry Krum. (2006) The Impact of Baseline HR and BP on the Tolerability of Carvedilol in the Elderly. American Journal of Cardiovascular Drugs 6:6, 401-405
CrossRef439
Paolo Palatini, Athanase Benetos, Stevo Julius. (2006) Impact of Increased Heart Rate on Clinical Outcomes in Hypertension. Drugs 66:2, 133-144
CrossRef440
Noritoshi Nagaya, Kenji Kangawa. (2006) Therapeutic Potential of Ghrelin in the Treatment of Heart Failure. Drugs 66:4, 439-448
CrossRef441
Ernst R Schwarz, Pramod Sanghi. (2006) Conivaptan: a selective vasopressin antagonist for the treatment of heart failure. Expert Review of Cardiovascular Therapy 4:1, 17-23
CrossRef442
Genzou Takemura, Hisayoshi Fujiwara. (2006) Morphological aspects of apoptosis in heart diseases. Journal of Cellular and Molecular Medicine 10:1, 56-75
CrossRef443
Andrew J S Coats. (2006) ??-Adrenoceptor Antagonists in Elderly Patients with Chronic Heart Failure. Drugs & Aging 23:2, 93-99
CrossRef444
Bahri Akdeniz, Sema Guneri, Ilke Z. Savas, Özgür Aslan, Nezihi Baris, Özer Badak, Önder Kirimli, Özhan Göldeli. (2006) Effects of Carvedilol Therapy on Arrhythmia Markers in Patients With Congestive Heart Failure. International Heart Journal 47:4, 565-573
CrossRef445
Yoshihisa Matsumura, Jun Takata, Hiroaki Kitaoka, Toru Kubo, Yuichi Baba, Eri Hoshikawa, Tomoyuki Hamada, Makoto Okawa, Nobuhiko Hitomi, Kyoko Sato, Naohito Yamasaki, Toshikazu Yabe, Takashi Furuno, Masanori Nishinaga, Yoshinori Doi. (2006) Long-Term Prognosis of Dilated Cardiomyopathy Revisited. Circulation Journal 70:4, 376-383
CrossRef446
Renzo M R Lombardo, Caterina Reina, Maurizio G Abrignani, Patrizia A Rizzo, Annabella Braschi, Stefano De Castro. (2006) Effects of Nebivolol versus Carvedilol on Left Ventricular Function in Patients with Chronic Heart Failure and Reduced Left Ventricular Systolic Function. American Journal of Cardiovascular Drugs 6:4, 259-263
CrossRef447
Mutsuko Honda, Yumi Ogura, Wakako Toyoda, Masato Taguchi, Takashi Nozawa, Hiroshi Inoue, Yukiya Hashimoto. (2006) Multiple Regression Analysis of Pharmacogenetic Variability of Carvedilol Disposition in 54 Healthy Japanese Volunteers. Biological & Pharmaceutical Bulletin 29:4, 772-778
CrossRef448
Hiroyuki Tsutsui, Miyuki Tsuchihashi-Makaya, Shintaro Kinugawa, Daisuke Goto, Akira Takeshita, The JCARE-CARD Investigators. (2006) Clinical Characteristics and Outcome of Hospitalized Patients With Heart Failure in Japan. Circulation Journal 70:12, 1617-1623
CrossRef449
Takashi Kobayashi, Kyoko Fukumoto, Yoshimasa Tsuchishita, Masaaki Kusumoto, Kazuyuki Ueno. (2006) Study on Stereoselective Pharmacokinetics of Carvedilol in Japanese Patients. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 32:8, 772-775
CrossRef450
Y JUILLIERE, J TROCHU, P JOURDAIN. (2006) Importance de l'éducation thérapeutique dans la prise en charge multidisciplinaire de l'insuffisance cardiaque. Annales de Cardiologie et d'Angéiologie 55:1, 11-16
CrossRef451
Natasa Duborija-Kovacevic, Zdenko Tomic. (2006) Did a reform strategy in drug management improve doctors’ prescribing habits in Montenegro: The example for the cardiovascular drugs. Vojnosanitetski pregled 63:5, 451-456
CrossRef452
José A. Tallaj, Verónica Franco, Barry K. Rayburn, Laura Pinderski, Raymond L. Benza, Salpy Pamboukian, Brian Foley, Robert C. Bourge. (2005) Response of Doxorubicin-induced Cardiomyopathy to the Current Management Strategy of Heart Failure. The Journal of Heart and Lung Transplantation 24:12, 2196-2201
CrossRef453
W. S. Aronow. (2005) Drug Treatment of Systolic and of Diastolic Heart Failure in Elderly Persons. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60:12, 1597-1605
CrossRef454
P. Christian Schulze, Jürgen Kratzsch. (2005) Leptin as a new diagnostic tool in chronic heart failure. Clinica Chimica Acta 362:1-2, 1-11
CrossRef455
John R. Bullinga, Rami Alharethi, Mark S. Schram, Michael R. Bristow, Edward M. Gilbert. (2005) Changes in Heart Rate Variability Are Correlated to Hemodynamic Improvement With Chronic CARVEDILOL Therapy in Heart Failure. Journal of Cardiac Failure 11:9, 693-699
CrossRef456
Keith C Ferdinand. (2005) Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety. Expert Review of Cardiovascular Therapy 3:6, 993-1001
CrossRef457
Stefania Ferrua, Marco Bobbio, Elisa Catalano, Giorgio Grassi, Nicola Massobrio, Silvia Pinach, Claudio Rossi, Massimo Veglio, Gian Paolo Trevi. (2005) Does Carvedilol Impair Insulin Sensitivity in Heart Failure Patients Without Diabetes?. Journal of Cardiac Failure 11:8, 590-594
CrossRef458
David S. Cannom, Morton Mower. (2005) Relationship of the Implantable Cardioverter Defibrillator and Chronic Resynchronization Therapy: The Perfect Marriage?. Annals of Noninvasive Electrocardiology 10:s4, 24-33
CrossRef459
Takashi Kohno, Tsutomu Yoshikawa, Akihiro Yoshizawa, Iwao Nakamura, Toshihisa Anzai, Toru Satoh, Satoshi Ogawa. (2005) Carvedilol Exerts More Potent Antiadrenergic Effect than Metoprolol in Heart Failure. Cardiovascular Drugs and Therapy 19:5, 347-355
CrossRef460
Clyde W. Yancy. (2005) Heart Failure in African Americans. The American Journal of Cardiology 96:7, 3-12
CrossRef461
Juan Fernández-Yáñez, Jesús Palomo, Esteban G. Torrecilla, David Pascual, Gregorio Garrido, José J. Gómez de Diego, Marta Domínguez, Jesús Almendral. (2005) Pronóstico de una población inicialmente candidata a trasplante cardíaco controlada con tratamiento médico. Revista Española de Cardiología 58:10, 1162-1170
CrossRef462
JOHN J V MCMURRAY. (2005) Chronic kidney disease in patients with cardiac disease: A review of evidence-based treatment. Kidney International 68:4, 1419-1426
CrossRef463
Iain Squire. (2005) Neurohormonal Intervention to Reduce Sudden Cardiac Death in Heart Failure: What is the Optimal Pharmacologic Strategy?. Heart Failure Reviews 9:4, 337-345
CrossRef464
Alfred W. H. Stanley, Constantine L. Athanasuleas, Gerald D. Buckberg, . (2005) Heart Failure Following Anterior Myocardial Infarction: An Indication for Ventricular Restoration, a Surgical Method to Reverse Post-Infarction Remodeling. Heart Failure Reviews 9:4, 241-254
CrossRef465
L Robbiano, A Martelli, G Brambilla. (2005) Discrepancies between use of antihypertensive drugs and guidelines indications: pharmacoeconomic implications. Journal of Human Hypertension 19:10, 819-822
CrossRef466
NABIL EL-SHERIF, GIOIA TURITTO. (2005) Electrophysiologic Effects of Carvedilol: Is Carvedilol an Antiarrhythmic Agent?. Pacing and Clinical Electrophysiology 28:9, 985-990
CrossRef467
Randall E. Williams. (2005) Early Initiation of ? Blockade in Heart Failure: Issues and Evidence. The Journal of Clinical Hypertension 7:9, 520-528
CrossRef468
Christine E. Lawless, Thomas Tamlyn, Rajesh Shah, Fouzia Muhammed Karim, Erum Khan, Steve Creech. (2005) Titration of Carvedilol in Elderly Heart Failure Patients. The American Journal of Geriatric Cardiology 14:5, 230-235
CrossRef469
Luís Beck-da-Silva, Adolfo Bold, Margaret Fraser, Kathryn Williams, Haissam Haddad. (2005) BNP-Guided Therapy Not Better Than Expert's Clinical Assessment for ?-Blocker Titration in Patients With Heart Failure. Congestive Heart Failure 11:5, 248-255
CrossRef470
Srinivas Iyengar, William T Abraham. (2005) Role of medical therapy in the device era for the treatment of heart failure. Expert Review of Cardiovascular Therapy 3:5, 783-785
CrossRef471
Sharon Ann Hunt. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Journal of the American College of Cardiology 46:6, e1-e82
CrossRef472
Sharon Ann Hunt, William T. Abraham, Marshall H. Chin, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Mariell Jessup, Marvin A. Konstam, Donna M. Mancini, Keith Michl, John A. Oates, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy, Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article. Journal of the American College of Cardiology 46:6, 1116-1143
CrossRef473
John V Terrovitis, Maria I Anastasiou-Nana, John N Nanas. (2005) Out-patient management of chronic heart failure. Expert Opinion on Pharmacotherapy 6:11, 1857-1881
CrossRef474
(2005) Rationale and Design of a Randomized Trial to Assess the Effects of β-blocker in Diastolic Heart Failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure 11:7, 542-547
CrossRef475
(2005) Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca crónica. Versión resumida (actualización 2005). Revista Española de Cardiología 58:9, 1062-1092
CrossRef476
Daniel J. Garry, Sean C. Goetsch, Amanda J. McGrath, Pradeep P.A. Mammen. (2005) Alternative Therapies for Orthotopic Heart Transplantation. The American Journal of the Medical Sciences 330:2, 88-101
CrossRef477
Peter S. Rahko. (2005) An Echocardiographic Analysis of the Long-Term Effects of Carvedilol on Left Ventricular Remodeling, Systolic Performance, and Ventricular Filling Patterns in Dilated Cardiomyopathy. Echocardiography 22:7, 547-554
CrossRef478
Graeme Eisenhofer. (2005) Sympathetic nerve function. Clinical Autonomic Research 15:4, 264-283
CrossRef479
John L. Jefferies, Anthony C. Chang. (2005) The neurohormonal axis and biochemical markers of heart failure. Cardiology in the Young 15:4, 333-344
CrossRef480
Haruhiko Kondoh, Yoshiki Sawa, Norihide Fukushima, Goro Matsumiya, Shigeru Miyagawa, Satoru Kitagawa-Sakakida, Imran A. Memon, Naomasa Kawaguchi, Nariaki Matsuura, Hikaru Matsuda. (2005) Reorganization of cytoskeletal proteins and prolonged life expectancy caused by hepatocyte growth factor in a hamster model of late-phase dilated cardiomyopathy. The Journal of Thoracic and Cardiovascular Surgery 130:2, 295-302
CrossRef481
Catherine Demers, Robert S McKelvie. (2005) Growth hormone therapy in heart failure: a novel therapy worthy of further consideration?. Expert Opinion on Investigational Drugs 14:8, 1009-1018
CrossRef482
U. C. Hoppe, M. Böhm, R. Dietz, P. Hanrath, H. K. Kroemer, A. Osterspey, A. A. Schmaltz, E. Erdmann. (2005) Leitlinien zur Therapie der chronischen Herzinsuffizienz. Zeitschrift für Kardiologie 94:8, 488-509
CrossRef483
Zhen Liu, Ji Yuan, Bobby Yanagawa, Dexin Qiu, Bruce M McManus, Decheng Yang. (2005) Coxsackievirus-induced myocarditis: new trends in treatment. Expert Review of Anti-infective Therapy 3:4, 641-650
CrossRef484
Hiromitsu Miyamoto, Hisashi Kai, Hiroyuki Nakaura, Katsunori Osada, Yoshihiko Mizuta, Akira Matsumoto, Tsutomu Imaizumi. (2005) Safety and Efficacy of Repeated Sauna Bathing in Patients With Chronic Systolic Heart Failure: A Preliminary Report. Journal of Cardiac Failure 11:6, 432-436
CrossRef485
Shyam Bhakta, Mark E. Dunlap. (2005) Treatment of heart failure with a normal ejection fraction. Current Treatment Options in Cardiovascular Medicine 7:4, 317-325
CrossRef486
Ney Carter do Carmo Borges, Gustavo Duarte Mendes, Diogo de Oliveira Silva, Vinicius Marcondes Rezende, Rafael Eliseo Barrientos-Astigarraga, Gilberto De Nucci. (2005) Quantification of carvedilol in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Journal of Chromatography B 822:1-2, 253-262
CrossRef487
Sandeep A. Kamath, Clyde W. Yancy. (2005) Treatment of the african-american patient with congestive heart failure. Current Treatment Options in Cardiovascular Medicine 7:4, 307-315
CrossRef488
R. Marchioli, G. Levantesi, A. Macchia, A.P. Maggioni, R.M. Marfisi, M.G. Silletta, L. Tavazzi, G. Tognoni, F. Valagussa. (2005) Antiarrhythmic Mechanisms of n-3 PUFA and the Results of the GISSI-Prevenzione Trial. Journal of Membrane Biology 206:2, 117-128
CrossRef489
Yi-Lan Sun, Shen-Jiang Hu, Li-Hong Wang, Ying Hu, Jian-Ying Zhou. (2005) COMPARISON OF LOW and HIGH DOSES OF CARVEDILOL ON RESTORATION OF CARDIAC FUNCTION and CALCIUM-HANDLING PROTEINS IN RAT FAILING HEART. Clinical and Experimental Pharmacology and Physiology 32:7, 553-560
CrossRef490
Robert D Winslow, Davendra Mehta, Valentin Fuster. (2005) Sudden cardiac death: mechanisms, therapies and challenges. Nature Clinical Practice Cardiovascular Medicine 2:7, 352-360
CrossRef491
Roy S. Gardner, Kwok S. Chong, James J. Morton, Theresa A. Mcdonagh. (2005) N-Terminal Brain Natriuretic Peptide, But Not Anemia, Is a Powerful Predictor of Mortality in Advanced Heart Failure. Journal of Cardiac Failure 11:5, S47-S53
CrossRef492
Victor G. Sharov, Anastassia V. Todor, Hani N. Sabbah. (2005) Left Ventricular Histomorphometric Findings in Dogs with Heart Failure Treated with the Acorn Cardiac Support Device. Heart Failure Reviews 10:2, 141-147
CrossRef493
I.P. Garrido Bravo, J.Á. Rodríguez Fernández, J. García de Lara, A. Castro Beiras. (2005) Tratamiento de la insuficiencia cardíaca crónica. Medicine - Programa de Formación Médica Continuada Acreditado 9:35, 2318-2326
CrossRef494
Iver A. Juster. (2005) Technology-Driven Interactive Care Management Identifies and Resolves More Clinical Issues than a Claims-Based Alerting System. Disease Management 8:3, 188-197
CrossRef495
Hani N. Sabbah. (2005) Global Left Ventricular Remodeling with the Acorn Cardiac Support Device: Hemodynamic and Angiographic Findings in Dogs with Heart Failure. Heart Failure Reviews 10:2, 109-115
CrossRef496
Sharad Rastogi, Sudhish Mishra, Ramesh C. Gupta, Hani N. Sabbah. (2005) Reversal of Maladaptive Gene Program in Left Ventricular Myocardium of Dogs with Heart Failure Following Long-Term Therapy with the Acorn Cardiac Support Device. Heart Failure Reviews 10:2, 157-163
CrossRef497
Gregg C. Fonarow. (2005) When to initiate beta-blockers in heart failure: Is it ever too early?. Current Heart Failure Reports 2:2, 94-99
CrossRef498
Murray Esler, Tye Dawood. (2005) Is “cardiovascular protection” by estrogens due to inhibition of the sympathetic nervous system?. Clinical Autonomic Research 15:3, 186-188
CrossRef499
Patricia A. Howard, Theresa I. Shireman. (2005) Heart Failure Drug Utilization Patterns for Medicaid Patients Before and After a Heart Failure-Related Hospitalization. Congestive Heart Failure 11:3, 124-128
CrossRef500
M. Cabré Roure. (2005) Tratamiento de la insuficiencia cardíaca en fase muy avanzada. FMC - Formación Médica Continuada en Atención Primaria 12:5, 315-324
CrossRef501
Min Pu, Zhaohui Gao, Jianhua Li, Lawrence Sinoway, William R. Davidson. (2005) Development of a New Animal Model of Chronic Mitral Regurgitation in Rats Under Transesophageal Echocardiographic Guidance. Journal of the American Society of Echocardiography 18:5, 468-474
CrossRef502
Wendy M. Book. (2005) Heart Failure in the Adult Patient with Congenital Heart Disease. Journal of Cardiac Failure 11:4, 306-312
CrossRef503
Michele Senni, Renata De Maria, Dario Gregori, Lucio Gonzini, Marco Gorini, Giuseppe Cacciatore, Antonello Gavazzi, Giovanni Pulignano, Maurizio Porcu, Aldo P. Maggioni. (2005) Temporal Trends in Survival and Hospitalizations in Outpatients With Chronic Systolic Heart Failure in 1995 and 1999. Journal of Cardiac Failure 11:4, 270-278
CrossRef504
Ragnar Watz, Ann-Britt Ekstrand, Victoria Engelbrektson, Björn Beermann. (2005) Treatment with angiotensin converting enzyme inhibitors, angiotensin-II-antagonists and beta-blockers in an unselected group of patients with chronic heart failure. European Journal of Clinical Pharmacology 61:3, 209-214
CrossRef505
Denise D. Barnard. (2005) Heart failure in women. Current Cardiology Reports 7:3, 159-165
CrossRef506
Lisa C Costello-Boerrigter, John C Burnett. (2005) The prognostic value of N-terminal proB-type natriuretic peptide. Nature Clinical Practice Cardiovascular Medicine 2:4, 194-201
CrossRef507
Gerald V. Naccarelli, Mary Ann Lukas. (2005) Carvedilol's antiarrhythmic properties: Therapeutic implications in patients with left ventricular dysfunction. Clinical Cardiology 28:4, 165-173
CrossRef508
Lilian Grigorian Shamagian, Alfonso Varela Román, Alejandro Virgos Lamela, Pedro Rigueiro Veloso, José M. García Acuña, José R. González-Juanatey. (2005) Evolución a largo plazo de la prescripción de fármacos en pacientes hospitalizados por insuficiencia cardíaca congestiva. Influencia del patrón de disfunción. Revista Española de Cardiología 58:4, 381-388
CrossRef509
Daniel J. Garry, Amanda M. Masino, R Haris Naseem, Cindy M. Martin, Norman M. Kaplan, Biff F. Palmer. (2005) Ponce de Leon???s Fountain: Stem Cells and the Regenerating Heart. The American Journal of the Medical Sciences 329:4, 190-201
CrossRef510
Ernesto R. Soltero, Nancy J. Petersen, Nan R. Earle, Donald H. Glaeser, Diana L. Urbauer, Anita Deswal. (2005) Long-Term Results of Coronary Artery Bypass Grafting in Patients With Ischemic Cardiomyopathy: The Impact of Renal Insufficiency and Noncardiac Vascular Disease. Journal of Cardiac Failure 11:3, 206-212
CrossRef511
Giorgio Cinquegrana, Luigi D'Aniello, Massimo Landi, Letizia Spinelli, Giovanni Grande, Francesco de Prisco, Mario Petretta. (2005) Effects of Different Degrees of Sympathetic Antagonism on Cytokine Network in Patients With Ischemic Dilated Cardiomyopathy. Journal of Cardiac Failure 11:3, 213-219
CrossRef512
Kiran R. Kareti, Jun R. Chiong, Steve S. Hsu, Alan B. Miller. (2005) Congestive Heart Failure and Atrial Fibrillation: Rhythm Versus Rate Control. Journal of Cardiac Failure 11:3, 164-172
CrossRef513
Jonathan A. Abbott, Richard V. Broadstone, Daniel L. Ward, R. Lee Pyle. (2005) Hemodynamic effects of orally administered carvedilol in healthy conscious dogs. American Journal of Veterinary Research 66:4, 637-641
CrossRef514
Daniel Nul, Carola Zambrano, Alejandro Diaz, Daniel Ferrante, Sergio Varini, Saúl Soifer, Hugo Grancelli, . (2005) Impact of a Standardized Titration Protocol with Carvedilol in Heart Failure: Safety, Tolerability, and Efficacy—A Report from the GESICA Registry. Cardiovascular Drugs and Therapy 19:2, 125-134
CrossRef515
Willem J. Remme. (2005) Do Standardized Beta-Blocker Titration Protocols in Heart Failure Improve Compliance? The GESICA Registry Experience. Cardiovascular Drugs and Therapy 19:2, 99-101
CrossRef516
Marcio Lerch Stürmer, Mario Talajic, Bernard Thibault, Peter G. Guerra, Marc Dubuc, Paul Novak, Denis Roy. (2005) Management of Atrial Fibrillation in Patients With Congestive Heart Failure. The American Journal of Geriatric Cardiology 14:2, 91-94
CrossRef517
Klaus K.A. Witte, Andrew L. Clark. (2005) β-Blockers and Inspiratory Pulmonary Function in Chronic Heart Failure. Journal of Cardiac Failure 11:2, 112-116
CrossRef518
Kou-Gi Shyu, Ming-Jen Lu, Hang Chang, Hsien-Yi Sun, Bao-Wei Wang, Peiliang Kuan. (2005) Carvedilol Modulates the Expression of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor in a Rat Model of Volume-Overload Heart Failure. Journal of Cardiac Failure 11:2, 152-159
CrossRef519
Daniel M. Hartung, Jacquelyn Hunt, Joseph Siemienczuk, Heather Miller, Daniel R. Touchette. (2005) Clinical Implications of an Accurate Problem List on Heart Failure Treatment. Journal of General Internal Medicine 20:2, 143-147
CrossRef520
Milton Packer, John McMurray, Barry M. Massie, Abraham Caspi, Vincent Charlon, Alain Cohen-Solal, Wolfgang Kiowski, William Kostuk, Henry Krum, Barry Levine, Paolo Rizzon, Jordi Soler, Karl Swedberg, Susan Anderson, David L. Demets. (2005) Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. Journal of Cardiac Failure 11:1, 12-20
CrossRef521
Shinichiro Fujimoto, Aritomo Inoue, Shinji Hisatake, Shohei Yamashina, Hisayo Yamashina, Hajime Nakano, Junichi Yamazaki. (2005) Usefulness of meta-[123I]iodobenzylguanidine myocardial scintigraphy for predicting cardiac events in patients with dilated cardiomyopathy who receive long-term beta blocker treatment. Nuclear Medicine Communications 26:2, 97-102
CrossRef522
Christian J.F. Holubarsch. (2005) Evidenz-basierte Medizin mit Wei
dorn-Extrakt: Ein Phytopharmakon ist einen weiten Weg gegangen. Pharmazie in unserer Zeit 34:1, 58-64
CrossRef523
Mutsuko Honda, Takashi Nozawa, Norio Igarashi, Hiroshi Inoue, Rie Arakawa, Yumi Ogura, Hiromi Okabe, Masato Taguchi, Yukiya Hashimoto. (2005) Effect of CYP2D6*10 on the Pharmacokinetics of R- and S-Carvedilol in Healthy Japanese Volunteers. Biological & Pharmaceutical Bulletin 28:8, 1476-1479
CrossRef524
Justine I. Davies, Miles D. Witham, Allan D. Struthers. (2005) Autonomic Effects of Spironolactone and MR Blockers in Heart Failure. Heart Failure Reviews 10:1, 63-69
CrossRef525
Martin Wehling. (2005) Differences in the Basic Pharmacology of Beta-Blocking Agents. Heart Drug 5:1, 2-5
CrossRef526
(2005) Documento de Consenso de Expertos sobre bloqueadores de los receptores ß-adrenérgicos. Revista Española de Cardiología 58:1, 65-90
CrossRef527
Peter M Rothwell. (2005) External validity of randomised controlled trials: “To whom do the results of this trial apply?”. The Lancet 365:9453, 82-93
CrossRef528
Justine I Davies, Allan D Struthers. (2005) Beyond blood pressure: pulse wave analysis – a better way of assessing cardiovascular risk?. Future Cardiology 1:1, 69-78
CrossRef529
Fabio Zac??, Alberto Benassi, Roberto Bolzani, Italo Ghidoni, Giuseppina Santese, Antonietta Schipani, Cosimo Stefanio. (2005) Comparative Effects of Doxazosin and Carvedilol on Clinical Status and Left Ventricular Function in Hypertensive Patients with Mild Heart Failure. High Blood Pressure & Cardiovascular Prevention 12:1, 37-44
CrossRef530
Toshio Ogihara, Hiromi Rakugi. (2005) Hypertension in the Elderly. Drugs & Aging 22:4, 297-314
CrossRef531
Gisli Jonsson, Michael Abdelnoor, Carl Müller, Sverre Erik Kjeldsen, Ingrid Os, Arne Westheim. (2005) A Comparison of the Two β-Blockers Carvedilol and Atenolol on Left Ventricular Ejection Fraction and Clinical Endpoints after Myocardial Infarction. Cardiology 103:3, 148-155
CrossRef532
Nobuyuki Shiba, Jun Watanabe, Tsuyoshi Shinozaki, Yoshito Koseki, Masahito Sakuma, Yutaka Kagaya, Kunio Shirato. (2005) Poor Prognosis of Japanese Patients With Chronic Heart Failure Following Myocardial Infarction. Circulation Journal 69:2, 143-149
CrossRef533
Kae Itoh, Naohiko Osada, Koji Inoue, Hisanori Samejima, Atsushi Seki, Kazuto Omiya, Fumihiko Miyake. (2005) Relationship Between Exercise Intolerance and Levels of Neurohormonal Factors and Proinflammatory Cytokines in Patients With Stable Chronic Heart Failure. International Heart Journal 46:6, 1049-1059
CrossRef534
Yuji Hara, Katsuji Inoue, Akiyoshi Ogimoto, Tomoaki Ohtsuka, Yuji Shigematsu, Shigeru Nakata, Jitsuo Higaki. (2005) Effect of Beta-Blocker Therapy on Myocardial Perfusion Defects in Thallium-201 Scintigraphy in Patients with Dilated Cardiomyopathy. Cardiology 104:1, 16-21
CrossRef535
Stephan Jacob, Erik J. Henriksen. (2004) Metabolic Properties of Vasodilating ? Blockers: Management Considerations for Hypertensive Diabetic Patients and Patients With the Metabolic Syndrome. The Journal of Clinical Hypertension 6:12, 690-696
CrossRef536
Keyur B. Shah, Stephen S. Gottlieb. (2004) Current concepts for the neurohormonal management of left ventricular dysfunction after myocardial infarction. Current Heart Failure Reports 1:4, 161-167
CrossRef537
P. Cía Gómez, A. Martínez Berganza, J.I. Pérez Calvo. (2004) Tratamiento farmacológico de la hipertensión arterial. Medicine - Programa de Formación Médica Continuada Acreditado 9:23, 1481-1493
CrossRef538
Brian K. Irons, James P. Tsikouris, Audra A. Thomas. (2004) The Use of Angiotensin Receptor Blockers in the Treatment of Chronic Heart Failure. Journal of Cardiovascular Pharmacology 44:6, 718-724
CrossRef539
Michael A. Acker. (2004) Surgical therapies for heart failure. Journal of Cardiac Failure 10:6, S220-S224
CrossRef540
David Rosenthal, Maryanne R.K. Chrisant, Erik Edens, Lynn Mahony, Charles Canter, Steven Colan, Anne Dubin, Jacque Lamour, Robert Ross, Robert Shaddy, Linda Addonizio, Lee Beerman, Stuart Berger, Daniel Bernstein, Elizabeth Blume, Mark Boucek, Paul Checchia, Anne Dipchand, Jonathan Drummond-Webb, Jay Fricker, Richard Friedman, Sara Hallowell, Robert Jaquiss, Seema Mital, Elfriede Pahl, Bennett Pearce, Larry Rhodes, Kathy Rotondo, Paolo Rusconi, Janet Scheel, Tajinder Pal Singh, Jeffrey Towbin. (2004) International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. The Journal of Heart and Lung Transplantation 23:12, 1313-1333
CrossRef541
Todd M. Koelling, Susan Joseph, Keith D. Aaronson. (2004) Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving β-blockers. The Journal of Heart and Lung Transplantation 23:12, 1414-1422
CrossRef542
John C Somberg, Janos Molnar. (2004) The Pharmacologic Treatment of Heart Failure. American Journal of Therapeutics 11:6, 480-488
CrossRef543
Robert E Hobbs. (2004) Guidelines for the Diagnosis and Management of Heart Failure. American Journal of Therapeutics 11:6, 467-472
CrossRef544
Valluvan Jeevanandam. (2004) The Quest for Permanent Ventricular Assistance: The Role of Aortic Counterpulsation. ASAIO Journal 50:6, xxvii-xlii
CrossRef545
Srinivas Iyengar, William T. Abraham. (2004) Pharmacogenomics and Heart Failure: Tailor-Made Therapy?. Congestive Heart Failure 10:6, 273-288
CrossRef546
van de Wal Rma, Voors AA, Plokker HWM, van Gilst WH, van Veldhuisen DJ. (2004) New Pharmacological Strategies in Chronic Heart Failure. Cardiovascular Drugs and Therapy 18:6, 491-501
CrossRef547
E. Hery, P. Jourdain, F. Funck, M. Bellorini, J. Loiret, B. Thebault, N. Guillard, A. El Hallak, M. Desnos. (2004) Prédiction du risque d’intolérance du traitement bêtabloquant chez l’insuffisant cardiaque chronique par le dosage du BNP. Annales de Cardiologie et d'Angéiologie 53:6, 298-304
CrossRef548
Mary Clare Derfler, Mark Jacob, Robert E. Wolf, Frank Bleyer, Paul J. Hauptman. (2004) Mode of Death From Congestive Heart Failure: Implications for Clinical Management. The American Journal of Geriatric Cardiology 13:6, 299-304
CrossRef549
Robert M. Lobel, Daniel L. Lustgarten. (2004) Treatment of arrhythmias in patients with congestive heart failure. Current Treatment Options in Cardiovascular Medicine 6:6, 519-529
CrossRef550
Lutz Hein. (2004) Entwicklung der Beta-Blocker: Ein historischer R
CrossRef551
Lofty L. Basta. (2004) Better Late Than Never: How Congestive Heart Failure Patients Die. The American Journal of Geriatric Cardiology 13:6, 321-322
CrossRef552
Dennis M. McNamara, Richard Holubkov, Lisa Postava, Karen Janosko, Guy A. MacGowan, Michael Mathier, Srinivas Murali, Arthur M. Feldman, Barry London. (2004) Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Journal of the American College of Cardiology 44:10, 2019-2026
CrossRef553
Eric Yang, Sherry Wang, John Kratz, Matthew J. Cyronak. (2004) Stereoselective analysis of carvedilol in human plasma using HPLC/MS/MS after chiral derivatization. Journal of Pharmaceutical and Biomedical Analysis 36:3, 609-615
CrossRef554
Dennis M. McNamara. (2004) Pharmacogenetics in Heart Failure: Genomic Markers of Endothelial and Neurohumoral Function. Congestive Heart Failure 10:6, 302-308
CrossRef555
Christoph Maack, Michael B
CrossRef556
Shinichiro Fujimoto, Hideo Amano, Aritomo Inoue, Shuichi Ishida, Shohei Yamashdma, Hisayo Yamashina, Hajime Nakano, Junichi Yamazaki. (2004) Usefulness of123I-metaiodobenzylguanidine myocardial scintigraphy in the prediction of cardiac events in patients with cardiomyopathy showing stabilization of symptoms or preserved cardiac function. Annals of Nuclear Medicine 18:7, 591-598
CrossRef557
Todd W. Rice, Gordon R. Bernard. (2004) Drotrecogin Alfa (Activated) for the Treatment of Severe Sepsis and Septic Shock. The American Journal of the Medical Sciences 328:4, 205-214
CrossRef558
Vanina Bongard, Jean-Pierre Cambou, Alain Lezorovcz, Jean Ferr??res, Alec Vahanan, G??rard Jullen, G??rard Coppe, Martine Guerllot, Marie-Annick Herrmann, Jean-Louis Mas. (2004) Comparison of cardiovascular risk factors and drug use in 14???544 French patients with a history of myocardial infarction, ischaemic stroke and/or peripheral arterial disease. European Journal of Cardiovascular Prevention & Rehabilitation 11:5, 394-402
CrossRef559
Robert C. Gorman, Joseph H. Gorman, Landi M. Parish, Martin G. St. John-Sutton. (2004) Infarction Induced Ventricular Remodeling. The Annals of Thoracic Surgery 78:4, 1507-1510
CrossRef560
Stephan E. Lehnart, Xander H.T. Wehrens, Andrew R. Marks. (2004) Calstabin deficiency, ryanodine receptors, and sudden cardiac death. Biochemical and Biophysical Research Communications 322:4, 1267-1279
CrossRef561
H.-P. Hermann, G. Hasenfuss. (2004) Therapie der Herzinsuffizienz. Intensivmedizin und Notfallmedizin 41:7, 451-464
CrossRef562
Genzou Takemura, Hisayoshi Fujiwara. (2004) Role of apoptosis in remodeling after myocardial infarction. Pharmacology & Therapeutics 104:1, 1-16
CrossRef563
Steven Kang, David S. Cannom. (2004) Current role of device therapy to reduce sudden cardiac death in heart failure. Current Heart Failure Reports 1:3, 104-110
CrossRef564
Flávio Danni Fuchs. (2004) Blood pressure-lowering drugs: essential therapy for some patients with normal blood pressure. Expert Review of Cardiovascular Therapy 2:5, 771-775
CrossRef565
Liviu Klein, Mihai Gheorghiade. (2004) Coronary artery disease and prevention of heart failure. Medical Clinics of North America 88:5, 1209-1235
CrossRef566
Clyde W. Yancy. (2004) The prevention of heart failure in minority communities and discrepancies in health care delivery systems. Medical Clinics of North America 88:5, 1347-1368
CrossRef567
Lars H. Lund, Donna Mancini. (2004) Heart failure in women. Medical Clinics of North America 88:5, 1321-1345
CrossRef568
Jacob N Schroder, Matthew L Williams, Walter J Koch. (2004) Gene delivery approaches to heart failure treatment. Expert Opinion on Biological Therapy 4:9, 1413-1422
CrossRef569
Ali Khoynezhad, Ziba Jalali, Anthony J. Tortolani. (2004) Apoptosis: Pathophysiology and therapeutic implications for the cardiac surgeon. The Annals of Thoracic Surgery 78:3, 1109-1118
CrossRef570
Ali Ahmed, Louis J. Dell???Italia. (2004) Use of Beta-Blockers in Older Adults with Chronic Heart Failure. The American Journal of the Medical Sciences 328:2, 100-111
CrossRef571
Eliot H Ohlstein, Anne M Romanic. (2004) New developments in the use of β-blockers for the management of heart failure. Expert Opinion on Investigational Drugs 13:8, 999-1005
CrossRef572
Deepak Bhakta, William J Groh. (2004) Cardiac function tests in neuromuscular diseases. Neurologic Clinics 22:3, 591-617
CrossRef573
Murray Esler, Alan Lux, Garry Jennings, Jacqui Hastings, Flora Socratous, Gavin Lambert. (2004) Rilmenidine sympatholytic activity preserves mental stress, orthostatic sympathetic responses and adrenaline secretion. Journal of Hypertension 22:8, 1529-1534
CrossRef574
Alex Adler, Barry H. Greenberg. (2004) Use of beta blockers in patients with post-MI left ventricular dysfunction. Current Treatment Options in Cardiovascular Medicine 6:4, 335-343
CrossRef575
Richard D. Patten, Prem Soman. (2004) Prevention and reversal of LV remodeling with neurohormonal inhibitors. Current Treatment Options in Cardiovascular Medicine 6:4, 313-325
CrossRef576
Xander H. T. Wehrens, Andrew R. Marks. (2004) Novel therapeutic approaches for heart failure by normalizing calcium cycling. Nature Reviews Drug Discovery 3:7, 565-574
CrossRef577
Paolo Rusconi, Orlando Gómez-Marín, Marie Rossique-González, Esmail Redha, Jennifer R. Marín, Ming Lon-Young, Grace S. Wolff. (2004) Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. The Journal of Heart and Lung Transplantation 23:7, 832-838
CrossRef578
Bradley P Knight, Aseem Desai, James Coman, Mitchell Faddis, Patrick Yong. (2004) Long-term retention of cardiac resynchronization therapy. Journal of the American College of Cardiology 44:1, 72-77
CrossRef579
C LECLERCQ. (2004) Comparative effects of ventricular resynchronization therapy in heart failure patients with or without coronary artery disease. Annales de Cardiologie et d?Ang
CrossRef580
Andrea Di Lenarda, Gastone Sabbadini, Michele Moretti, Gianfranco Sinagra. (2004) Long-term oral carvedilol in chronic heart failure. Expert Opinion on Pharmacotherapy 5:6, 1359-1372
CrossRef581
Steven R. Goldsmith. (2004) Interactions between the sympathetic nervous system and the RAAS in heart failure. Current Heart Failure Reports 1:2, 45-50
CrossRef582
Michele Emdin, Claudio Passino, Concetta Prontera, Annalisa Iervasi, Andrea Ripoli, Silvano Masini, Gian Carlo Zucchelli, Aldo Clerico. (2004) Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clinical Chemistry and Laboratory Medicine 42:6, 627-636
CrossRef583
Deborah Moyer-Knox, Teresa M. Mueller, Karen Vuckovic, Lisa Mischke, Randall E. Williams. (2004) Remote titration of carvedilol for heart failure patients by advanced practice nurses. Journal of Cardiac Failure 10:3, 219-224
CrossRef584
John G. F. Cleland. (2004) Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET. Current Heart Failure Reports 1:2, 82-88
CrossRef585
Feras M. Bader, John F. MacGregor, Edward M. Gilbert. (2004) Initiation and use of beta-blockers in class IV heart failure. Current Heart Failure Reports 1:2, 72-76
CrossRef586
Kadish, Alan, Dyer, Alan, Daubert, James P., Quigg, Rebecca, Estes, N.A. Mark, Anderson, Kelley P., Calkins, Hugh, Hoch, David, Goldberger, Jeffrey, Shalaby, Alaa, Sanders, William E., Schaechter, Andi, Levine, Joseph H., . (2004) Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy. New England Journal of Medicine 350:21, 2151-2158
Full Text587
Gregory Giesler, Daniel J. Lenihan, Jean-Bernard Durand. (2004) The update on the rationale, use and selection of ??-blockers in heart failure. Current Opinion in Cardiology 19:3, 250-253
CrossRef588
Outi Saijonmaa, Tuulikki Nyman, Frej Fyhrquist. (2004) Carvedilol Inhibits Basal and Stimulated ACE Production in Human Endothelial Cells. Journal of Cardiovascular Pharmacology 43:5, 616-621
CrossRef589
Xiao-Jun Du, Xinheng Feng, Xiao-Ming Gao, Tze Ping Tan, Helen Kiriazis, Anthony M Dart. (2004) I f channel inhibitor ivabradine lowers heart rate in mice with enhanced sympathoadrenergic activities. British Journal of Pharmacology 142:1, 107-112
CrossRef590
William B Hood, Jr., Antonio L Dans, Gordon H Guyatt, Roman Jaeschke, John JV McMurray, William B Hood, Jr.. 2004. Digitalis for treatment of congestive heart failure in patients in sinus rhythm. .
CrossRef591
Elijah Saunders. (2004) Managing Hypertension in African-American Patients. The Journal of Clinical Hypertension 6:s4, 19-25
CrossRef592
William B. Hood, Antonio L. Dans, Gordon H. Guyatt, Roman Jaeschke, John J.V. McMurray. (2004) Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. Journal of Cardiac Failure 10:2, 155-164
CrossRef593
Torstein Hole, Gisle Froland, Lars Gullestad, Jon Offstad, Terje Skjaerpe. (2004) Metoprolol CR/XL Improves Systolic and Diastolic Left Ventricular Function in Patients with Chronic Heart Failure. Echocardiography 21:3, 215-223
CrossRef594
Jean L Rouleau, Ellen B Roecker, Michal Tendera, Paul Mohacsi, Henry Krum, Hugo A Katus, Michael B Fowler, Andrew J.S Coats, Alain Castaigne, Armin Scherhag, Terry L Holcslaw, Milton Packer. (2004) Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure. Journal of the American College of Cardiology 43:8, 1423-1429
CrossRef595
Emma J. Birks, Magdi H. Yacoub, Nicholas R. Banner, Asghar Khaghani. (2004) The role of bridge to transplantation: should LVAD patients be transplanted?. Current Opinion in Cardiology 19:2, 148-153
CrossRef596
Jari M. Tapanainen, Kai S. Lindgren, Timo H. Mäkikallio, Olli Vuolteenaho, Juhani Leppäluoto, Heikki V. Huikuri. (2004) Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. Journal of the American College of Cardiology 43:5, 757-763
CrossRef597
Matthew L. Williams, Walter J. Koch. (2004) Viral-Based Myocardial Gene Therapy Approaches to Alter Cardiac Function. Annual Review of Physiology 66:1, 49-75
CrossRef598
Richard L. Summers, Charles W. Parrott, Cheryl Quale, Deborah L. Lewis. (2004) Case Report. Use of Noninvasive Hemodynamics to Aid Decision Making in the Initiation and Titration of Neurohormonal Agents. Congestive Heart Failure 10:s2, 28-31
CrossRef599
Javed Butler, Ghazanfar Khadim, Kimberly M. Paul, Stacy F. Davis, Marvin W. Kronenberg, Don B. Chomsky, Richard N. Pierson, John R. Wilson. (2004) Selection of patients for heart transplantationin the current era of heart failure therapy. Journal of the American College of Cardiology 43:5, 787-793
CrossRef600
Norman Sharpe. (2004) Pharmacologic effects on cardiac remodeling. Current Heart Failure Reports 1:1, 9-13
CrossRef601
P.A. Mehta. (2004) Heart failure in a district general hospital: are target doses of beta-blockers realistic?. QJM 97:3, 133-139
CrossRef602
Babar B Chaudhri, Federica del Monte, Sian E Harding, Roger J Hajjar. (2004) Gene transfer in cardiac myocytes. Surgical Clinics of North America 84:1, 141-159
CrossRef603
G.William Dec. (2004) Management of heart failure: crossing boundary over to the surgical country. Surgical Clinics of North America 84:1, 1-25
CrossRef604
F. Formiga. (2004) One-year follow-up of heart failure patients after their first admission. QJM 97:2, 81-86
CrossRef605
Yuichi Abe, Kenichi Watanabe, Shinji Sato, Yusuke Nagai, Fadia A. Kamal, Mir I.I. Wahed, Juan Wen, Gurusamy Narasimman, Meilie Ma, Palaniyandi Suresh, Toshihiro Takahashi, Hitoshi Tachikawa, Takeshi Kashimura, Naohito Tanabe, Makoto Kodama, Yoshifusa Aizawa, Kenichi Yamaguchi, Makoto Miyazaki, Masao Kakemi. (2004) Hemodynamic Effects of Carvedilol Infusion and the Contribution of the Sympathetic Nervous System in Rats with Heart Failure. Pharmacology 72:4, 213-219
CrossRef606
Rosemary S. Bubien, Elizabeth A. Ching, G. Neal Kay. (2004) Cardiac Defibrillation and Resynchronization Therapies. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 15:3, 340-361
CrossRef607
Sheila A Doggrell. (2004) Has COMET solved the controversy as to whether carvedilol is better than metoprolol in heart failure?. Expert Opinion on Pharmacotherapy 5:1, 205-208
CrossRef608
Wan-Jing Ho, Pei-Kwei Tsay, Po-Hsien Chu, Chi-Jen Chang, Chi-Tai Kuo, Wei-Jan Chen. (2004) Predictors of Stable Outcome in Treating Chronic Heart Failure Patients With Carvedilol. Japanese Heart Journal 45:5, 823-832
CrossRef609
Nobuyuki Shiba, Jun Watanabe, Tsuyoshi Shinozaki, Yoshito Koseki, Masahito Sakuma, Yutaka Kagaya, Kunio Shirato, the CHART investigators. (2004) Analysis of Chronic Heart Failure Registry in the Tohoku District. Circulation Journal 68:5, 427-434
CrossRef610
Thomas S Mir, Stephanie L??er, Michele Eiselt, Jan Falkenberg, Urda Gottschalk, Jochen Weil. (2004) Effect of Carvedilol on QT Duration in Paediatric Patients with Congestive Heart Failure. Clinical Drug Investigation 24:1, 9-15
CrossRef611
Mitsuyoshi Hadase, Akihiro Azuma, Kan Zen, Satoshi Asada, Tatsuya Kawasaki, Tadaaki Kamitani, Shingo Kawasaki, Hiroki Sugihara, Hiroaki Matsubara. (2004) Very Low Frequency Power of Heart Rate Variability is a Powerful Predictor of Clinical Prognosis in Patients With Congestive Heart Failure. Circulation Journal 68:4, 343-347
CrossRef612
Yoshihiko Seino. (2004) Back to the Future: Pathophysiology and Therapeutic Strategies in Heart Failure. Journal of Nippon Medical School 71:6, 421-425
CrossRef613
Satoru Komura, Masaomi Chinushi, Michiko Kudo, Takashi Saikawa, Yasutaka Tanabe, Hiroshi Furushima, Takashi Washizuka, Makoto Kodama, Hirotaka Oda, Seiichi Miyajima, Fumiaki Masani, Yutaka Igarashi, Minoru Murata, Yoshifusa Aizawa. (2004) Potential Candidates for Cardiac Resynchronization Therapy in Japanese Patients With Idiopathic Dilated Cardiomyopathy. Circulation Journal 68:12, 1104-1109
CrossRef614
Miguel Quintana, Thomas Kahan, Paul Hjemdahl. (2004) Pharmacological Prevention of Reperfusion Injury in Acute Myocardial Infarction. American Journal of Cardiovascular Drugs 4:3, 159-167
CrossRef615
Takayuki Inomata, Tohru Izumi, Makoto Kobayashi. (2004) Cost-Effectiveness Analysis of Carvedilol for the Treatment of Chronic Heart Failure in Japan. Circulation Journal 68:1, 35-40
CrossRef616
Suad Catovic, Petar Otasevic, Milutin Miric, Aleksandar Neskovic, Zoran Popovic. (2004) The outcome and prognosis following the surgical intervention in patients with severe aortic stenosis with respecttothe presence and severity of associated aortic regurgitation. Srpski arhiv za celokupno lekarstvo 132:7-8, 219-229
CrossRef617
Barry M Massie. (2003) A comment on COMET: how to interpret a positive trial?. Journal of Cardiac Failure 9:6, 425-428
CrossRef618
Matthew A Movsesian. (2003) PDE3 inhibition in dilated cardiomyopathy: reasons to reconsider. Journal of Cardiac Failure 9:6, 475-480
CrossRef619
Katarzyna Hryniewicz, Ana Silvia Androne, Alhakam Hudaihed, Stuart D Katz. (2003) Partial reversal of Cachexia by β-adrenergic receptor blocker therapy in patients with chronic heart failure. Journal of Cardiac Failure 9:6, 464-468
CrossRef620
Michael R. Bristow, Arthur M. Feldman, Kirkwood F. Adams, Sidney Goldstein. (2003) Selective versus nonselective β-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?. Journal of Cardiac Failure 9:6, 444-453
CrossRef621
Pedro Monteiro, Ana I Duarte, António Moreno, Lino M Gonçalves, Luı́s A Providência. (2003) Carvedilol improves energy production during acute global myocardial ischaemia. European Journal of Pharmacology 482:1-3, 245-253
CrossRef622
Kenichi Watanabe, Yuichi Abe, Shinji Sato, Mir Wahed, Juan Wen, Gurusamy Narasimman, Meilei Ma, Fadia Ali, Yuki Saito, Palaniyandi Suresh, Ken Shirai, Mayako Soga, Yusuke Nagai, Toshihiro Takahashi, Go Hasegawa, Makoto Naito, Hitoshi Tachikawa, Naohito Tanabe, Makoto Kodama, Yoshifusa Aizawa, Kenichi Yamaguchi, Makoto Miyazaki, Masao Kakemi. (2003) Contribution of Sympathetic Nervous System Activity during Administration of Carvedilol in Rats with Dilated Cardiomyopathy. Journal of Cardiovascular Pharmacology 42, S93-S97
CrossRef623
Matthew J. Sorrentino. (2003) Beta-blockers for congestive heart failure. Comprehensive Therapy 29:4, 210-214
CrossRef624
Aleem U Khand, Andrew C Rankin, William Martin, Jacqueline Taylor, Islay Gemmell, John G.F Cleland. (2003) Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?. Journal of the American College of Cardiology 42:11, 1944-1951
CrossRef625
Milton Packer. (2003) Do β-blockers prolong survival in heart failure only by inhibiting the β1-receptor? A perspective on the results of the COMET trial. Journal of Cardiac Failure 9:6, 429-443
CrossRef626
Jay Garg, George L Bakris. (2003) Are antihypertensive drugs used to maximally reduce cardiovascular risk in dialysis patients?. American Journal of Kidney Diseases 42:6, 1301-1304
CrossRef627
Wendy M. Book, Brenda J. Hott. (2003) Beta-adrenergic receptor blockers in heart failure. Current Treatment Options in Cardiovascular Medicine 5:6, 475-485
CrossRef628
Ileana L Piña. (2003) A better survival for women with heart failure? it's not so simple…. Journal of the American College of Cardiology 42:12, 2135-2138
CrossRef629
Todd F Griffith, Benjamin S.Y Chua, Andrew S Allen, Preston S Klassen, Donal N Reddan, Lynda A Szczech. (2003) Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients1. American Journal of Kidney Diseases 42:6, 1260-1269
CrossRef630
Aritomo Inoue, Shohei Yamashina, Junichi Yamazaki. (2003) The effect of β-blocker on hamster model BIO 53.58 with dilated cardiomyopathy determined using123I-MIBG myocardial scintigraphy. Annals of Nuclear Medicine 17:8, 677-683
CrossRef631
Daniel E. Forman, Michael W. Rich. (2003) Heart Failure in the Elderly. Congestive Heart Failure 9:6, 311-323
CrossRef632
Pallav J Shah, David L Hare, Jai S Raman, Ian Gordon, Robert K Chan, John D Horowitz, Alex Rosalion, Brian F Buxton. (2003) Survival after myocardial revascularization for ischemic cardiomyopathy: A prospective ten-year follow-up study. The Journal of Thoracic and Cardiovascular Surgery 126:5, 1320-1327
CrossRef633
Yrsa Bergmann Sverrisd??ttir, Mikael Elam, Kenneth Caidahl, Ann-Sofi S??derling, Hans Herlitz, Gudmundur Johannsson. (2003) The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults. Journal of Hypertension 21:10, 1905-1914
CrossRef634
Linda R Peterson, Kenneth B Schechtman, Gregory A Ewald, Edward M Geltman, Lisa de las Fuentes, Timothy Meyer, Pamela Krekeler, Martha L Moore, Joseph G Rogers. (2003) Timing of cardiac transplantation in patients with heart failure receiving β-adrenergic blockers. The Journal of Heart and Lung Transplantation 22:10, 1141-1148
CrossRef635
Philip R. Liebson. (2003) AVID and COMET. Preventive Cardiology 6:4, 218-220
CrossRef636
Georges Chahoud, Jacob Joseph. (2003) Beta-blockade in chronic heart failure: does it work in everyone?. Current Opinion in Cardiology 18:5, 400-405
CrossRef637
T. Barry Levine, Arlene B. Levine, Janet Bolenbaugh, Pamela R. Green. (2003) Reversal of heart failure remodeling: Is it maintained?. Clinical Cardiology 26:9, 419-423
CrossRef638
Pozehl Bunny, Kathleen Duncan, Steven Krueger, Patricia VerMaas. (2003) Adjunctive Effects of Exercise Training in Heart Failure Patients Receiving Maximum Pharmacologic Therapy. Progress in Cardiovascular Nursing 18:4, 177-183
CrossRef639
Marc A Pfeffer, Karl Swedberg, Christopher B Granger, Peter Held, John JV McMurray, Eric L Michelson, Bertil Olofsson, Jan Östergren, Salim Yusuf. (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. The Lancet 362:9386, 759-766
CrossRef640
Antje Habicht, Bruno Watschinger. (2003) Sympathische Überaktivität und Niere. Wiener Klinische Wochenschrift 115:17-18, 634-640
CrossRef641
Marrick L. Kukin. (2003) The Most Important Issue: Use Beta Blockers. Congestive Heart Failure 9:5, 251-254
CrossRef642
Christoph Maack, Thomas Elter, Michael Böhm. (2003) Beta-Blocker Treatment of Chronic Heart Failure: Comparison of Carvedilol and Metoprolol. Congestive Heart Failure 9:5, 263-270
CrossRef643
William T. Abraham. (2003) Switching Between Beta Blockers in Heart Failure Patients: Rationale and Practical Considerations. Congestive Heart Failure 9:5, 271-278
CrossRef644
Patrick M McCarthy. (2003) Ventricular aneurysms, shock, and late follow-up in patients with heart failure. The Journal of Thoracic and Cardiovascular Surgery 126:2, 323-325
CrossRef645
Bente Brendorp, Ole Dyg Pedersen, Hanne Elming, Lars Køber, Christian Torp-Pedersen. (2003) Can antiarrhythmic drugs save lives in patients with congestive heart failure?. Expert Review of Cardiovascular Therapy 1:2, 191-202
CrossRef646
Heikki V Huikuri, Jari M Tapanainen, Kai Lindgren, Pekka Raatikainen, Timo H Mäkikallio, K.E Juhani Airaksinen, Robert J Myerburg. (2003) Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era. Journal of the American College of Cardiology 42:4, 652-658
CrossRef647
Chang-seng Liang. (2003) Sympatholysis and cardiac sympathetic nerve function in the treatment of congestive heart failure. Journal of the American College of Cardiology 42:3, 549-551
CrossRef648
Reza Tabrizchi. (2003) Should βblockers form the cornerstone for the treatment of congestive heart failure?. Expert Review of Cardiovascular Therapy 1:2, 157-160
CrossRef649
Wilbert S Aronow. (2003) Might losartan reduce sudden cardiac death in diabetic patients with hypertension?. The Lancet 362:9384, 591-592
CrossRef650
Mary Montrella Waybill, Peter N. Waybill. (2003) A Practical Approach to Hypertension in the 21st Century. Journal of Vascular and Interventional Radiology 14:8, 961-975
CrossRef651
David M Kaye, Belinda Smirk, Carolyn Williams, Garry Jennings, Murray Esler, Dianne Holst. (2003) ??-Adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 13:7, 379-382
CrossRef652
Paola A. Lanfranchi, Virend K. Somers. (2003) Sleep-disordered breathing in heart failure: characteristics and implications. Respiratory Physiology & Neurobiology 136:2-3, 153-165
CrossRef653
Wilbert S. Aronow. (2003) Mortality in Nursing Home Patients with Congestive Heart Failure. Journal of the American Medical Directors Association 4:4, 220-221
CrossRef654
Henry J Dargie. (2003) β blockers in heart failure. The Lancet 362:9377, 2-3
CrossRef655
Thomachan Kalapura, Hector O. Ventura. (2003) Beta-Blocker Therapy and Severe Heart Failure: Myth or Reality?. Congestive Heart Failure 9:4, 197-202
CrossRef656
Philip A Poole-Wilson, Karl Swedberg, John GF Cleland, Andrea Di Lenarda, Peter Hanrath, Michel Komajda, Jacobus Lubsen, Beatrix Lutiger, Marco Metra, Willem J Remme, Christian Torp-Pedersen, Armin Scherhag, Allan Skene. (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. The Lancet 362:9377, 7-13
CrossRef657
Wilbert S. Aronow. (2003) Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure in Elderly Patients. Heart Disease 5:4, 279-294
CrossRef658
Noritoshi Nagaya, Kenji Kangawa. (2003) Ghrelin, a novel growth hormone-releasing peptide, in the treatment of chronic heart failure. Regulatory Peptides 114:2-3, 71-77
CrossRef659
Michael W. Rich. (2003) Drug Therapy Of Heart Failure in the Elderly. The American Journal of Geriatric Cardiology 12:4, 235-242
CrossRef660
Maryanne Crowther. (2003) Optimal Management of Outpatients With Heart Failure Using Advanced Practice Nurses in a Hospital-Based Heart Failure Center. Journal of the American Academy of Nurse Practitioners 15:6, 260-265
CrossRef661
Jacques Amar, Bernard Chamontin, Nathalie Genes, Christelle Cantet, Michel Salvador, Jean Pierre Cambou. (2003) Why is hypertension so frequently uncontrolled in secondary prevention?. Journal of Hypertension 21:6, 1199-1205
CrossRef662
Anthony Cox, Nigel Langford. (2003) Drug-induce cardiac failure. Adverse Drug Reaction Bulletin &NA;:220, 843-846
CrossRef663
F Mouquet, S Susen, E Van Belle, C Bauters, B Jude. (2003) Thérapie cellulaire et insuffisance cardiaque. La Revue de Médecine Interne 24:6, 401-404
CrossRef664
Paul G. Shekelle, Michael W. Rich, Sally C. Morton, Col.Sid W. Atkinson, Wenli Tu, Margaret Maglione, Shannon Rhodes, Michael Barrett, Gregg C. Fonarow, Barry Greenberg, Paul A. Heidenreich, Tom Knabel, Marvin A. Konstam, Anthony Steimle, Lynne Warner Stevenson. (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. Journal of the American College of Cardiology 41:9, 1529-1538
CrossRef665
S.Adam Strickberger, John D Hummel, Thomas G Bartlett, Howard I Frumin, Claudio D Schuger, Scott L Beau, Cynthia Bitar, Fred Morady. (2003) Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemicdilated cardiomyopathy and asymptomaticnonsustained ventricular tachycardia—AMIOVIRT. Journal of the American College of Cardiology 41:10, 1707-1712
CrossRef666
Gennaro Cice, Luigi Ferrara, Antonello D’Andrea, Salvatore D’Isa, Attilio Di Benedetto, Antonio Cittadini, Pina Elvira Russo, Paolo Golino, Raffaele Calabrò. (2003) Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy. Journal of the American College of Cardiology 41:9, 1438-1444
CrossRef667
Bobbi L. Hoppe, Denise D. Hermann. (2003) Sex differences in the causes and natural history of heart failure. Current Cardiology Reports 5:3, 193-199
CrossRef668
Soccorso Capomolla. (2003) Reply. Journal of the American College of Cardiology 41:10, 1850-1851
CrossRef669
Wilbert S. Aronow. (2003) Treatment of Heart Failure in Older Persons.. Congestive Heart Failure 9:3, 142-147
CrossRef670
Mitja Lainscak, Alojz Horvat, Irena Keber. (2003) The management of patients with heart failure in a Slovenian community hospital: What has changed between 1997 and 2000?. Wiener Klinische Wochenschrift 115:10, 334-339
CrossRef671
Roberto F. E. Pedretti, Giovanna Prete, Robert D. Foreman, Philip B. Adamson, Emilio Vanoli. (2003) Autonomic Modulation during Acute Myocardial Ischemia by Low-Dose Pirenzepine in Conscious Dogs with a Healed Myocardial Infarction: A Comparison with β-Adrenergic Blockade. Journal of Cardiovascular Pharmacology 41:5, 671-677
CrossRef672
Stephen A. Morse, An Dang, Vashu Thakur, Rubin Zhang, Efrain Reisin. (2003) Hypertension in Chronic Dialysis Patients: Pathophysiology, Monitoring, and Treatment. The American Journal of the Medical Sciences 325:4, 194-201
CrossRef673
J. Herbert Patterson, Jo E. Rodgers. (2003) Expanding Role of β-Blockade in the Management of Chronic Heart Failure. Pharmacotherapy 23:4, 451-459
CrossRef674
Hong Kan, Mitchell S. Finkel. (2003) Inflammatory mediators and reversible myocardial dysfunction. Journal of Cellular Physiology 195:1, 1-11
CrossRef675
Lip-Bun Tan, Jatin G. Burniston, William A. Clark, YeeLan Ng, David F. Goldspink. (2003) Characterization of Adrenoceptor Involvement in Skeletal and Cardiac Myotoxicity Induced by Sympathomimetic Agents: Toward a New Bioassay for β-blockers. Journal of Cardiovascular Pharmacology 41:4, 518-525
CrossRef676
Guido Iaccarino, Walter J. Koch. (2003) Transgenic Mice Targeting the Heart Unveil G Protein-Coupled Receptor Kinases as Therapeutic Targets. ASSAY and Drug Development Technologies 1:2, 347-355
CrossRef677
Zsuzsanna Callaerts-Vegh, Kenda L J Evans, Gregory L Shipley, Peter J A Davies, Donald L Cuba, Hunaid A Gurji, Heather Giles, Richard A Bond. (2003) Effects of different beta adrenoceptor ligands in mice with permanent occlusion of the left anterior descending coronary artery. British Journal of Pharmacology 138:8, 1505-1516
CrossRef678
Kaneko, Yasuyuki, Floras, John S., Usui, Kengo, Plante, Julie, Tkacova, Ruzena, Kubo, Toshihiko, Ando, Shin-ichi, Bradley, T. Douglas, . (2003) Cardiovascular Effects of Continuous Positive Airway Pressure in Patients with Heart Failure and Obstructive Sleep Apnea. New England Journal of Medicine 348:13, 1233-1241
Full Text679
M. Esler, G. Lambert, H. P. Brunner-La Rocca, G. Vaddadi, D. Kaye. (2003) Sympathetic nerve activity and neurotransmitter release in humans: translation from pathophysiology into clinical practice. Acta Physiologica Scandinavica 177:3, 275-284
CrossRef680
Justine Ina Davies, Allan D Struthers. (2003) Pulse wave analysis and pulse wave velocity. Journal of Hypertension 21:3, 463-472
CrossRef681
John G.F Cleland. (2003) β-Blockers for heart failure: why, which, when, and where. Medical Clinics of North America 87:2, 339-371
CrossRef682
Sean W. Murphy. (2003) THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Management of Heart Failure and Coronary Artery Disease in Patients with Chronic Kidney Disease. Seminars in Dialysis 16:2, 165-172
CrossRef683
Lilian Clohs, Keith M McErlane. (2003) Comparison between capillary electrophoresis and high-performance liquid chromatography for the stereoselective analysis of carvedilol in serum. Journal of Pharmaceutical and Biomedical Analysis 31:3, 407-412
CrossRef684
Sanjay Rajagopalan, Bertram Pitt. (2003) Aldosterone as a target in congestive heart failure. Medical Clinics of North America 87:2, 441-457
CrossRef685
Arnold M Katz. (2003) Pathophysiology of heart failure: identifying targets for pharmacotherapy. Medical Clinics of North America 87:2, 303-316
CrossRef686
N. Frey, E.N. Olson. (2003) C
ARDIAC HYPERTROPHY : The Good, the Bad, and the Ugly. Annual Review of Physiology 65:1, 45-79
CrossRef687
Ariyaporn Thawornkaiwong, Surin Preawnim, Jonggonnee Wattanapermpool. (2003) Upregulation of β1-adrenergic receptors in ovariectomized rat hearts. Life Sciences 72:16, 1813-1824
CrossRef688
Catherine Demers, Robert S. McKelvie. (2003) Growth Hormone Therapy in Heart Failure: Where Are We Now?. Congestive Heart Failure 9:2, 84-90
CrossRef689
Lionel Thomas, Bernard Gasser, Pascal Bousquet, Laurent Monassier. (2003) Hemodynamic and Cardiac Anti-Hypertrophic Actions of Clonidine in Goldblatt One-Kidney, One-Clip Rats. Journal of Cardiovascular Pharmacology 41:2, 203-209
CrossRef690
Yuji Hara, Mareomi Hamada, Yuji Shigematsu, Tomoaki Ohtsuka, Akiyoshi Ogimoto, Jitsuo Higaki. (2003) Effect of Beta-Blockers on Insulin Resistance in Patients With Dilated Cardiomyopathy. Circulation Journal 67:8, 701-704
CrossRef691
Amar L Pohwani, Srinivas Murali, Michael M Mathier, Tammy Tokarczyk, Robert L Kormos, Dennis M McNamara, Guy A MacGowan. (2003) Impact of β-blocker therapy on functional capacity criteria for heart transplant listing. The Journal of Heart and Lung Transplantation 22:1, 78-86
CrossRef692
Kenneth M. Leclerc, Wayne C. Levy. (2003) The Role of Norepinephrine in Exercise Impairment in Congestive Heart Failure. Congestive Heart Failure 9:1, 25-28
CrossRef693
Stuart D. Russell, Tracy DeWald. (2003) Vasopressin Receptor Antagonists. American Journal of Cardiovascular Drugs 3:1, 13-20
CrossRef694
Toshio OGIHARA, Kunio HIWADA, Shigeto MORIMOTO, Hiroaki MATSUOKA, Masayuki MATSUMOTO, Shuichi TAKISHITA, Kazuaki SHIMAMOTO, Kazuyuki SHIMADA, Isao ABE, Yasuyoshi OUCHI, Hisaichiro TSUKIYAMA, Shigehiro KATAYAMA, Yutaka IMAI, Hiromichi SUZUKI, Katsuhiko KOHARA, Kohya OKAISHI, Hiroshi MIKAMI. (2003) Guidelines for Treatment of Hypertension in the Elderly. 2002 Revised Version.. Hypertension Research 26:1, 1-36
CrossRef695
Yuji Hara, Mareomi Hamada, Yuji Shigematsu, Tomoaki Ohtsuka, Akiyoshi Ogimoto, Jun Suzuki, Jitsuo Higaki. (2003) Effect of Beta-Blocker Therapy in Elderly Patients With Dilated Cardiomyopathy. Circulation Journal 67:10, 826-829
CrossRef696
A. M. Katz. (2003) Heart failure: a hemodynamic disorder complicated by maladaptive proliferative responses. Journal of Cellular and Molecular Medicine 7:1, 1-10
CrossRef697
J WLODARCZYK, A KEOGH, K SMITH, C MCCOSKER. (2003) CHART: Congestive cardiac failure in hospitals, an Australian review of treatment. Heart, Lung and Circulation 12:2, 94-102
CrossRef698
Gillian M Keating, Blair Jarvis. (2003) Carvedilol. Drugs 63:16, 1697-1741
CrossRef699
Yuejin Yang, Yida Tang, Yingmao Ruan, Yanwu Wang, Runlin Gao, Jilin Chen, Zaijia Chen. (2003) Comparison of Metoprolol With Low, Middle and High Doses of Carvedilol in Prevention of Postinfarction Left Ventricular Remodeling in Rats. Japanese Heart Journal 44:6, 979-988
CrossRef700
Atsushi Namiki, Tetsuya Kubota, Masayuki Fukazawa, Michiro Ishikawa, Masao Moroi, Jo Aikawa, Kunio Ebine, Tetsu Yamaguchi. (2003) Endothelin-1 Concentrations in Pericardial Fluid Are More Elevated in Patients with Ischemic Heart Disease Than in Patients With Nonischemic Heart Disease. Japanese Heart Journal 44:5, 633-644
CrossRef701
Linda R Peterson, Kenneth B Schechtman, Gregory A Ewald, Edward M Geltman, Timothy Meyer, Pamela Krekeler, Joseph G Rogers. (2003) The effect of β-adrenergic blockers on the prognostic value of peak exercise oxygen uptake in patients with heart failure. The Journal of Heart and Lung Transplantation 22:1, 70-77
CrossRef702
Bradley R Williams, Jiwon Kim. (2003) Cardiovascular Drug Therapy in the Elderly: Theoretical and Practical Considerations. Drugs & Aging 20:6, 445-463
CrossRef703
Atsushi Yao, Osami Kohmoto, Tomomi Oyama, Yasuyuki Sugishita, Tatsuya Shimizu, Kazumasa Harada, Hiroshi Matsui, Issei Komuro, Ryozo Nagai, Hiroshi Matsuo, Takashi Serizawa, Takashi Maruyama, Toshiyuki Takahashi. (2003) Characteristic Effects of α1-β1,2-Adrenergic Blocking Agent, Carvedilol, on [Ca2+]i in Ventricular Myocytes Compared With Those of Timolol and Atenolol. Circulation Journal 67:1, 83-90
CrossRef704
Ali Ahmed. (2003) American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management Guidelines: Relevance to the Geriatric Practice. Journal of the American Geriatrics Society 51:1, 123-126
CrossRef705
Eugene Kotlyar, Anne M Keogh, Peter S Macdonald, Ruth H Arnold, Dermot J McCaffrey, Allan R Glanville. (2002) Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. The Journal of Heart and Lung Transplantation 21:12, 1290-1295
CrossRef706
Ravi K. Garg, A. Nasser Khan, Allen S. Anderson. (2002) Contemporary use of beta receptor antagonists in chronic heart failure. Comprehensive Therapy 28:4, 207-213
CrossRef707
Estela Azeka, José Antonio Franchini Ramires, Constante Valler, Edimar Alcides Bocchi. (2002) Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. Journal of the American College of Cardiology 40:11, 2034-2038
CrossRef708
Matthew A Movsesian, Rami Alharethi. (2002) Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy. Expert Opinion on Investigational Drugs 11:11, 1529-1536
CrossRef709
B. John Hynes, Jerry C. Luck, Deborah L. Wolbrette, John Boehmer, Gerald V. Naccarelli. (2002) Arrhythmias in patients with heart failure. Current Treatment Options in Cardiovascular Medicine 4:6, 467-485
CrossRef710
Mandeep R. Mehra, Patricia A. Uber, Srinivasa Potluri. (2002) Renin Angiotensin Aldosterone and Adrenergic Modulation in Chronic Heart Failure: Contemporary Concepts. The American Journal of the Medical Sciences 324:5, 267-275
CrossRef711
Paul A Gould, David M Kaye. (2002) Clinical treatment regimens for chronic heart failure: a review. Expert Opinion on Pharmacotherapy 3:11, 1569-1576
CrossRef712
Paul J Lama. (2002) Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. American Journal of Ophthalmology 134:5, 749-760
CrossRef713
M. L. Kukin. (2002) -Blockers in Chronic Heart Failure: Considerations for Selecting an Agent. Mayo Clinic Proceedings 77:11, 1199-1206
CrossRef714
Levy, Daniel, Kenchaiah, Satish, Larson, Martin G., Benjamin, Emelia J., Kupka, Michelle J., Ho, Kalon K.L., Murabito, Joanne M., Vasan, Ramachandran S., . (2002) Long-Term Trends in the Incidence of and Survival with Heart Failure. New England Journal of Medicine 347:18, 1397-1402
Full Text715
David L. DeMets. (2002) Clinical trials in the new millennium. Statistics in Medicine 21:19, 2779-2787
CrossRef716
Hajjar, Roger J., MacRae, Calum A., . (2002) Adrenergic-Receptor Polymorphisms and Heart Failure. New England Journal of Medicine 347:15, 1196-1199
Full Text717
O. Gabrielli, A. M. Puyo, A. Rosa, I. Armando, M. Barontini, G. Levin. (2002) Atenolol improves ventricular function without changing plasma noradrenaline but decreasing plasma atrial natriuretic factor in chronic heart failure. Autonomic and Autacoid Pharmacology 22:5-6, 261-268
CrossRef718
Marco Metra, Savina Nodari, Antonio D’Aloia, Claudio Muneretto, Alastair D Robertson, Michael R Bristow, Livio Dei Cas. (2002) Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure. Journal of the American College of Cardiology 40:7, 1248-1258
CrossRef719
Kishore J. Harjai, Eduardo Nunez, Mehul Shah, Jeff Newman. (2002) Does racial bias exist in the medical management of heart failure?. Clinical Cardiology 25:10, 479-483
CrossRef720
Robert P. Blankfield. (2002) Pulmonary Hypertension, Sleep-Disordered Breathing, and Beta Blockers in Heart Failure Patients. Sleep and Breathing 6:4, 181-187
CrossRef721
T. Barry Levine, Arlene B. Levine, Janet Bolenbaugh, Pamela R. Green. (2002) Reversal of Heart Failure Remodeling With Age. The American Journal of Geriatric Cardiology 11:5, 299-304
CrossRef722
Eugene S. Smith, Suzanne Trussell, Laura J. Mencer. (2002) Prevention of heart failure. Current Opinion in Cardiology 17:5, 512-517
CrossRef723
Steven R. Goldsmith. (2002) Congestive Heart Failure: Potential Role of Arginine Vasopressin Antagonists in the Therapy of Heart Failure. Congestive Heart Failure 8:5, 251-256
CrossRef724
Michael J. Reiter. (2002) β-Adrenergic blocking drugs as antifibrillatory agents. Current Cardiology Reports 4:5, 426-433
CrossRef725
Maylene Wong, Lidia Staszewsky, Roberto Latini, Simona Barlera, Alberto Volpi, Yann-Tong Chiang, Raymond L Benza, Sidney O Gottlieb, Thomas D Kleemann, Franco Rosconi, Pieter M Vandervoort, Jay N Cohn. (2002) Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. Journal of the American College of Cardiology 40:5, 970-975
CrossRef726
Denise D. Hermann. (2002) Beta-Adrenergic Blockade 2002: A Pharmacologic Odyssey in Chronic Heart Failure. Congestive Heart Failure 8:5, 262-283
CrossRef727
Keith C. Ferdinand, Claudia C. Serrano, Daphne P. Ferdinand. (2002) Contemporary treatment of heart failure: Is there adequate evidence to support a unique strategy for African-Americans? con position. Current Hypertension Reports 4:4, 311-318
CrossRef728
Sante D. Pierdomenico, Anna Bucci, Domenico Lapenna, Franco Cuccurullo, Andrea Mezzetti. (2002) Heart Rate in Hypertensive Patients Treated With ACE Inhibitors and Long-Acting Dihydropyridine Calcium Antagonists. Journal of Cardiovascular Pharmacology 40:2, 288-295
CrossRef729
A. M. Pritchett, M. M. Redfield. (2002) -Blockers: New Standard Therapy for Heart Failure. Mayo Clinic Proceedings 77:8, 839-846
CrossRef730
Lindsay Brown, Sheila A Doggrell. (2002) Present and future pharmacotherapy for heart failure. Expert Opinion on Pharmacotherapy 3:7, 915-930
CrossRef731
L. Michael Prisant. (2002) Should β Blockers Be Used in the Treatment of Hypertension in the Elderly?. The Journal of Clinical Hypertension 4:4, 286-294
CrossRef732
Cecilia Linde, Christophe Leclercq, Steve Rex, Stephane Garrigue, Thomas Lavergne, Serge Cazeau, William McKenna, Melissa Fitzgerald, Jean-Claude Deharo, Christine Alonso, Stuart Walker, Frieder Braunschweig, Christophe Bailleul, Jean-Claude Daubert. (2002) Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. Journal of the American College of Cardiology 40:1, 111-118
CrossRef733
Harold L Kennedy, Robert S Rosenson. (2002) Physicians’ interpretation of “class effects”. Journal of the American College of Cardiology 40:1, 19-26
CrossRef734
P Jourdain. (2002) Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol. European Journal of Heart Failure 4:3, 269-276
CrossRef735
Danielle Pape, Sonia Goineau, Pascal Guillo, Marie-Paule Ramée, Eric Bellissant. (2002) Early Anti-Remodeling Effect of Labetalol in the Congestive Heart Failure Model Induced by Aortic Constriction in the Guinea Pig. Journal of Cardiovascular Pharmacology 39:5, 746-753
CrossRef736
A.Mark Richards, John G Lainchbury, M.Gary Nicholls, Richard W Troughton, Timothy G Yandle. (2002) BNP in hormone-guided treatment of heart failure. Trends in Endocrinology & Metabolism 13:4, 151-155
CrossRef737
Christian Zugck, Armin Haunstetter, Carsten Krüger, Robert Kell, Dieter Schellberg, Wolfgang Kübler, Markus Haass. (2002) Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. Journal of the American College of Cardiology 39:10, 1615-1622
CrossRef738
Wendy M. Book. (2002) Carvedilol: A Nonselective ? Blocking Agent With Antioxidant Properties. Congestive Heart Failure 8:3, 173-190
CrossRef739
Paul J. Hauptman, Daniel Woods, Marc R. Pritzker. (2002) Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure. Clinical Cardiology 25:5, 247-249
CrossRef740
E. Putz, R. Vagelos. (2002) Clinical assessment in ischaemic cardiomyopathy. Nuclear Medicine Communications 23:4, 341-345
CrossRef741
Ulrich Lotze, Stefan Heinke, Michael Fritzenwanger, Andreas Krack, Siegfried Müller, Hans R. Figulla. (2002) Carvedilol Inhibits Platelet-Derived Growth Factor-Induced Signal Transduction in Human Cardiac Fibroblasts. Journal of Cardiovascular Pharmacology 39:4, 576-589
CrossRef742
G. A. MacGowan, D. M. McNamara. (2002) New molecular insights into heart failure and cardiomyopathy: potential strategies and therapies. Irish Journal of Medical Science 171:2, 99-104
CrossRef743
Mustafa Ridha, Timo H. Makikallio, Gustavo Lopera, Juan Pastor, Eduardo Marchena, Simon Chakko, Heikki V. Huikuri, Agustin Castellanos, Robert J. Myerburg. (2002) Effects of Carvedilol on Heart Rate Dynamics in Patients with Congestive Heart Failure. Annals of Noninvasive Electrocardiology 7:2, 133-138
CrossRef744
Juha S. Perkiömäki. (2002) Heart Rate Variability: Recent Developments. Annals of Noninvasive Electrocardiology 7:2, 83-85
CrossRef745
Jeremy J. Pereira, Michael S. Lauer, Mohammad Bashir, Imran Afridi, Eugene H. Blackstone, William J. Stewart, Patrick M. McCarthy, James D. Thomas, Craig R. Asher. (2002) Survival after aortic valve replacement forsevere aortic stenosis with low transvalvular gradients and severe left ventricular dysfunction. Journal of the American College of Cardiology 39:8, 1356-1363
CrossRef746
Mohammad M. Najib, Ren??e J. Goldberg Arnold, Diana J. Kaniecki, Krista G. Pettit, David Roth, Laura Antell, Jianwei Xuan. (2002) Medical Resource Use and Costs of Congestive Heart Failure after Carvedilol Use. Heart Disease70-77
CrossRef747
Mickey Stanley, Marilyn Prasun. (2002) Heart Failure in Older Adults: Keys to Successful Management. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 13:1, 94-102
CrossRef748
Douglas L. Mann, Anita Deswal, Biykem Bozkurt, Guillermo Torre-Amione. (2002) N
EW THERAPEUTICS FOR CHRONIC HEART FAILURE . Annual Review of Medicine 53:1, 59-74
CrossRef749
David Zeltsman, Michael A. Acker. (2002) S
URGICAL MANAGEMENT OF HEART FAILURE : An Overview. Annual Review of Medicine 53:1, 383-391
CrossRef750
Arnold M Katz. (2002) Proliferative Signaling and Disease Progression in Heart Failure. Circulation Journal 66:3, 225-225
CrossRef751
Kenichi YASUNARI, Kensaku MAEDA, Munehiro NAKAMURA, Junichi YOSHIKAWA. (2002) Carvedilol Inhibits Pressure-Induced Increase in Oxidative Stress in Coronary Smooth Muscle Cells.. Hypertension Research 25:3, 419-425
CrossRef752
Andrew Owen. (2002) Optimising the Use of ??-Blockers in Older Patients with Heart Failure. Drugs & Aging 19:9, 671-684
CrossRef753
T TOYOOKA, T KAWADA, H XI, M NAKAZAWA, F MASUI, C HEMMI, J NAKATA, A TEZUKA, K IWASAWA, M URABE. (2002) Gene therapy prevents disruption of dystrophin-related proteins in a model of hereditary dilated cardiomyopathy in hamsters. Heart, Lung and Circulation 11:3, 174-181
CrossRef754
Patricia A. Howard, Marvin I. Dunn. (2002) Severe Heart Failure in the Elderly. Drugs & Aging 19:4, 249-256
CrossRef755
Ayan R. Patel, Marvin A. Konstam. (2002) Recent Advances in the Treatment of Heart Failure. Circulation Journal 66:2, 117-117
CrossRef756
Andrey K. Gurevich, Sandor A. Falk, Raphael A. Nemenoff, Howard D. Weinberger, Sandra N. Summer, Mona Rizeq, Patricia E. Gengaro, Martin P. Bedigian, Robert W. Schrier. (2002) Effects of Angiotensin Receptor Blockade on Haemodynamics and Gene Expression after Myocardial Infarction. Drugs in R & D 3:4, 239-249
CrossRef757
Akira Matsumori, Yutaka Furukawa, Koji Hasegawa, Yukihito Sato, Hideaki Nakagawa, Yuko Morikawa, Katsuyuki Miura, Yoshiyuki Ohno, Akiko Tamakoshi, Yutaka Inaba, Shigetake Sasayama, Co-research workers. (2002) Epidemiologic and Clinical Characteristics of Cardiomyopathies in Japan. Circulation Journal 66:4, 323-323
CrossRef758
Franco Naccarella, Gerald V Naccarelli, Stefano Sdringola Maranga, Giovannina Lepera, Maria Carmela Grippo, Francesco Melandri, Mauro Gatti, Stefano Pazzaglia, Giovanna Spinelli, Vittorio Angelini, Ettore Ambrosioni, Claudio Borghi, Maria Teresa Giovagnorio, Seah Nisam. (2002) Do ACE inhibitors or angiotensin II antagonists reduce total mortality and arrhythmic mortality? A critical review of controlled clinical trials. Current Opinion in Cardiology 17:1, 6-18
CrossRef759
Stanley Nattel, Paul Khairy, Denis Roy, Bernard Thibault, Peter Guerra, Mario Talajic, Marc Dubuc. (2002) New Approaches to Atrial Fibrillation Management. Drugs 62:16, 2377-2397
CrossRef760
Kurt Stoschitzky, Robert Zweiker, Werner Klein, Sabine Zitta, Leonhard Gruber, Günter Lamprecht, Wolfgang Lindner. (2002) Unpredicted Lack of Effect of Exercise on Plasma Concentrations of Carvedilol. Journal of Cardiovascular Pharmacology 39:1, 58-60
CrossRef761
Luke A. Bruns, Charles E. Canter. (2002) Should ??-Blockers be Used for the Treatment of Pediatric Patients with Chronic Heart Failure?. Pediatric Drugs 4:12, 771-778
CrossRef762
Ying Tung Sia, Thomas G. Parker, James N. Tsoporis, Peter Liu, Albert Adam, Jean L. Rouleau. (2002) Long-Term Effects of Carvedilol on Left Ventricular Function, Remodeling, and Expression of Cardiac Cytokines After Large Myocardial Infarction in the Rat. Journal of Cardiovascular Pharmacology 39:1, 73-87
CrossRef763
Hidetsuna Kitamura, Yoshio Ohnishi, Katsunori Okajima, Akihiko Ishida, ErdulfoJavier Galeano, Kazumasa Adachi, Mitsuhiro Yokoyama. (2002) Onset heart rate of microvolt-level T-wave alternans provides clinical and prognostic value in nonischemic dilated cardiomyopathy. Journal of the American College of Cardiology 39:2, 295-300
CrossRef764
Emile Levy, Pierre Levy. (2002) Pharmacoeconomic Considerations in Assessing and Selecting Congestive Heart Failure Therapies. PharmacoEconomics 20:14, 963-977
CrossRef765
Isao Nishi, Keiji Iida, Satoru Kawano, Tomoko Masumi, Yuko Fumikura, Sadanori Ohtsuka, Shigeyuki Watanabe, Iwao Yamaguchi. (2002) Effects of Anti-vasospastic Agents in Japanese Patients with Dilated Cardiomyopathy and Coronary Vasospasm.. Japanese Heart Journal 43:4, 333-342
CrossRef766
Kanu Chatterjee. (2002) Congestive Heart Failure. American Journal of Cardiovascular Drugs 2:1, 1-6
CrossRef767
Steven J. Lavine, Steven D. Gellman. (2002) Treatment of Heart Failure in Patients with Diabetes Mellitus. Drugs 62:2, 285-307
CrossRef768
Barry M Massie. (2002) Neurohormonal blockade in chronic heart failure. Journal of the American College of Cardiology 39:1, 79-82
CrossRef769
Yuji Hara, Mareomi Hamada, Tomoaki Ohtsuka, Akiyoshi Ogimoto, Hideyuki Saeki, Jun Suzuki, Tsuyoshi Matsunaka, Shigeru Nakata, Yuji Shigematsu. (2002) Use of Thallium-201 Myocardial Scintigraphy for the Prediction of the Response to β-Blocker Therapy in Patients With Dilated Cardiomyopathy. Circulation Journal 66:12, 1139-1143
CrossRef770
B. M. Curtis, J. H. O'Keefe. (2002) Autonomic Tone as a Cardiovascular Risk Factor: The Dangers of Chronic Fight or Flight. Mayo Clinic Proceedings 77:1, 45-54
CrossRef771
Dragan Tavciovski, Radoslav Romanovic, Srdjan Boskovic, Predrag Djuran, Radomir Matunovic. (2002) Kombinovana alfa- i beta-blokada u terapiji kardiovaskularnih bolesti. Vojnosanitetski pregled 59:4, 405-410
CrossRef772
Cohn, Jay N., Tognoni, Gianni, . (2001) A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure. New England Journal of Medicine 345:23, 1667-1675
Full Text773
P Bousquet, L Monassier, J Feldman. (2001) Does It Make Sense To Develop New Centrally Acting Cardiovascular Drugs?. Clinical and Experimental Pharmacology and Physiology 28:12, 976-978
CrossRef774
Paul M. L. Janssen, Oliver Zeitz, Alexander Rahman, Gerd Hasenfuss. (2001) Protective Role of Nebivolol in Hydroxyl Radical Induced Injury. Journal of Cardiovascular Pharmacology 38, S17-S23
CrossRef775
Carl V. Leier. (2001) Dilated cardiomyopathy. Current Treatment Options in Cardiovascular Medicine 3:6, 451-462
CrossRef776
Irene Gavras, Athanasios J. Manolis, Haralambos Gavras. (2001) The α2-adrenergic receptors in hypertension and heart failure: experimental and clinical studies. Journal of Hypertension 19:12, 2115-2124
CrossRef777
Ettore Ambrosioni, Stefano Bacchelli, Daniela Degli Esposti, Claudio Borghi. (2001) β-Blockade in Hypertension and Congestive Heart Failure. Journal of Cardiovascular Pharmacology 38, S25-S31
CrossRef778
Masao Endoh, Hiromi Sugawara, Masahiro Mineshima. (2001) Pharmacology of SCH00013: A Novel Ca2+ Sensitizer. Cardiovascular Drug Reviews 19:4, 345-368
CrossRef779
Susan Ammon. (2001) Managing Patients with Heart Failure. American Journal of Nursing 101:12, 34-40
CrossRef780
P Duc. (2001) Insuffisance cardiaque du sujet âgéCongestive heart failure in the elderly. Annales de Cardiologie et d'Angéiologie 50:7-8, 426-433
CrossRef781
William L. Lombardi, Edward M. Gilbert. (2001) Carvedilol in the failing heart. Clinical Cardiology 24:12, 757-766
CrossRef782
Nicolas W. Shammas, Melodee L. Harris, Dawn Mckinney, William J. Hauber. (2001) Digoxin withdrawal in patients with dilated cardiomyopathy following normalization of ejection fraction with beta blockers. Clinical Cardiology 24:12, 786-787
CrossRef783
James M. Ritter. (2001) Nebivolol: Endothelium-Mediated Vasodilating Effect. Journal of Cardiovascular Pharmacology 38, S13-S16
CrossRef784
Andreas Kjaer, Birger Hesse. (2001) Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives. Clinical Physiology 21:6, 661-672
CrossRef785
Antonis A. Armoundas, Richard Wu, George Juang, Eduardo Marbán, Gordon F. Tomaselli. (2001) Electrical and structural remodeling of the failing ventricle. Pharmacology & Therapeutics 92:2-3, 213-230
CrossRef786
Toshihiko Kubo, Eduardo R Azevedo, Gary E Newton, John D Parker, John S Floras. (2001) Lack of evidence for peripheral alpha1- adrenoceptor blockade during long-term treatment of heart failure with carvedilol. Journal of the American College of Cardiology 38:5, 1463-1469
CrossRef787
Soccorso Capomolla, GianDomenico Pinna, Oreste Febo, Angelo Caporotondi, Giampaolo Guazzotti, Maria Teresa La Rovere, Marco Gnemmi, Andrea Mortara, Roberto Maestri, Franco Cobelli. (2001) Echo-Doppler mitral flow monitoring: an operative tool to evaluate day-to-day tolerance to and effectiveness of beta-adrenergic blocking agent therapy in patients with chronic heart failure. Journal of the American College of Cardiology 38:6, 1675-1684
CrossRef788
Stephan B. Felix, Verena Stangl, Arne Kieback, Wolf Doerffel, Alexander Staudt, Klaus D. Wernecke, Gert Baumann, Karl Stangl. (2001) Acute Hemodynamic Effects of β-Blockers in Patients with Severe Congestive Heart Failure: Comparison of Celiprolol and Esmolol. Journal of Cardiovascular Pharmacology 38:5, 666-671
CrossRef789
M Borgarelli, A Tarducci, A Tidholm, J Häggström. (2001) Canine Idiopathic Dilated Cardiomyopathy. Part II: Pathophysiology and therapy. The Veterinary Journal 162:3, 182-195
CrossRef790
Wilbert S. Aronow. (2001) Treatment of the Elderly Post-Myocardial Infarction Patient. The American Journal of Geriatric Cardiology 10:6, 316-323
CrossRef791
Philip A. Poole-Wilson. (2001) Implications of recent heart failure trials for patients with hypertension. Current Cardiology Reports 3:6, 504-510
CrossRef792
Victoria Y Wong, Nicholas J Laping, Allen H Nelson, Lisa C Contino, Barbara A Olson, Eugene Gygielko, Wallace G Campbell, Frank Barone, David P Brooks. (2001) Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGFβ expression. British Journal of Pharmacology 134:5, 977-984
CrossRef793
Martin Hülsmann, Barbara Sturm, Richard Pacher, Rudolf Berger, Anja Bojic, Bernhard Frey, Brigitte Stanek. (2001) Long-term effect of atenolol on ejection fraction, symptoms, and exercise variables in patients with advanced left ventricular dysfunction. The Journal of Heart and Lung Transplantation 20:11, 1174-1180
CrossRef794
J. Auer, R. Berent, B. Eber. (2001) Pathophysiologische und therapeutische Aspekte des linksventrikularen "Remodelings" in der Postinfarktphase. Acta Medica Austriaca 28:5, 117-122
CrossRef795
C Maack. (2001) Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure. Journal of the American College of Cardiology 38:4, 939-946
CrossRef796
Su-chiung Chen. (2001) Cardiomyopathy in children. Current Treatment Options in Cardiovascular Medicine 3:5, 403-413
CrossRef797
Kenichi Watanabe, Yoshimi Ohta, Mikio Inoue, Meilei Ma, Mir I. I. Wahed, Mikio Nakazawa, Go Hasegawa, Makoto Naito, Koichi Fuse, Masahiro Ito, Kiminori Kato, Haruo Hanawa, Makoto Kodama, Yoshifusa Aizawa. (2001) Bisoprolol Improves Survival in Rats with Heart Failure. Journal of Cardiovascular Pharmacology 38, S55-S58
CrossRef798
Robert E. Shaddy. (2001) Optimizing treatment for chronic congestive heart failure in children. Critical Care Medicine 29:Supplement, S237-S240
CrossRef799
Eugene Kotlyar, Peter S Macdonald, Anne M Keogh, Ruth H Arnold, Dermot J McCaffrey, Michael K Wilson, Philip M Spratt. (2001) Optimization of left ventricular function with carvedilol before high-risk cardiac surgery. The Journal of Heart and Lung Transplantation 20:10, 1129-1131
CrossRef800
Anna Barkman, Charlotte Pooler. (2001) Carvedilol: A countermeasure to heart failure. Dimensions of Critical Care Nursing 20:5, 11-16
CrossRef801
I Kondo. (2001) Ultrasonic tissue characterization can predict β-blocker efficacy in dilated cardiomyopathy. Ultrasound in Medicine & Biology 27:8, 1079-1086
CrossRef802
Ilan S Wittstein, David A Kass, Peter H Pak, W.Lowell Maughan, Barry Fetics, Joshua M Hare. (2001) Cardiac nitric oxide production due to angiotensin-converting enzyme inhibition decreases beta-adrenergic myocardial contractility in patients with dilated cardiomyopathy. Journal of the American College of Cardiology 38:2, 429-435
CrossRef803
Thomas C. Gerber, Rick A. Nishimura, David R. Holmes, Margaret A. Lloyd, Kenton J. Zehr, A. Jamil Tajik, David L. Hayes. (2001) Left Ventricular and Biventricular Pacing in Congestive Heart Failure. Mayo Clinic Proceedings 76:8, 803-812
CrossRef804
T C Gerber, R A Nishimura, D R Holmes, M A Lloyd, K J Zehr, A J Tajik, D L Hayes. (2001) Left ventricular and biventricular pacing in congestive heart failure.. Mayo Clinic Proceedings 76:8, 803-812
CrossRef805
Tarik M. Ramahi, Kate Rohlfs, Natalie Sheynberg, Katherine M. Engle, Marcella D. Longo. (2001) Clinic Dosing of ? Blockers in Chronic Heart Failure. Congestive Heart Failure 7:4, 196-200
CrossRef806
Yeun-Chih Huang, Bin-Nan Wu, Jwu-Lai Yeh, Sheue-Jiun Chen, Jyh-Chong Liang, Yi-Ching Lo, Ing-Jun Chen. (2001) A new aspect of view in synthesizing new type β-adrenoceptor blockers with ancillary antioxidant activities. Bioorganic & Medicinal Chemistry 9:7, 1739-1746
CrossRef807
Christian Delles, Roland E. Schmieder. (2001) The Kidney in Congestive Heart Failure: Renal Adverse Event Rate of Treatment. Journal of Cardiovascular Pharmacology 38:1, 99-107
CrossRef808
F. Behn, S. Läer, T. S. Mir, H. Scholz. (2001) HPLC quantification of carvedilol in small plasma volumes from children. Chromatographia 53:11-12, 641-644
CrossRef809
Tomie Kawada, Aiji Sakamoto, Mikio Nakazawa, Masashi Urabe, Fujiko Masuda, Chieko Hemmi, Yue Wang, Wee Soo Shin, Yoko Nakatsuru, Hiroshi Sato, Keiya Ozawa, Teruhiko Toyo-oka. (2001) Morphological and Physiological Restorations of Hereditary Form of Dilated Cardiomyopathy by Somatic Gene Therapy. Biochemical and Biophysical Research Communications 284:2, 431-435
CrossRef810
A.Mark Richards, Robert Doughty, M.Gary Nicholls, Stephen MacMahon, Norman Sharpe, Judy Murphy, Eric A Espiner, Christopher Frampton, Timothy G Yandle. (2001) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. Journal of the American College of Cardiology 37:7, 1781-1787
CrossRef811
Reinaldo B. Bestetti. (2001) Predictors of unfavourable prognosis in chronic Chagas' disease. Tropical Medicine and International Health 6:6, 476-483
CrossRef812
Jianhua Cheng, Kaichiro Kamiya, Itsuo Kodama. (2001) Carvedilol: Molecular and Cellular Basis for Its Multifaceted Therapeutic Potential. Cardiovascular Drug Reviews 19:2, 152-171
CrossRef813
Andreas Bundkirchen, Klara Brixius, Birgit Bölck, Uwe Mehlhorn, Wilhelm Bloch, Robert H.G Schwinger. (2001) Nebivolol, carvedilol and metoprolol do not influence cardiac Ca2+ sensitivity. European Journal of Pharmacology 422:1-3, 175-180
CrossRef814
Packer, Milton, Coats, Andrew J.S., Fowler, Michael B., Katus, Hugo A., Krum, Henry, Mohacsi, Paul, Rouleau, Jean L., Tendera, Michal, Castaigne, Alain, Roecker, Ellen B., Schultz, Melissa K., Staiger, Christoph, Curtin, Ellen L., DeMets, David L., . (2001) Effect of Carvedilol on Survival in Severe Chronic Heart Failure. New England Journal of Medicine 344:22, 1651-1658
Full Text815
Braunwald, Eugene, . (2001) Expanding Indications for Beta-Blockers in Heart Failure. New England Journal of Medicine 344:22, 1711-1712
Full Text816
WB Hood, AL Dans, GH Guyatt, R Jaeschke, JJV McMurray. 2001. Digitalis for treatment of congestive heart failure in patients in sinus rhythm. .
CrossRef817
Yancy, Clyde W., Fowler, Michael B., Colucci, Wilson S., Gilbert, Edward M., Bristow, Michael R., Cohn, Jay N., Lukas, Mary Ann, Young, Sarah T., Packer, Milton, . (2001) Race and the Response to Adrenergic Blockade with Carvedilol in Patients with Chronic Heart Failure. New England Journal of Medicine 344:18, 1358-1365
Full Text818
Exner, Derek V., Dries, Daniel L., Domanski, Michael J., Cohn, Jay N., . (2001) Lesser Response to Angiotensin-Converting–Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction. New England Journal of Medicine 344:18, 1351-1357
Full Text819
Wood, Alastair J.J., . (2001) Racial Differences in the Response to Drugs — Pointers to Genetic Differences. New England Journal of Medicine 344:18, 1394-1396
Full Text820
Eugen C. Palma. (2001) Therapeutic options in patients with reduced ejection fraction and nonsustained ventricular tachycardia. Current Cardiology Reports 3:3, 219-223
CrossRef821
Wendy A. Gattis. (2001) Metoprolol CR/XL in the Treatment of Chronic Heart Failure. Pharmacotherapy 21:5, 604-613
CrossRef822
Michal Tendera, Andrzej Ochala. (2001) Overview of the results of recent beta blocker trials. Current Opinion in Cardiology 16:3, 180-185
CrossRef823
Pasi Tavi, Mika Laine, Matti Weckström, Heikki Ruskoaho. (2001) Cardiac mechanotransduction: from sensing to disease and treatment. Trends in Pharmacological Sciences 22:5, 254-260
CrossRef824
Simon F. Shakar, Michael R. Bristow. (2001) Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving β-blocking agents. Current Cardiology Reports 3:3, 224-231
CrossRef825
(2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. The Lancet 357:9266, 1385-1390
CrossRef826
Michael B Fowler, Montserrat Vera-Llonch, Gerry Oster, Michael R Bristow, Jay N Cohn, Wilson S Colucci, Edward M Gilbert, Mary Ann Lukas, Michael J Lacey, Randel Richner, Sarah T Young, Milton Packer. (2001) Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. Journal of the American College of Cardiology 37:6, 1692-1699
CrossRef827
Daniel E. Hilleman, Jerry L. Bauman. (2001) Role of Antiarrhythmic Therapy in Patients at Risk for Sudden Cardiac Death: An Evidence-Based Review. Pharmacotherapy 21:5, 556-575
CrossRef828
Gordon Moe. (2001) Carvedilol in the treatment of chronic heart failure. Expert Opinion on Pharmacotherapy 2:5, 831-843
CrossRef829
Sheila A Doggrell. (2001) Carvedilol versus other β-blockers in heart failure. Expert Opinion on Investigational Drugs 10:5, 971-980
CrossRef830
Sheila A Doggrell, Lindsay Brown. (2001) The spironolactone renaissance. Expert Opinion on Investigational Drugs 10:5, 943-954
CrossRef831
Philip B Adamson, Emilio Vanoli. (2001) Early autonomic and repolarization abnormalities contribute to lethal arrhythmias in chronic ischemic heart failure. Journal of the American College of Cardiology 37:6, 1741-1748
CrossRef832
Clyde W. Yancy. (2001) Heart failure in blacks: Etiologic and epidemiologic differences. Current Cardiology Reports 3:3, 191-197
CrossRef833
Kalev Freeman, Imanuel Lerman, Evangelia G. Kranias, Teresa Bohlmeyer, Michael R. Bristow, Robert J. Lefkowitz, Guido Iaccarino, Walter J. Koch, Leslie A. Leinwand. (2001) Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. Journal of Clinical Investigation 107:8, 967-974
CrossRef834
H Krum. (2001) New and emerging pharmacological strategies in the management of chronic heart failure. Current Opinion in Pharmacology 1:2, 126-133
CrossRef835
Doron Aronson, Andrew J. Burger. (2001) Effect of Beta-Blockade on Autonomic Modulation of Heart Rate and Neurohormonal Profile in Decompensated Heart Failure. Annals of Noninvasive Electrocardiology 6:2, 98-106
CrossRef836
Anuradha Aggarwal, Murray D Esler, Flora Socratous, David M Kaye. (2001) Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure. Journal of the American College of Cardiology 37:5, 1246-1251
CrossRef837
A. M. Katz. (2001) Crossovers between functional and proliferative signaling: key to understanding the pathophysiology and management of heart failure. Journal of Cellular and Molecular Medicine 5:2, 125-131
CrossRef838
Walid I. Saliba, Andrea Natale. (2001) Ventricular Tachycardia Syndromes. Medical Clinics of North America 85:2, 267-304
CrossRef839
G. Michael Felker, Christopher M. O’Connor. (2001) Rational use of inotropic therapy in heart failure. Current Cardiology Reports 3:2, 108-113
CrossRef840
Tarik M Ramahi, Marcella D Longo, Arina R Cadariu, Kate Rohlfs, Stella A Carolan, Kathryn M Engle, Habib Samady, Frans J.Th Wackers. (2001) Left ventricular inotropic reserve and right ventricular function predict increase of left ventricular ejection fraction after beta-blocker therapy in nonischemic cardiomyopathy. Journal of the American College of Cardiology 37:3, 818-824
CrossRef841
Alan B. Miller. (2001) Is there a role for calcium channel blockers in congestive heart failure?. Current Cardiology Reports 3:2, 114-118
CrossRef842
Kirkwood F. Adams. (2001) Translating heart failure guidelines into clinical practice: Clinical science and the art of medicine. Current Cardiology Reports 3:2, 130-135
CrossRef843
Donald D. Tresch. (2001) Evaluation and Management of Cardiac Arrhythmias in the Elderly. Medical Clinics of North America 85:2, 527-550
CrossRef844
Stephen S. Gottlieb. (2001) Are all β-blockers the same for chronic heart failure?. Current Cardiology Reports 3:2, 124-129
CrossRef845
Wilbert S. Aronow. (2001) Effect of Beta Blockers on Mortality and Morbidity in Persons Treated for Congestive Heart Failure. Journal of the American Geriatrics Society 49:3, 331-333
CrossRef846
S. L. Nuttall, N. J. Langford, M. J. Kendall. (2001) Beta-blockers in heart failure. 2. Mode of action. Journal of Clinical Pharmacy and Therapeutics 26:1, 1-4
CrossRef847
Gennaro Cice, Luigi Ferrara, Attilio Di Benedetto, Pina Elvira Russo, Giancarlo Marinelli, Francesco Pavese, Aldo Iacono. (2001) Dilated cardiomyopathy in dialysis patients—beneficial effects of carvedilol: a double-blind, placebo-controlled trial. Journal of the American College of Cardiology 37:2, 407-411
CrossRef848
Michikado Iwata, Tsutomu Yoshikawa, Akiyasu Baba, Toshihisa Anzai, Hideo Mitamura, Satoshi Ogawa. (2001) Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. Journal of the American College of Cardiology 37:2, 418-424
CrossRef849
M. W. Rich. (2001) Heart Failure in the 21st Century: A Cardiogeriatric Syndrome. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 56:2, M88-M96
CrossRef850
R. Isnard. (2001) Le traitement médical de l'insuffisance cardiaque chronique. Annales de Cardiologie et d Angéiologie 50:1, 30
CrossRef851
Marco Metra, Savina Nodari, Livio Dei Cas. (2001) ??-Blockade in Heart Failure. American Journal of Cardiovascular Drugs 1:1, 3-14
CrossRef852
Jose L. Merino. (2001) Mechanisms Underlying Ventricular Arrhythmias in Idiopathic Dilated Cardiomyopathy. American Journal of Cardiovascular Drugs 1:2, 105-118
CrossRef853
Lena Brynne, John L. McNay, Hans G. Schaefer, Karl Swedberg, Curtis G. Wiltse, Mats O. Karlsson. (2001) Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. British Journal of Clinical Pharmacology 51:1, 35-43
CrossRef854
Makoto Kodama, Kiminori Kato, Satoru Hirono, Haruo Hanawa, Yuji Okura, Masahiro Ito, Koichi Fuse, Takaaki Shiono, Hitoshi Tachikawa, Manabu Hayashi, Satoru Abe, Tsuyoshi Yoshida, Yoshifusa Aizawa. (2001) Changes in the Occurrence of Mechanical Alternans After Long-Term β-Blocker Therapy in Patients With Chronic Heart Failure. Japanese Circulation Journal 65:8, 711-716
CrossRef855
Isao Nishi, Keiji Iida, Satoru Kawano, Tomoko Masumi, Iwao Yamaguchi. (2001) Using Isoproterenol Stress Echocardiography to Predict the Response to Carvedilol in Patients With Dilated Cardiomyopathy. Japanese Circulation Journal 65:6, 514-518
CrossRef856
Eileen M. MacCallum. (2001) The role of beta-blockers in the management of patients with heart failure. Dimensions of Critical Care Nursing 20:1, 24-29
CrossRef857
Mazen S. Matalka, Prakash C. Deedwania. (2001) Atrial Fibrillation in Patients with Heart Failure: Pharmacologic Options. Congestive Heart Failure 7:1, 22-29
CrossRef858
D Logeart. (2001) Perspectives médicamenteuses dans le traitement de l'insuffisance cardiaque. Annales de Cardiologie et d Angéiologie 50:1, 38
CrossRef859
David C. White, Walter J. Koch. (2001) Myocardial gene transfer. Current Cardiology Reports 3:1, 37-42
CrossRef860
Kazumasa Adachi, Yoshio Ohnishi, Mitsuhiro Yokoyama. (2001) Risk Stratification for Sudden Cardiac Death in Dilated Cardiomyopathy Using Microvolt-Level T-Wave Alternans. Japanese Circulation Journal 65:2, 76-80
CrossRef861
Michael A. Moore. (2001) Choosing Initial Antihypertensive Drug Therapy for the Uncomplicated Hypertensive Patient. The Journal of Clinical Hypertension 3:1, 37-44
CrossRef862
M Gary Nicholls, John G Lainchbury, A Mark Richards, Richard W Troughton, Timothy G Yandle. (2001) Brain natriuretic peptide-guided therapy for heart failure. Annals of Medicine 33:6, 422-427
CrossRef863
Mark Lanzieri, Richard Hobbs, Patricia Roy, Roberta Richmond. (2001) Use of a Clinical Care Map for the Management of Congestive Heart Failure in a Community Hospital. Congestive Heart Failure 7:1, 37-42
CrossRef864
Wilbert S. Aronow. (2001) Drug Treatment of Elderly Patients with Acute Myocardial Infarction. Drugs & Aging 18:11, 807-818
CrossRef865
Mattias Ekman, Niklas Zethraeus, Bengt J??nsson. (2001) Cost Effectiveness of Bisoprolol in the Treatment of Chronic Congestive Heart Failure in Sweden. PharmacoEconomics 19:9, 901-916
CrossRef866
Fidelma Dunne, Martin J. Kendall, Una Martin. (2001) ??-Blockers in the Management of Hypertension in Patients with Type 2 Diabetes Mellitus. Drugs 61:4, 429-435
CrossRef867
Keiji Hirooka, Yoshio Yasumura, Yoshio Ishida, Akihisa Hanatani, Satoshi Nakatani, Kazuo Komamura, Masatsugu Hori, Masakazu Yamagishi, Kunio Miyatake. (2001) Comparative Left Ventricular Functional and Neurohumoral Effects of Chronic Treatment With Carvedilol Versus Metoprolol in Patients With Dilated Cardiomyopathy. Japanese Circulation Journal 65:11, 931-936
CrossRef868
Tarik M. Ramahi, Marcella D. Longo, Kate Rohlfs, Natalie Sheynberg. (2000) Effect of Heart Failure Program on Cardiovascular Drug Utilization and Dosage in Patients with Chronic Heart Failure. Clinical Cardiology 23:12, 909-914
CrossRef869
S. L. Nuttall, N. J. Langford, M. J. Kendall. (2000) Beta-blockers in heart failure. 1. Clinical evidence. Journal of Clinical Pharmacy and Therapeutics 25:6, 395-398
CrossRef870
Bjoern A Groenning, Jens C Nilsson, Lars Sondergaard, Thomas Fritz-Hansen, Henrik B.W Larsson, Per R Hildebrandt. (2000) Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. Journal of the American College of Cardiology 36:7, 2072-2080
CrossRef871
Lothar Rössig, Judith Haendeler, Ziad Mallat, Benedicte Hugel, Jean-Marie Freyssinet, Alain Tedgui, Stefanie Dimmeler, Andreas M Zeiher. (2000) Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. Journal of the American College of Cardiology 36:7, 2081-2089
CrossRef872
Guillem Pons-Lladó, Manel Ballester, Xavier Borrás, Francesc Carreras, Ignasi Carrió, Joaquı́n López-Contreras, Alex Roca-Cusachs, Jaume Marrugat, Jagat Narula. (2000) Myocardial cell damage in human hypertension. Journal of the American College of Cardiology 36:7, 2198-2203
CrossRef873
Gian Domenico Pinna, Cristina Opasich, Antonio Mazza, Antonio Tangenti, Roberto Maestri, Maurizio Sanarico. (2000) Reproducibility of the six-minute walking test in chronic heart failure patients. Statistics in Medicine 19:22, 3087-3094
CrossRef874
Simon Maxwell, William S. Waring. (2000) Therapeutics Drugs used in secondary prevention after myocardial infarction: Case presentation. British Journal of Clinical Pharmacology 50:5, 405-417
CrossRef875
Jeffrey J Goldberger, Suresh Neelagaru. (2000) Therapeutic developments in sudden cardiac death. Expert Opinion on Investigational Drugs 9:11, 2543-2554
CrossRef876
George A. Mensah. (2000) The Role of Echocardiography in Hypertensive Heart Disease in the Elderly. The American Journal of Geriatric Cardiology 9:6, 330-341
CrossRef877
Colm G. Hanratty, Paul McGlinchey, G. Dennis Johnston, A. Peter Passmore. (2000) Differential Pharmacokinetics of Digoxin in Elderly Patients. Drugs & Aging 17:5, 353-362
CrossRef878
Kirkwood F. Adams. (2000) Developing Clinical Practice Guidelines for Heart Failure: Creative Process and Practice Implications. Pharmacotherapy 20:11 Part 2, 379S-384S
CrossRef879
Wendy A. Gattis. (2000) Practical Issues in the Treatment of Patients with Heart Failure. Pharmacotherapy 20:11 Part 2, 385S-391S
CrossRef880
Hector O. Ventura, Ileana L. Piña. (2000) The AHF SCENE II Preceptorship Program: Rationale and Design of an Educational Program to Optimize Management of Advanced Heart Failure. Congestive Heart Failure 6:6, 319-324
CrossRef881
Mark A. Munger, Kai Ian Cheang. (2000) β-Blocker Therapy: A Standard of Care for Heart Failure. Pharmacotherapy 20:11 Part 2, 359S-367S
CrossRef882
Nazim Uddin Azam Khan, Assad Movahed. (2000) Role of
CrossRef883
David Baran, Evelyn M. Horn, Katarzyna Hryniewicz, Stuart D. Katz. (2000) Effects of ??-Blockers on Neurohormonal Activation in Patients with Congestive Heart Failure. Drugs 60:5, 997-1016
CrossRef884
S. Kenneth Pehrsson, Ivar Ringqvist, Sten Ekdahl, BjÖRn W. Karlson, GÖRan Ulvenstam, Stig Persson. (2000) Monotherapy with amlodipine or atenolol versus their combination in stable angina pectoris. Clinical Cardiology 23:10, 763-770
CrossRef885
Leslie W. Miller, Bradley Berry, Emil Missov. (2000) Idiopathic cardiomyopathy. Current Treatment Options in Cardiovascular Medicine 2:5, 421-430
CrossRef886
Petra Schnabel, Christoph Maack, Florian Mies, Stephan Tyroller, Alexander Scheer, Michael B??hm. (2000) Binding Properties of ??-Blockers at Recombinant ??1-, ??2-, and ??3-Adrenoceptors. Journal of Cardiovascular Pharmacology 36:4, 466-471
CrossRef887
Henry Krum. (2000) New and emerging pharmacologic strategies in the management of chronic heart failure. Clinical Cardiology 23:10, 724-730
CrossRef888
Feng Gao, Jun Chen, Bernard L Lopez, Theodore A Christopher, Juanli Gu, Paul Lysko, Robert R Ruffolo, Eliot H Ohlstein, Xin L Ma, Tian-Li Yue. (2000) Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. European Journal of Pharmacology 406:1, 109-116
CrossRef889
R. L. Nicol, N. Frey, E. N. Olson. (2000) F
ROM THE SARCOMERE TO THE NUCLEUS : Role of Genetics and Signaling in Structural Heart Disease. Annual Review of Genomics and Human Genetics 1:1, 179-223
CrossRef890
Amitabh Prakash, Anthony Markham. (2000) Metoprolol. Drugs 60:3, 647-678
CrossRef891
Thomas D. Giles. (2000) Beta Blockers in Treatment of Heart Failure and Hypertension in Diabetes: Ugly Misconceptions Slain by Beautiful Clinical Data. The American Journal of Geriatric Cardiology 9:5, 290-291
CrossRef892
H. Krum. (2000) Recent advances in the management of chronic heart failure. Australian and New Zealand Journal of Medicine 30:4, 475-482
CrossRef893
Walter Kao, Maria Rosa Costanzo. (2000) Sudden death in heart failure patients: effects of optimized medical therapy. The Journal of Heart and Lung Transplantation 19:8, S32-S37
CrossRef894
P. Touboul. (2000) Primary prevention of sudden cardiac death — the role of antiarrhythmic drug therapy. Resuscitation 45:3, S11-S15
CrossRef895
Kenichi Watanabe, Yoshimi Ohta, Mikio Nakazawa, Hiroshi Higuchi, Go Hasegawa, Makoto Naito, Koichi Fuse, Masahiro Ito, Satoru Hirono, Naohito Tanabe, Haruo Hanawa, Kiminori Kato, Makoto Kodama, Yoshifusa Aizawa. (2000) Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. British Journal of Pharmacology 130:7, 1489-1495
CrossRef896
Jean L Rouleau, Marc A Pfeffer, Duncan J Stewart, Debra Isaac, Francois Sestier, Edmund K Kerut, Charles B Porter, Guy Proulx, Chunlin Qian, Alan J Block. (2000) Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. The Lancet 356:9230, 615-620
CrossRef897
Adam S. Betkowski, Paul J. Hauptman. (2000) Update on recent clinical trials in congestive heart failure. Current Opinion in Cardiology 15:4, 293-303
CrossRef898
Thomas Kurz, Doreen Richardt, Bettina Görge, &NA; Hartmann, Ralph Tölg, Hugo A. Katus, Gert Richardt. (2000) Differential Effects of Carvedilol on Norepinephrine Release in Normoxic and Ischemic Heart. Journal of Cardiovascular Pharmacology 36:1, 96-100
CrossRef899
Maryann Z. Skrabal, Julie A. Stading, Kathryn A. Behmer-Miller, Daniel E. Hilleman. (2000) Advances in the Treatment of Congestive Heart Failure: New Approaches for an Old Disease. Pharmacotherapy 20:7, 787-804
CrossRef900
Wybe Nieuwland, Marike A Berkhuysen, Dirk J van Veldhuisen, Johan Brügemann, Martin L.J Landsman, Eric van Sonderen, K.I Lie, Harry J.G.M Crijns, Piet Rispens. (2000) Differential effects of high-frequency versus low-frequency exercise training in rehabilitation of patients with coronary artery disease. Journal of the American College of Cardiology 36:1, 202-207
CrossRef901
Martinez-Rubio, Fahlin, Llanos. (2000) Role of neuropeptides in heart failure: preliminary information or knowledge?. European Journal of Clinical Investigation 30:7, 561-562
CrossRef902
Shan Wei, Louis T.C Chow, John E Sanderson. (2000) Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. Journal of the American College of Cardiology 36:1, 276-281
CrossRef903
Wolfram Doehner, Stefan D. Anker, Andrew J. S. Coats. (2000) Defects in insulin action in chronic heart failure. Diabetes, Obesity and Metabolism 2:4, 203-212
CrossRef904
Derek V. Exner. (2000)
CrossRef905
T. Barry Levine, Arlene B. Levine, Patricia Kaminski, Robert J. Stomel. (2000) Reversal of Heart Failure Remodeling in Women. Journal of Women's Health & Gender-Based Medicine 9:5, 513-519
CrossRef906
Laurent Fauchier, Bruno Giraudeau. (2000) Beta-blockers and ventricular arrhythmias in dilated cardiomyopathy. Journal of the American College of Cardiology 35:7, 1993
CrossRef907
Wilbert S. Aronow. (2000) Beta-blockers, angiotensin-converting enzyme inhibitors, and calcium antagonists in treatment of elderly patients with acute myocardial infarction. Coronary Artery Disease 11:4, 331-338
CrossRef908
Prabashni Reddy, Alisha B. Dunn. (2000) The Effect of β-Blockers on Health-Related Quality of Life in Patients with Heart Failure. Pharmacotherapy 20:6, 679-689
CrossRef909
Andrea Di Lenarda, Gastone Sabbadini, Dario Gregori, Gianfranco Sinagra. (2000) Reply. Journal of the American College of Cardiology 35:7, 1993-1994
CrossRef910
Pascale Mansuy, Nathalie Mougenot, Juan Fernando Ramirez-Gil, Dominique Bonnefont-Rousselot, Françoise Raillecove, Michel Komajda, Philippe Lechat. (2000) Effects of Prolonged Propranolol Treatment on Left Ventricular Remodeling and Oxidative Stress After Myocardial Infarction in Rats. Journal of Cardiovascular Pharmacology 35:5, 806-813
CrossRef911
Kirkwood F. Adams, Kenneth L. Baughman, William G. Dec, Uri Elkayam, Alan D. Forker, Mihai Gheorghiade, Denise Hermann, Marvin A. Konstam, Peter Liu, Barry M. Massie, J. Herbert Patterson, Marc A. Silver, Lynne Warner Stevenson, Arthur M. Feldman, Jay N. Cohn, Gary S. Francis, Barry Greenberg, Marvin A. Konstam, Carl Leier, Beverly H. Lorell, Milton Packer, Bertram Pitt, Marc A. Silver, Edmund Sonnenblick, John Strobeck, Richard Walsh, Salim Yusuf. (2000) HFSA Guidelines for Management of Patients With Heart Failure Caused by Left Ventricular Systolic Dysfunction—Pharmacological Approaches. Pharmacotherapy 20:5, 495-522
CrossRef912
Patrizia Ferrari, Giuseppe Bianchi. (2000) The Genomics of Cardiovascular Disorders. Drugs 59:5, 1025-1042
CrossRef913
Marrick L. Kukin. (2000) Are All
CrossRef914
Marco Metra, Savina Nodari, Emiliano Boldi, Livio Dei Cas. (2000) Selective or nonselective β-adrenergic blockade in patients with congestive heart failure. Current Cardiology Reports 2:3, 252-257
CrossRef915
Edward M. Gilbert, J. David Port. (2000) Deactivation of the sympathetic nervous system in patients with chronic congestive heart failure. Current Cardiology Reports 2:3, 225-232
CrossRef916
Matthew A Movsesian. (2000) Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure. Expert Opinion on Investigational Drugs 9:5, 963-973
CrossRef917
Robert H. G. Schwinger, Marcus Pietsch, Konrad Frank, Klara Brixius. (2000) Crataegus Special Extract WS 1442 Increases Force of Contraction in Human Myocardium cAMP-Independently. Journal of Cardiovascular Pharmacology 35:5, 700-707
CrossRef918
S Åsbrink. (2000) No effect of carvedilol on nitric oxide generation in phagocytes but modulation of production of superoxide ions. Biochemical Pharmacology 59:8, 1007-1013
CrossRef919
Leslie A. Saxon, Uday N. Kumar, Teresa Marco. (2000) Heart Failure and Cardiac Resynchronization Therapies: U.S. Experience in the Year 2000. Annals of Noninvasive Electrocardiology 5:2, 188-194
CrossRef920
Toshimasa Yoshioka, Noriko Iwamoto, Fujiko Tsukahara, Kaoru Irie, Ikuko Urakawa, Takamura Muraki. (2000) Anti-NO action of carvedilol in cell-free system and in vascular endothelial cells. British Journal of Pharmacology 129:7, 1530-1535
CrossRef921
Robert W Schrier, Joseph G Abdallah, Howard H D Weinberger, William T Abraham. (2000) Therapy of heart failure. Kidney International 57:4, 1418-1425
CrossRef922
Jay N Cohn, Roberto Ferrari, Norman Sharpe. (2000) Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Journal of the American College of Cardiology 35:3, 569-582
CrossRef923
Robert N. Doughty, Gillian A. Whalley, Greg Gamble, Stephen Macmahon, Norman Sharpe. (2000) Effects of carvedilol on left ventricular regional wall motion in patients with heart failure caused by ischemic heart disease. Journal of Cardiac Failure 6:1, 11-18
CrossRef924
E. Loh. (2000) Maximizing management of patients with decompensated heart failure. Clinical Cardiology 23:S3, III1-III5
CrossRef925
Mitsunori Fujimura, Yoshio Yasumura, Yoshio Ishida, Satoshi Nakatani, Kazuo Komamura, Masakazu Yamagishi, Kunio Miyatake. (2000) Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. Journal of Cardiac Failure 6:1, 3-10
CrossRef926
Marrick L. Kukin. (2000) Beta-blockers and spironolactone in heart failure. Current Cardiology Reports 2:2, 87-89
CrossRef927
Jirí Widimský. (2000) The fixed combination of verapamil SR/trandolapril. Expert Opinion on Pharmacotherapy 1:3, 515-535
CrossRef928
ALAN KADISH, REBECCA QUIGG, I SCHAECHTER, KELLEY P. ANDERSON, MARK ESTES, JOSEPH LEVINE. (2000) Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation. Pacing and Clinical Electrophysiology 23:3, 338-343
CrossRef929
B. D. Lowes, M. A. Simon, T. O. Tsvetkova, M. R. Bristow. (2000) Inotropes in the beta-blocker era. Clinical Cardiology 23:S3, III11-III16
CrossRef930
William L. Lombardi, Edward M. Gilbert. (2000) The effects of neurohormonal antagonism on pathologic left ventricular remodeling in heart failure. Current Cardiology Reports 2:2, 90-98
CrossRef931
Robert Rho, David DeNofrio, Evan Loh. (2000) Cardiomyopathy and embolization: risks and benefits of anticoagulation in sinus rhythm. Current Cardiology Reports 2:2, 106-111
CrossRef932
Jonathan D. Sackner-Bernstein. (2000) The myocardial matrix and the development and progression of ventricular remodeling. Current Cardiology Reports 2:2, 112-119
CrossRef933
Dorothea McAreavey, Derek V Exner, Ellen Leigh Curtin, Michael J Domanski. (2000) β-blockers in heart failure: recently completed and ongoing clinical trials. Expert Opinion on Investigational Drugs 9:2, 415-428
CrossRef934
Brigitte Stanek. (2000) Optimising Management of Patients with Advanced Heart Failure. Drugs & Aging 16:2, 87-106
CrossRef935
C.Allyson Walker, Fred A. Crawford, Francis G. Spinale. (2000) Myocyte contractile dysfunction with hypertrophy and failure: Relevance to cardiac surgery. The Journal of Thoracic and Cardiovascular Surgery 119:2, 388-400
CrossRef936
Karl Swedberg, Claes-Håkan Bergh, Kenneth Dickstein, John McNay, Mitchell Steinberg. (2000) The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Journal of the American College of Cardiology 35:2, 398-404
CrossRef937
Wendy Gattis, Christopher M. O??Connor. (2000) Utilisation des inhibiteurs calciques dans le traitement de l??insuffisance cardiaque. Drugs 59:Special Issue 2, 17-24
CrossRef938
A. Nordin-Johansson, K. Asplund. (2000) Randomized controlled trials and consensus as a basis for interventions in internal medicine. Journal of Internal Medicine 247:1, 94-104
CrossRef939
Ross T. Tsuyuki, Finlay A. McAlister, Koon K. Teo. (2000) ??-Blockers For Congestive Heart Failure. Drugs & Aging 16:1, 1-7
CrossRef940
LARS ECKARDT, WILHELM HAVERKAMP, ROBERT JOHNA, DIRK BÖCKER, MARIO C. DENG, GÜNTER BREITHARDT, MARTIN BORGGREEE. (2000) Arrhythmias in Heart Failure:.. Journal of Cardiovascular Electrophysiology 11:1, 106-117
CrossRef941
Frank Lloyd Dini, Roberto Cogo. (2000) Doxofylline: A New Generation Xanthine Bronchodilator Devoid of Major Cardiovascular Adverse Effects. Current Medical Research and Opinion 16:4, 258-268
CrossRef942
Ren?? R. Wenzel, Heike Bruck, Georg Noll, Rafael F. Sch??fers, Anton E. Daul, Thomas Philipp. (2000) Antihypertensive Drugs and the Sympathetic Nervous System. Journal of Cardiovascular Pharmacology 35, S43-S52
CrossRef943
Yoshimi Ohta, Kenichi Watanabe, Mikio Nakazawa, Tadashi Yamamoto, Meilei Ma, Koichi Fuse, Masahiro Ito, Satoru Hirono, Naohito Tanabe, Haruo Hanawa, Kiminori Kato, Makoto Kodama, Yoshifusa Aizawa. (2000) Carvedilol Enhances Atrial and Brain Natriuretic Peptide mRNA Expression and Release in Rat Heart. Journal of Cardiovascular Pharmacology 36, S19-S23
CrossRef944
Wilbert S. Aronow. (2000) Treatment of Hypertension in the Institutionalized Elderly. The American Journal of Geriatric Cardiology 9:1, 34-41
CrossRef945
Michael Kim, Marrick Kukin. (2000) New advances in the pharmacological management of chronic heart failure. Expert Opinion on Pharmacotherapy 1:2, 261-269
CrossRef946
Murray Esler, David Kaye. (2000) Sympathetic Nervous System Activation in Essential Hypertension, Cardiac Failure and Psychosomatic Heart Disease. Journal of Cardiovascular Pharmacology 35, S1-S7
CrossRef947
Iain B. Squire, David B. Barnett. (2000) The rational use of β-adrenoceptor blockers in the treatment of heart failure. The changing face of an old therapy. British Journal of Clinical Pharmacology 49:1, 1-9
CrossRef948
Marrick L Kukin, Michael M Mannino, Ronald S Freudenberger, Jill Kalman, Cathleen Buchholz-Varley, Ofelia Ocampo. (2000) Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. Journal of the American College of Cardiology 35:1, 45-50
CrossRef949
Jonathan A. Abbott. 2000. Canine Dilated Cardiomyopathy. , 230-237.
CrossRef950
Jonathan A. Abbott. 2000. Beta-Adrenergic Antagonists. , 68-72.
CrossRef951
Jonathan A. Abbott. 2000. Emergency Management of Congestive Heart Failure. , 159-169.
CrossRef952
Jonathan A. Abbott. 2000. Management of Chronic Congestive Heart Failure. , 170-178.
CrossRef953
W W Parmley. (2000) Surviving heart failure: Robert L. Frye lecture.. Mayo Clinic Proceedings 75:1, 111-118
CrossRef954
Steven R. Goldsmith. (1999) Vasopressin: A therapeutic target in congestive heart failure?. Journal of Cardiac Failure 5:4, 347-356
CrossRef955
B. Fink, M. Schwemmer, N. Fink, E. Bassenge. (1999) Tolerance to Nitrates with Enhanced Radical Formation Suppressed by Carvedilol. Journal of Cardiovascular Pharmacology 34:6, 800-805
CrossRef956
Heart Failure Society Of America. (1999) HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches. Journal of Cardiac Failure 5:4, 357-382
CrossRef957
Antonio Rapacciuolo, Howard A. Rockman. (1999) Role of β-Adrenoceptor Desensitization in Heart Failure. Cardiovascular Drug Reviews 17:4, 384-394
CrossRef958
Robert Moskowitz, Marrick Kukin. (1999) β-blockers in congestive heart failure. Expert Opinion on Investigational Drugs 8:11, 1795-1805
CrossRef959
Olivier Frankenberger, Jonathan S. Steinber. (1999) Beta-blockers and amiodarone for the primary prevention of sudden cardiac death. Current Cardiology Reports 1:4, 274-281
CrossRef960
John E Sanderson, Skiva K.W Chan, Gabriel Yip, Leata Y.C Yeung, Kam W Chan, Kenneth Raymond, Kam S Woo. (1999) Beta-blockade in heart failure. Journal of the American College of Cardiology 34:5, 1522-1528
CrossRef961
Hiroko Uemura, Naoya Sakamoto, Haruaki Nakaya. (1999) Electropharmacological effects of UK-1745, a novel cardiotonic drug, in guinea-pig ventricular myocytes. European Journal of Pharmacology 383:3, 361-371
CrossRef962
Martin J Kendall, Sarah L Nuttall. (1999) Anti-oxidant therapy for the treatment of coronary artery disease. Expert Opinion on Investigational Drugs 8:11, 1763-1784
CrossRef963
Tasneem Z. Naqvi, Rishi K. Goel, James S. Forrester, Robert J. Siegel. (1999) Myocardial contractile reserve on dobutamine echocardiography predicts late spontaneous improvement in cardiac function in patients with recent onset idiopathic dilated cardiomyopathy. Journal of the American College of Cardiology 34:5, 1537-1544
CrossRef964
Michael O???Leary, Michael Davis, David Bihari. (1999) Myocardial protection in the intensive care unit. Current Opinion in Critical Care 5:5, 400-407
CrossRef965
Anthony M. Cosentino. (1999) The Congested State in Renal Failure: A Historical and Diagnostic Perspective. Seminars in Dialysis 12:5, 307-310
CrossRef966
Salpy V Pamboukian, Amin Aminbakhsh, Christopher R Thompson, Haitham Amin, Susan Mortimer, Yulia D'Yachkova, Andrew P Ignaszewski. (1999) Carvedilol improves functional class in patients with severe left ventricular dysfunction referred for heart transplantation. Clinical Transplantation 13:5, 426-431
CrossRef967
Dong-Ju Choi, Howard A. Rockman. (1999) β-adrenergic receptor desensitization in cardiac hypertrophy and heart failure. Cell Biochemistry and Biophysics 31:3, 321-329
CrossRef968
Pitt, Bertram, Zannad, Faiez, Remme, Willem J., Cody, Robert, Castaigne, Alain, Perez, Alfonso, Palensky, Jolie, Wittes, Janet, . (1999) The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine 341:10, 709-717
Full Text969
Kuniya Asai, Gui-Ping Yang, Yong-Jian Geng, Gen Takagi, Sanford Bishop, Yoshihiro Ishikawa, Richard P. Shannon, Thomas E. Wagner, Dorothy E. Vatner, Charles J. Homcy, Stephen F. Vatner. (1999) β-Adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gsα mouse. Journal of Clinical Investigation 104:5, 551-558
CrossRef970
Kathy A. Crispell, Anita Wray, Hanyu Ni, Deirdre J. Nauman, Ray E. Hershberger. (1999) Clinical profiles of four large pedigrees with familial dilated cardiomyopathy. Journal of the American College of Cardiology 34:3, 837-847
CrossRef971
A Mark Richards, M Gary Nicholls. (1999) Aldosterone antagonism in heart failure. The Lancet 354:9181, 789-790
CrossRef972
Simon Stewart, John E Marley, John D Horowitz. (1999) Effects of a multidisciplinary, home-based intervention on planned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study. The Lancet 354:9184, 1077-1083
CrossRef973
M BORGARELLI. (1999) Lymphocyte β -adrenoceptor Downregulation in Great Danes with Occult Dilated Cardiomyopathy (DCM) and with DCM and Heart Failure. The Veterinary Journal 158:2, 128-134
CrossRef974
Epstein, Franklin H., , Schrier, Robert W., Abraham, William T., . (1999) Hormones and Hemodynamics in Heart Failure. New England Journal of Medicine 341:8, 577-585
Full Text975
Stephen S. Gottlieb. (1999) Beta blockade improves survival in patients with congestive heart failure. Current Treatment Options in Cardiovascular Medicine 1:2, 101-103
CrossRef976
Jeffrey J. Goldberger. (1999) Sudden cardiac death. Current Treatment Options in Cardiovascular Medicine 1:2, 127-135
CrossRef977
Matthew A. Movsesian. (1999) Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate. Journal of the American College of Cardiology 34:2, 318-324
CrossRef978
Hideo Matsui, Itsuro Morishima, Yasushi Numaguchi, Yukio Toki, Kenji Okumura, Tetsuo Hayakawa. (1999) Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sciences 65:12, 1265-1274
CrossRef979
Derek V. Exner, James A. Reiffel, Andrew E. Epstein, Robert Ledingham, Michael J. Reiter, Qing Yao, Henry J. Duff, Dean Follmann, Eleanor Schron, H.Leon Greene, Mark D. Carlson, Michael A. Brodsky, Toshio Akiyama, Christina Baessler, Jeffrey L. Anderson. (1999) Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the antiarrhythmics versus implantable defibrillators (AVID) trial. Journal of the American College of Cardiology 34:2, 325-333
CrossRef980
Rafael Ba
CrossRef981
Michael A. Blazing, Christopher M. O’Connor. (1999) Evidence supporting secondary prevention strategies. Current Opinion in Cardiology 14:4, 303-309
CrossRef982
Jianhua Cheng, Ryoko Niwa, Kaichiro Kamiya, Junji Toyama, Itsuo Kodama. (1999) Carvedilol blocks the repolarizing K+ currents and the L-type Ca2+ current in rabbit ventricular myocytes. European Journal of Pharmacology 376:1-2, 189-201
CrossRef983
Steven R. Goldsmith. (1999) Angiotensin II and sympathoactivation in heart failure. Journal of Cardiac Failure 5:2, 139-145
CrossRef984
Avijit Lahiri, Roxy Senior, Raj Khattar. (1999) The Role of Neurohormonal Antagonists in Hibernating Myocardium. Journal of Cardiovascular Pharmacology 33:Supplement 3, S9-S16
CrossRef985
L. F. Arnolda, I. J. Llewellyn-Smith, J. B. Minson. (1999) Animal models of heart failure. Australian and New Zealand Journal of Medicine 29:3, 403-409
CrossRef986
Roxy Senior, Sanjiv Kaul, Avijit Lahiri. (1999) Myocardial viability on echocardiography predicts long-term survival after revascularization in patients with ischemic congestive heart failure. Journal of the American College of Cardiology 33:7, 1848-1854
CrossRef987
Kjell Jansson, Rolf Östlund, Eva Nylander, Ulf Dahlström, Inger Hagerman, Karl-Erik Karlberg, Olof Nyquist. (1999) The effects of metoprolol and captopril on heart rate variability in patients with idiopathic dilated cardiomyopathy. Clinical Cardiology 22:6, 397-402
CrossRef988
John G.F. Cleland, James McGowan. (1999) Heart Failure due to Ischaemic Heart Disease: Epidemiology, Pathophysiology and Progression. Journal of Cardiovascular Pharmacology 33, S17-S29
CrossRef989
Ferenc Follath. (1999) Nonischemic Heart Failure: Epidemiology, Pathophysiology and Progression of Disease. Journal of Cardiovascular Pharmacology 33:Supplement 3, S31-S35
CrossRef990
William T. Abraham, Balkrishna Singh. (1999) Ischemic and Nonischemic Heart Failure do not Require Different Treatment Strategies. Journal of Cardiovascular Pharmacology 33:Supplement 3, S1-S7
CrossRef991
Avijit Lahiri, Roxy Senior, Raj Khattar. (1999) The Role of Neurohormonal Antagonists in Hibernating Myocardium. Journal of Cardiovascular Pharmacology 33, S9-S16
CrossRef992
Andrea Di Lenarda, Gastone Sabbadini, Luca Salvatore, Gianfranco Sinagra, Luisa Mestroni, Bruno Pinamonti, Dario Gregori, Fulvio Ciani, Aureo Muzzi, Silvio Klugmann, Fulvio Camerini. (1999) Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. Journal of the American College of Cardiology 33:7, 1926-1934
CrossRef993
H. Krum. (1999) Sympathetic activation and the role of beta-blockers in chronic heart failure. Australian and New Zealand Journal of Medicine 29:3, 418-427
CrossRef994
Norman Sharpe. (1999) Benefit of β-blockers for heart failure: proven in 1999. The Lancet 353:9169, 1988-1989
CrossRef995
Ferenc Follath. (1999) Nonischemic Heart Failure: Epidemiology, Pathophysiology and Progression of Disease. Journal of Cardiovascular Pharmacology 33, S31-S35
CrossRef996
Ramachandran S Vasan, Martin G Larson, ScD, Emelia J Benjamin, Jane C Evans, Craig K Reiss, Daniel Levy. (1999) Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction. Journal of the American College of Cardiology 33:7, 1948-1955
CrossRef997
William T. Abraham, Balkrishna Singh. (1999) Ischemic and Nonischemic Heart Failure do not Require Different Treatment Strategies. Journal of Cardiovascular Pharmacology 33, S1-S7
CrossRef998
John R. Hampton. (1999) Different Causes of Heart Failure Need Different Treatment Strategies. Journal of Cardiovascular Pharmacology 33, S37-S41
CrossRef999
John G.F. Cleland, James McGowan. (1999) Heart Failure due to Ischaemic Heart Disease: Epidemiology, Pathophysiology and Progression. Journal of Cardiovascular Pharmacology 33:Supplement 3, S17-S29
CrossRef1000
Jay N. Cohn, Gianni Tognoni, Robert D. Glazer, Dirk Spormann, Allen Hester. (1999) Rationale and design of the valsartan heart failure trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. Journal of Cardiac Failure 5:2, 155-160
CrossRef1001
(1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). The Lancet 353:9169, 2001-2007
CrossRef1002
John R. Hampton. (1999) Different Causes of Heart Failure Need Different Treatment Strategies. Journal of Cardiovascular Pharmacology 33:Supplement 3, S37-S41
CrossRef1003
David M Kaye, Anthony M Dart, Garry L Jennings, Murray D Esler. (1999) Antiadrenergic effect of chronic amiodarone therapy in human heart failure. Journal of the American College of Cardiology 33:6, 1553-1559
CrossRef1004
Guido Iaccarino, Walter J Koch. (1999) Therapeutic potential of G-protein coupled receptor kinases in the heart. Expert Opinion on Investigational Drugs 8:5, 545-554
CrossRef1005
Juan Carlos Rozo, William L. Barry, George A. Stouffer. (1999) New Treatment Strategies in Patients with Impaired Left Ventricular Systolic Function.. The American Journal of the Medical Sciences 317:5, 312
CrossRef1006
Paolo Palatini, Stevo Julius. (1999) Relevance of heart rate as a risk factor in hypertension. Current Hypertension Reports 1:3, 219-224
CrossRef1007
Biykem Bozkurt. (1999) Medical and surgical therapy for cardiac remodeling. Current Opinion in Cardiology 14:3, 196
CrossRef1008
Guillermo Torre-Amione. (1999) The syndrome of heart failure: emerging concepts in the understanding of its pathogenesis and treatment. Current Opinion in Cardiology 14:3, 193
CrossRef1009
Robert Moskowitz, Marrick Kukin. (1999) Current issues regarding beta-adrenergic blockade in patients with congestive heart failure: Patient selection, non-selective versus selective blockade, management of adverse effects, and indications for withdrawal of therapy. Current Cardiology Reports 1:1, 47-54
CrossRef1010
K. Jansson, U. Dahlstrom, B. E. Karlberg, E. Karlsson, E. Nylander, O. Nyquist, K.-E. Karlberg. (1999) The circulating renin-angiotensin system during treatment with metoprolol or captopril in patients with heart failure due to non-ischaemic dilated cardiomyopathy. Journal of Internal Medicine 245:5, 435-443
CrossRef1011
Audrey H. Wu, Sunil K. Das. (1999) Sudden death in dilated cardiomyopathy. Clinical Cardiology 22:4, 267-272
CrossRef1012
Johannes Feenstra, Diederick E Grobbee, Willem J Remme, Bruno H.Ch Stricker. (1999) Drug-induced heart failure. Journal of the American College of Cardiology 33:5, 1152-1162
CrossRef1013
Edward P Havranek, Ignatius Thomas, William B Smith, George A Ponce, Martin Bilsker, Mark A Munger, Robert A Wolf. (1999) Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. Journal of the American College of Cardiology 33:5, 1174-1181
CrossRef1014
P. D. Kessler, B. J. Byrne. (1999) MYOBLAST CELL GRAFTING INTO HEART MUSCLE: Cellular Biology and Potential Applications. Annual Review of Physiology 61:1, 219-242
CrossRef1015
Michael W. Rich. (1999) Heart failure disease management: a critical review. Journal of Cardiac Failure 5:1, 64-75
CrossRef1016
Robert E Shaddy, Lloyd Y Tani, Samuel S Gidding, Elfriede Pahl, Garth S Orsmond, Edward M Gilbert, Vicente Lemes. (1999) Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. The Journal of Heart and Lung Transplantation 18:3, 269-274
CrossRef1017
Peter S Macdonald, Anne M Keogh, Christina L Aboyoun, Mayanna Lund, Raul Amor, Dermot J McCaffrey. (1999) Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. Journal of the American College of Cardiology 33:4, 924-931
CrossRef1018
Derek V Exner, Daniel L Dries, Myron A Waclawiw, Brent Shelton, Michael J Domanski. (1999) Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction. Journal of the American College of Cardiology 33:4, 916-923
CrossRef1019
Andrew P. Davie, Caroline E. Morrison, J.Ewing Forrester, John J.V. McMurray. (1999) Prescribing and emergency admissions for heart failure in greater glasgow. Journal of Cardiac Failure 5:1, 3-7
CrossRef1020
Peter E Carson. (1999) Beta blocker treatment in heart failure. Progress in Cardiovascular Diseases 41:4, 301-321
CrossRef1021
CRAIG M. PRATT. (1999) Predicting Antiarrhythmic Performance. Journal of Cardiovascular Electrophysiology 10:2, 302-306
CrossRef1022
L Fisher. (1999) Carvedilol and the Food and Drug Administration-Approval Process A Brief Response to Professor Moyé's Article. Controlled Clinical Trials 20:1, 50-51
CrossRef1023
Edward F. Philbin. (1999) Comprehensive Multidisciplinary Programs for the Management of Patients with Congestive Heart Failure. Journal of General Internal Medicine 14:2, 130-135
CrossRef1024
Paul J Hauptman, Rekha Garg, Ralph A Kelly. (1999) Cardiac glycosides in the next millennium
CrossRef1025
Jacob Joseph, Jorge Saucedo, J. David Talley. (1999) Progress in Interventional Cardiology. Journal of Interventional Cardiology 12:1, 95-98
CrossRef1026
Takayoshi Tsutamoto, Atsuyuki Wada, Tomoko Hisanaga, Keiko Maeda, Masato Ohnishi, Naoko Mabuchi, Masahide Sawaki, Masaru Hayashi, Masanori Fujii, Masahiko Kinoshita. (1999) Relationship between endothelin-1 extraction in the peripheral circulation and systemic vascular resistance in patients with severe congestive heart failure. Journal of the American College of Cardiology 33:2, 530-537
CrossRef1027
Paul M.L. Janssen, Oliver Zeitz, Gerd Hasenfuss. (1999) Transient and sustained impacts of hydroxyl radicals on sarcoplasmic reticulum function: protective effects of nebivolol. European Journal of Pharmacology 366:2-3, 223-232
CrossRef1028
Eduardo R Azevedo, Gary E Newton, John D Parker. (1999) Cardiac and systemic sympathetic activity in response to clonidine in human heart failure. Journal of the American College of Cardiology 33:1, 186-191
CrossRef1029
Jan E. Otterstad, Koos Lubsen, Andr. (1999) Left Ventricular Remodelling in Post-myocardial Infarction Patients with Left Ventricular Ejection Fraction 40-50% vs 25-39%. Influence of Nisoldipine Treatment?: An Echocardiographic Substudy from the DEFIANT II Study. Scandinavian Cardiovascular Journal 33:4, 234-241
CrossRef1030
Harold L. Kennedy. (1999) The importance of randomized clinical trials and evidence-based medicine: A clinician's perspective. Clinical Cardiology 22:1, 6-12
CrossRef1031
(1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. The Lancet 353:9146, 9-13
CrossRef1032
Wood, Alastair J.J., , Frishman, William H., . (1998) Carvedilol. New England Journal of Medicine 339:24, 1759-1765
Full Text1033
T. Barry Levine, Arlene B. Levine, Steven J. Keteyian, Barbara Narins. (1998) The impact of beta-receptor blocker addition to high-dose angiotensin-converting enzyme inhibitor-nitrate therapy in heart failure. Clinical Cardiology 21:12, 899-904
CrossRef1034
Andreas Luchner, John C. Burnett, Michihisa Jougasaki, Hans-Werner Hense, Günter A.J. Riegger, Heribert Schunkert. (1998) Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. Journal of the American College of Cardiology 32:7, 1839-1844
CrossRef1035
Eric J. Eichhorn, Mohamed H. Hamdan. (1998) β-Blockade and amiodarone therapy: Twin brothers from different parents. Journal of Cardiac Failure 4:4, 289-294
CrossRef1036
Keiichiro Yoshinaga, Minoru Tahara, Hiroyuki Torii, Koichi Kihara. (1998) Predicting the effects on patients with dilated cardiomyopathy of β-blocker therapy, by using iodine-123 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) myocardial scintigraphy. Annals of Nuclear Medicine 12:6, 341-347
CrossRef1037
Michael R. Bristow, Robert L. Roden, Brian D. Lowes, Edward M. Gilbert, Eric J. Eichhorn. (1998) The role of third-generation beta-blocking agents in chronic heart failure. Clinical Cardiology 21:S1, I3-I13
CrossRef1038
Henry Krum, Neil Shusterman, Stephen MacMahon, Norman Sharpe. (1998) Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy. Journal of Cardiac Failure 4:4, 281-288
CrossRef1039
Eugene S. Chung, Stefano Perlini, Gerard P. Aurigemma, Richard A. Fenton, James G. Dobson, Theo E. Meyer. (1998) Effects of chronic adenosine uptake blockade on adrenergic responsiveness and left ventricular chamber function in pressure overload hypertrophy in the rat. Journal of Hypertension 16:12, 1813-1822
CrossRef1040
Hideki Watanabe, Masaaki Kakihana, Sadanori Ohtsuka, Yasuro Sugishita. (1998) Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. Journal of the American College of Cardiology 32:5, 1194-1200
CrossRef1041
Ferenc Follath, John G.F Cleland, Werner Klein, Richard Murphy. (1998) Etiology and response to drug treatment in heart failure. Journal of the American College of Cardiology 32:5, 1167-1172
CrossRef1042
Hideki Watanabe, Masaaki Kakihana, Sadanori Ohtsuka, Yasuro Sugishita. (1998) Preventive effects of carvedilol on nitrate tolerance—a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol. Journal of the American College of Cardiology 32:5, 1201-1206
CrossRef1043
Pascal de Groote, Alain Millaire, Claude Foucher-Hossein, Olivier Nugue, Xavier Marchandise, Gérard Ducloux, Jean-Marc Lablanche. (1998) Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. Journal of the American College of Cardiology 32:4, 948-954
CrossRef1044
Mette Bjørn, Connie Brendstrup, Sven Karlsen, Jan E. Carlsen. (1998) Consecutive screening and enrollment in clinical trials: The way to representative patient samples?. Journal of Cardiac Failure 4:3, 225-230
CrossRef1045
Chagriya Kitiyakara, S. Wilcox. (1998) Antioxidants for hypertension. Current Opinion in Nephrology and Hypertension 7:5, 531-538
CrossRef1046
DanielL Dries, DerekV Exner, BernardJ Gersh, MichaelJ Domanski, MyronA Waclawiw, LynneW Stevenson. (1998) Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Journal of the American College of Cardiology 32:3, 695-703
CrossRef1047
Serafino Fazio, Emiliano Antonio Palmieri, Beatrice Ferravante, Filomena Bon È, Bernadette Biondi. (1998) Doxorubicin-induced cardiomyopathy treated with carvedilol. Clinical Cardiology 21:10, 777-779
CrossRef1048
Barry M. Massie. (1998) Clinical trials in heart failure: Can we expect the results to be replicated in clinical practice?. Journal of Cardiac Failure 4:3, 243-247
CrossRef1049
Gottlieb, Stephen S., McCarter, Robert J., Vogel, Robert A., . (1998) Effect of Beta-Blockade on Mortality among High-Risk and Low-Risk Patients after Myocardial Infarction. New England Journal of Medicine 339:8, 489-497
Full Text1050
Radford, Martha J., , Krumholz, Harlan M., . (1998) Beta-Blockers after Myocardial Infarction — For Few Patients, or Many?. New England Journal of Medicine 339:8, 551-553
Full Text1051
Barry M Massie. (1998) 15 years of heart-failure trials: what have we learned?. The Lancet 352, SI29-SI33
CrossRef1052
Andrew JS Coats. (1998) Is preventive medicine responsible for the increasing prevalence of heart failure?. The Lancet 352, SI39-SI41
CrossRef1053
Lemuel A. Moyé. (1998) P-Value Interpretation and Alpha Allocation in Clinical Trials. Annals of Epidemiology 8:6, 351-357
CrossRef1054
John GF Cleland, Karl Swedberg, Philip A Poole-Wilson. (1998) Successes and failures of current treatment of heart failure. The Lancet 352, SI19-SI28
CrossRef1055
C Kimmelstiel. (1998) Current concepts in the treatment of patients with heart failure. ACC Current Journal Review 7:4, 39-43
CrossRef1056
Giora Feuerstein, Gao-Lin Liu, Tian-Li Yue, H-Y Cheng, J.Paul Hieble, Jonathan R.S Arch, Robert R Ruffolo, X.-L Ma. (1998) Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model. European Journal of Pharmacology 351:3, 341-350
CrossRef1057
P Bousquet, J Feldman, L Monassier. (1998) Imidazoline receptor ligands:cardiovascular applications. Expert Opinion on Emerging Drugs 3:1, 113-120
CrossRef1058
Lorna Schumann, Bobby Emerson. (1998) Continuing Education Forum. Diagnostic Evaluation for Hypertension. Journal of the American Academy of Nurse Practitioners 10:6, 269-280
CrossRef1059
P. Bousquet, L. Monassier, J. Feldman. (1998) AUTONOMIC NERVOUS SYSTEM AS A TARGET FOR CARDIOVASCULAR DRUGS. Clinical and Experimental Pharmacology and Physiology 25:6, 446-448
CrossRef1060
Frank C. Barone, Wallace G. Campbell, Allen H. Nelson, Giora Z. Feuerstein. (1998) Carvedilol prevents severe hypertensive cardiomyopathy and remodeling. Journal of Hypertension 16:6, 871-884
CrossRef1061
C Michel, Z Chati, P-M Mertes, J-M Escanye, F Zannad. (1998) Physical activity, skeletal muscle β-adrenoceptor changes and oxidative metabolism in experimental chronic heart failure. Fundamental & Clinical Pharmacology 12:3, 263-269
CrossRef1062
Carole C. Ballew, Juanita Reigle. (1998) Mechanisms and Management of Ventricular Dysrhythmias in Heart Failure. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 9:2, 208-224
CrossRef1063
Michiaki Usui, Hidehiro Matsuoka, Hiroshi Miyazaki, Seiji Ueda, Seiya Okuda, Tsutomu Imaizumi. (1998) Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sciences 62:26, 2425-2430
CrossRef1064
Katherine A. Michael, Kimberly J. Parnell. (1998) Innovations in the Pharmacologic Management of Heart Failure. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 9:2, 172-191
CrossRef1065
Debra K. Moser. (1998) Pathophysiology of Heart Failure Update: The Role of Neurohumoral Activation in the Progression of Heart Failure. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 9:2, 157-171
CrossRef1066
&NA; F.M. Van Den Heuvel, Martin van der Ent, Dirk J. van Veldhuisen, Dick A.C.M. Kruijssen, G. Louis Bartels, Willem J. Remme. (1998) Effects of Epanolol, a Selective β1-Blocker with Intrinsic Sympathomimetic Activity, in Patients with Ischemic Left Ventricular Dysfunction. Journal of Cardiovascular Pharmacology 31:4, 506-512
CrossRef1067
Günter Hufnagel, Sabine Pankuweit, Bernhard Maisch. (1998) Therapie der dilatativen Kardiomyopathie mit und ohne Entzündung. Medizinische Klinik 93:4, 240-251
CrossRef1068
Nader Moazami, Michael Argenziano, Takushi Kohomoto, Shahram Yazdani, Eric A Rose, Daniel Burkhoff, Mehmet C Oz. (1998) Inflow Valve Regurgitation During Left Ventricular Assist Device Support May Interfere With Reverse Ventricular Remodeling. The Annals of Thoracic Surgery 65:3, 628-631
CrossRef1069
Tian-Li Yue, Xin-Liang Ma, Juan-Li Gu, Robert R Ruffolo, Giora Z Feuerstein. (1998) Carvedilol inhibits activation of stress-activated protein kinase and reduces reperfusion injury in perfused rabbit heart. European Journal of Pharmacology 345:1, 61-65
CrossRef1070
Raimond L. Winslow, Jeremy Rice, Saleet Jafri. (1998) Modeling the cellular basis of altered excitation–contraction coupling in heart failure. Progress in Biophysics and Molecular Biology 69:2-3, 497-514
CrossRef1071
David M Kaye, Garry L Jennings, Anthony M Dart, Murray D Esler. (1998) Differential Effect of Acute Baroreceptor Unloading on Cardiac and Systemic Sympathetic Tone in Congestive Heart Failure. Journal of the American College of Cardiology 31:3, 583-587
CrossRef1072
JESSICA T. VERMEULEN. (1998) Mechanisms of Arrhythmias in Heart Failure. Journal of Cardiovascular Electrophysiology 9:2, 208-221
CrossRef1073
Gary S. Francis. (1998) Neurohormonal Activation and Progression of Heart Failure. Journal of Cardiovascular Pharmacology 32:Supplement 1, S16-S21
CrossRef1074
Su-chiung Chen. (1998) Recent advances in the treatment of congestive heart failure. The Indian Journal of Pediatrics 65:1, 13-20
CrossRef1075
Gary S. Francis. (1998) Neurohormonal Activation and Progression of Heart Failure: Hypothetical and Clinical Considerations. Journal of Cardiovascular Pharmacology 32, S16-S21
CrossRef1076
Michael Bristow, J. David Port. (1998) Beta-Adrenergic Blockade in Chronic Heart Failure. Scandinavian Cardiovascular Journal 32:47, 45-55
CrossRef1077
John G. F. Cleland, James McGowan, Peter J. Cowburn. (1998) ??-Blockers for Chronic Heart Failure. Journal of Cardiovascular Pharmacology 32:Supplement 1, S52-S60
CrossRef1078
Michihiro Suwa, Takahide Ito, Yoshiaki Otake, Ayaka Kobashi, Yuzo Hirota, Keishiro Kawamura. (1998) Effect of Beta-Blocker Treatment in Dilated Cardiomyopathy With Bradyarrhythmias. Japanese Circulation Journal 62:10, 765-769
CrossRef1079
Dirk J. van Veldhuisen, Wiek H. van Gilst, Gary S. Francis. (1998) Introduction. Journal of Cardiovascular Pharmacology 32, v-vi
CrossRef1080
Linda C. M. C. van Campen, Frans C. Visser, Cees A. Visser. (1998) Ejection Fraction Improvement by ??-Blocker Treatment in Patients with Heart Failure. Journal of Cardiovascular Pharmacology 32:Supplement 1, S31-S35
CrossRef1081
Linda C. M. C. van Campen, Frans C. Visser, Cees A. Visser. (1998) Ejection Fraction Improvement by β-Blocker Treatment in Patients with Heart Failure: An Analysis of Studies Published in the Literature. Journal of Cardiovascular Pharmacology 32, S31-S35
CrossRef1082
Dirk J. van Veldhuisen, Wiek H. van Gilst, Gary S. Francis. (1998) Introduction. Journal of Cardiovascular Pharmacology 32:Supplement 1, v-vi
CrossRef1083
Dirk J. van Veldhuisen, Ad F. M. van den Heuvel, Paul K. Blanksma, Harry J. G. M. Crijns. (1998) Ischemia and Left Ventricular Dysfunction. Journal of Cardiovascular Pharmacology 32:Supplement 1, S46-S51
CrossRef1084
Lennart Hansson. (1998) Hypertension-induced Congestive Heart Failure. Scandinavian Cardiovascular Journal 32:47, 5-7
CrossRef1085
Robert R. Ruffolo, Giora Z. Feuerstein. (1998) Neurohormonal Activation, Oxygen Free Radicals, and Apoptosis in the Pathogenesis of Congestive Heart Failure. Journal of Cardiovascular Pharmacology 32:Supplement 1, S22-S30
CrossRef1086
John G. F. Cleland, James McGowan, Peter J. Cowburn. (1998) β-Blockers for Chronic Heart Failure: From Prejudice to Enlightenment. Journal of Cardiovascular Pharmacology 32, S52-S60
CrossRef1087
Dirk J. van Veldhuisen, &NA; F. M. van den Heuvel, Paul K. Blanksma, Harry J. G. M. Crijns. (1998) Ischemia and Left Ventricular Dysfunction: A Reciprocal Relation?. Journal of Cardiovascular Pharmacology 32, S46-S51
CrossRef1088
Athanasios J. Manolis, Christoforos Olympios, Maria Sifaki, Nicholas Smirnioudis, Stelios Handanis, Spyridon Argirakis, Constantine Katsaros, Irene Gavras, Haralambos Gavras. (1998) Chronic Sympathetic Suppression in the Treatment of Chronic Congestive Heart Failure. Clinical and Experimental Hypertension 20:7, 717-731
CrossRef1089
Rutger L. Anthonio, Dirk J. van Veldhuisen, Wiek H. van Gilst. (1998) Left Ventricular Dilatation After Myocardial Infarction: ACE Inhibitors, β-Blockers, or Both?. Journal of Cardiovascular Pharmacology 32, S1-S8
CrossRef1090
Rutger L. Anthonio, Dirk J. van Veldhuisen, Wiek H. van Gilst. (1998) Left Ventricular Dilatation After Myocardial Infarction. Journal of Cardiovascular Pharmacology 32:Supplement 1, S1-S8
CrossRef1091
Robert R. Ruffolo, Giora Z. Feuerstein. (1998) Neurohormonal Activation, Oxygen Free Radicals, and Apoptosis in the Pathogenesis of Congestive Heart Failure. Journal of Cardiovascular Pharmacology 32, S22-S30
CrossRef1092
Lennart Hansson, Anders Himmelmann. (1998) Carvedilol in the Treatment of Hypertension - A Review of the Clinical Data Base. Scandinavian Cardiovascular Journal 32:47, 67-80
CrossRef1093
O. Uhlir, I. Dvorak, P. Gregor, I. Malek, L. Spinarova, J. Vojacek, L. Van Nueten. (1997) Nebivolol in the treatment of cardiac failure: A double-blind controlled clinical trial. Journal of Cardiac Failure 3:4, 271-276
CrossRef1094
Barry F Uretsky, Richard G Sheahan. (1997) Primary Prevention of Sudden Cardiac Death in Heart Failure: Will the Solution Be Shocking?. Journal of the American College of Cardiology 30:7, 1589-1597
CrossRef1095
Edward D. Freis. (1997) CURRENT STATUS OF DIURETICS, β-BLOCKERS, α-BLOCKERS, AND α-β–BLOCKERS IN THE TREATMENT OF HYPERTENSION. Medical Clinics of North America 81:6, 1305-1317
CrossRef1096
JOHANNES BRACHMANN, THOMAS HILBEL, EKKEHARD GRUJNIG, ANDREAS BENZ, MARKUS HAASS, WOLFGANG KUBLER. (1997) Ventricular Arrhythmias in Dilated Cardiomyopathy. Pacing and Clinical Electrophysiology 20:10, 2714-2718
CrossRef1097
R. Lange, M. Thielmann, S. Hagl. (1997) Dynamische Kardiomyoplastik. Herz 22:5, 253-261
CrossRef1098
Michael Böhm, Hans J Deutsch, Dagmar Hartmann, Karl La Rosée, Alexander Stäblein. (1997) Improvement of Postreceptor Events by Metoprolol Treatment in Patients With Chronic Heart Failure. Journal of the American College of Cardiology 30:4, 992-996
CrossRef1099
ROBERT P. FRANTZ, LYNE J. OLSON. (1997) Recipient Selection and Management Before Cardiac Transplantation. The American Journal of the Medical Sciences 314:3, 139-152
CrossRef1100
Jay N. Cohn, Michael B. Fowler, Michael R. Bristow, Wilson S. Colucci, Edward M. Gilbert, Vithal Kinhal, Steven K. Krueger, Thierry Lejemtel, Kenneth A. Narahara, Milton Packer, Sarah T. Young, Terry L. Holcslaw, Mary Ann Lukas. (1997) Safety and efficacy of carvedilol in severe heart failure. Journal of Cardiac Failure 3:3, 173-179
CrossRef1101
P Chatelain, R Massingham. (1997) Cardiac ischaemia: possibilities for future drug therapy. European Journal of Medicinal Chemistry 32:9, 687-707
CrossRef1102
William C. Stanley, Bin Li, Douglas W. Bonhaus, Lowell G. Johnson, Keiho Lee, Seth Porter, Keith Walker, Greg Martinez, Richard M. Eglen, Roger L. Whiting, Sharath S. Hegde. (1997) Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine- β -hydroxylase. British Journal of Pharmacology 121:8, 1803-1809
CrossRef1103
Anne Keogh. (1997) Heart failure - outlooks and strategies for treatment. Australian and New Zealand Journal of Medicine 27:4, 485-491
CrossRef1104
(1997) Digoxin in Patients with Heart Failure. New England Journal of Medicine 337:2, 129-131
Full Text1105
. (1997) Carvedilol bij chronisch hartfalen. Een langer leven of te vroeg gejuicht?. Medisch-Farmaceutische Mededelingen 35:7, 133-134
CrossRef1106
Paul A Heidenreich, Tina T Lee, Barry M Massie. (1997) Effect of Beta-Blockade on Mortality in Patients With Heart Failure: A Meta-Analysis of Randomized Clinical Trials. Journal of the American College of Cardiology 30:1, 27-34
CrossRef1107
J. Guindo, A. Bay
CrossRef1108
EA Dubois, PA van Zwieten. (1997) The introduction of β-adrenoceptor antagonists in the treatment of congestive heart failure. Expert Opinion on Emerging Drugs 2:1, 109-126
CrossRef1109
Daniel R. Nul, Hernán C. Doval, Hugo O. Grancelli, Sergio D. Varini, Saul Soifer, Sergio V. Perrone, Noemí Prieto, Omar Scapin. (1997) Heart Rate Is a Marker of Amiodarone Mortality Reduction in Severe Heart Failure. Journal of the American College of Cardiology 29:6, 1199-1205
CrossRef1110
Robert N. Doughty, Gillian A. Whalley, Greg Gamble, Stephen MacMahon, Norman Sharpe. (1997) Left Ventricular Remodeling With Carvedilol in Patients With Congestive Heart Failure Due to Ischemic Heart Disease. Journal of the American College of Cardiology 29:5, 1060-1066
CrossRef1111
The CIBIS II Scientific Committee. (1997) Design of the cardiac insufficiency bisoprolol study II (OBIS II). Fundamental & Clinical Pharmacology 11:2, 138-142
CrossRef1112
Simon RJ Maxwell. (1997) Anti-oxidant therapy: does it have a role in the treatment of human disease?. Expert Opinion on Investigational Drugs 6:3, 211-236
CrossRef1113
LESLIE A. SAXON. (1997) Atrial Fibrillation and Dilated Cardiomyopathy: Therapeutic Strategies When Sinus Rhythm Cannot be Maintained. Pacing and Clinical Electrophysiology 20:3, 720-725
CrossRef1114
K. Li, H. He, C. Li, P. Sirois, J.L. Rouleau. (1997) Myocardial α1-adrenoceptor: Inotropic effect and physiologic and pathologic implications. Life Sciences 60:16, 1305-1318
CrossRef1115
(1997) Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. The Lancet 349:9049, 375-380
CrossRef1116
L. Cloarec-Blanchard. (1997) Heart rate and blood pressure variability in cardiac diseases: pharmacological implications. Fundamental & Clinical Pharmacology 11:1, 19-28
CrossRef1117
Allan Gordon, Liisa-Maria Voipio-Pulkki. (1997) Crosstalk of the Heart and Periphery: Skeletal and Cardiac Muscle as Therapeutic Targets in Heart Failure. Annals of Medicine 29:4, 327-331
CrossRef1118
Vsevolod Panfilov, Gunnar Olsson. (1997) Do beta-blockers have a role in the treatment of chronic heart failure?. Expert Opinion on Investigational Drugs 6:1, 23-30
CrossRef1119
L. M. A. B. Van Bortel, J. N. J. M. de Hoon, M. J. F. Kool, J. A. G. Wijnen, C. I. M. Vertommen, L. G. M. Van Nueten. (1997) Pharmacological properties of nebivolol in man. European Journal of Clinical Pharmacology 51:5, 379-384
CrossRef1120
Peter E. Pool. (1997) The clinical significance of neurohormonal activation. Clinical Therapeutics 19, 53-73
CrossRef1121
Pascal Vantrimpont, Jean L. Rouleau. (1997) Medical treatment of heart failure: The Canadian Cardiovascular Society's Consensus Conference revisited. Cardiovascular Drugs and Therapy 10:6, 711-716
CrossRef1122
William G. stevenson, Michael O. Sweeney. (1997) Arrhythmias and Sudden Death in Heart Failure. Japanese Circulation Journal 61:9, 727-740
CrossRef1123
Tuan Peng Chua, BSc, MD, MRCP, Derek Harrington, BSc, MRCP, Piotr Ponikowski, MD, Katharine Webb-Peploe, MA, MRCP, Philip A Poole-Wilson, MD, FRCP, FESC, FACC, Andrew J.S Coats, DM, FRCP, FESC, FACC. (1997) Effects of Dihydrocodeine on Chemosensitivity and Exercise Tolerance in Patients With Chronic Heart Failure. Journal of the American College of Cardiology 29:1, 147-152
CrossRef1124
E. Erdmann. (1997) Zellbiologische kardiale Veränderungen bei transplantationspflichtiger Herzinsuffizienz. Zeitschrift für Herz-, Thorax- und Gefäßchirurgie 11:S1, 1-6
CrossRef1125
Outi Saijonmaa, Kaj Metsärinne, Frej Fyhrquist. (1997) Carvedilol and its Metabolites Suppress Endothelin-1 Production in Human Endothelial Cell Culture. Blood Pressure 6:1, 24-28
CrossRef1126
Takehiko Yamada, Akira Matsumori, Nagara Tamaki, Ryuji Nohara, Junji Konishi, Shigetake Sasayama. (1997) Indium-111 Antimyosin Antibody Imaging and Thallium-201 Imaging. Japanese Circulation Journal 61:10, 827-835
CrossRef1127
K.K. Talwar, B. Bhargava, P.T. Upasani, S. Verma, T. Kamlakar, P. Chopra. (1996) Hemodynamic predictors of early intoleranceand long-term effects of propranolol in dilated cardiomyopathy. Journal of Cardiac Failure 2:4, 273-277
CrossRef1128
David T. Kelly. (1996) Beta-blocker therapy in heart failure: Myths or realities. Journal of Cardiac Failure 2, S239-S242
CrossRef1129
R. Ferrari, C. Ceconi, S. Curello, F. Ferrari, R. Confortini, P. Pepi, O. Visioli. (1996) Activation of the neuroendocrine response in heart failure: Adaptive or maladaptive process?. Cardiovascular Drugs and Therapy 10:S2, 623-629
CrossRef1130
(1996) Carvedilol in Patients with Chronic Heart Failure. New England Journal of Medicine 335:17, 1318-1320
Full Text1131
Philip F. Binkley. (1996) Heart rate variability:Two eras of investigation. Journal of Cardiac Failure 2:3, 193-196
CrossRef1132
Wood, Alastair J.J., , Cohn, Jay N., . (1996) The Management of Chronic Heart Failure. New England Journal of Medicine 335:7, 490-498
Full Text1133
Pfeffer, Marc A., Stevenson, Lynne W., . (1996) β-Adrenergic Blockers and Survival in Heart Failure. New England Journal of Medicine 334:21, 1396-1397
Full Text
- Letters
